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Summary  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
1. The main aim of this study was to determine whether NGNG- asymmetric 
dimethylarginine (ADMA), like NG-monomethyl-L-arginine (L-NMMA), blocks 
basal but not acetylcholine-induced nitric oxide activity in female rat aorta, and if 
so, to investigate the possible mechanism(s) behind these seemingly differential 
actions.  
 
2. In the rat aorta, ADMA, like L-NMMA, blocked basal nitric oxide activity, as 
assessed by its ability to enhance sub-maximal phenylephrine-induced tone, and to 
inhibit the endothelium-dependent, nitric oxide-mediated relaxation induced by 
superoxide dismutase or the PDE5 inhibitor, T0156.  
 
3. In the rat aorta, ADMA had little effect on endothelium-dependent, nitric oxide-
mediated relaxation induced by acetylcholine or the calcium ionophore, A23187, 
when studied at the same level of tone used in control tissues. It did, however, 
significantly block relaxation induced by calcitonin gene-related peptide-1, an 
agonist that had a significantly lower maximum response than acetylcholine or 
A23187.    
 
4. ADMA did, however, produce potent, apparent blockade of acetylcholine-induced 
relaxation in tissues where the level of tone, due to blockade of basal nitric oxide 
activity, was permitted to rise above that of control tissues. This apparent blockade 
by ADMA was due to physiological antagonism rather than blockade of nitric 
oxide synthase, because control tissues taken to equivalent levels of tone were 
similarly inhibited.   
 
 iv
5. NGN' G-symmetric dimethylarginine (SDMA), the inert analogue of ADMA, had no 
effect on basal or acetylcholine-induced activity of nitric oxide in rat aorta. 
 
6.  ADMA and L-NMMA behaved similarly to the endogenous substrate, L-arginine, 
in protecting acetylcholine-induced relaxation against blockade by L-NAME.  
 
7. With the use of calmidazolium and wortmannin, respectively, the calcium-
calmodulin and the phosphatidylinositol 3-kinase transduction mechanisms were 
found to play only a minor role in the stimulation of basal nitric oxide production, 
as assessed by the enhancement of phenylephrine tone or by blocking relaxation to 
superoxide dismutase or T0156 in rat aorta. In contrast, nitric oxide activity 
induced by acetylcholine, A23187 or calcitonin gene-related peptide-1 seems to be 
mediated mainly by the calcium-calmodulin transduction mechanism.    
 
8. The M3 partial agonist, butyrylcholine, elicited concentration-dependent relaxation 
in rat endothelium-containing aortic rings with a maximal relaxant response lower 
than that elicited by the full agonist, acetylcholine. Moreover, unlike with 
acetylcholine, this relaxation was significantly blocked by ADMA.  
  
9. When rat endothelium-containing aortic rings were treated for 30 minutes with the 
irreversible receptor alkylating agent, phenoxybenzamine (3 µM), followed by 
washout and then submaximally contracted with endothelin-1, maximal relaxation 
to acetylcholine  was blocked by ~50%, while that to butyrylcholine was almost 
abolished.  
 v
10. Under conditions where the apparent efficacy of acetylcholine was reduced to that 
of a partial agonist using phenoxybenzamine, ADMA produced powerful 
concentration-dependent blockade of the relaxation.   
 
11.  The results of this study strongly suggest that the seemingly differential abilities of 
L-NMMA and ADMA to block basal, but not acetylcholine-induced relaxation in 
rat aorta may be explained by the blocking action being critically determined by the 
efficacy of the relaxant stimulus i.e. low efficacy basal activity in comparison to the 
high efficacy acetylcholine-stimulated activity.  
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Physiology of the vascular endothelium 
 
General functions of the vascular endothelium 
   The lining of the blood vessels and chambers of the heart consists of a monolayer of cells 
termed the endothelium (Celemajer, 1997; Sader and Celemajer, 2002; Galley and 
Webster, 2004; Flammer and Lüscher, 2010). The vascular endothelium was classically 
regarded as a simple, passive barrier that separates the vascular wall from the blood. We 
now know, however, that the endothelium is a highly dynamic structure whose functional 
integrity is vital for many important physiological processes (Vanhoutte, 1989; Celemajer, 
1997; Sader and Celemajer, 2002; Galley and Webster, 2004; Flammer and Lüscher, 
2010).   
    Figure 1.1, adopted from Galley and Webster (2004) illustrates many of these diverse 
functions. For example, although the endothelium is a barrier to the diffusion of large 
molecules, it is under dynamic regulation in immune and inflammatory processes. 
Specifically, immune mediators (such as histamine, leukotrienes C4 and D4) induce 
endothelial contraction at the post-capillary venules, leading to the vascular leakage (local 
oedema) that characterises the inflammatory response. Moreover, endothelial damage 
leading to barrier dysfunction permits entry into the vascular wall of large, normally 
restricted molecules, such as cholesterol-rich low density lipoproteins, thus contributing to 
atherosclerosis. The endothelium also regulates haemostasis vs thrombosis through the 
balance between the release of a variety of procoagulant (such as von Willebrand factor, 
thromboxane A2 and plasminogen activator inhibitor) and antithrombotic factors (such as 
prostacyclin, plasminogen activator inhibitor and antithrombin). Moreover, platelets 
adhesion and subsequent aggregation and activation is prevented by the synergistic actions 
of nitric oxide and the arachidonic acid derivative, prostacyclin. In addition, the 
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endothelium is an important site for the enzymatic activation of some mediators (e.g. 
angiotensin ІІ) and the destruction of others (e.g. bradykinin).  
  Also, vascular endothelial cells express receptors for some endogenous hormones, such as 
oestrogen, progesterone, androgens and insulin, which may suggest a role for these 
receptors in regulating endothelial dysfunction (Vanhoutte, 1989; Sader and Celemajer, 
2002, Flammer and Lüscher, 2010).  
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Figure 1.1. Functions of the vascular endothelium (Modified from Galley and Webster,  
 
2004). 
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Regulation of vascular tone 
   The main focus of this study is to investigate the role the vascular endothelium plays in 
the regulation of blood vessel tone.  
   The vascular endothelium has an important function in the control of blood vessel 
contractility by the manufacture and secretion of a variety of endothelium-derived relaxing 
factors (EDRF) and endothelium-derived constricting factors (EDCF) that can alter the 
tone of the vascular wall (Furchgott and Zawadzki, 1980; Vanhoutte, 1989; Rubanyi, 1991; 
Celemajer, 1997; Féléton and Vanhoutte, 2000; Widlansky et al., 2003; Galley and 
Webster, 2004; Kozłowska et al., 2007; Flammer and Lüscher, 2010; Thorin and Clozel, 
2010). The most important endothelium-derived relaxing factors are probably nitric oxide, 
which induces vasorelaxation via activation of the enzyme, soluble guanylate cyclase 
(sGC), in the vascular smooth muscle cells, and the endothelial-derived hyperpolarizing 
factor (EDHF) whose identity is still a matter of debate. Other important relaxing 
substances produced by the vascular endothelium include prostacyclin (Vane, 1971). 
Among the vasoconstricting substances released by the vascular endothelium is the peptide 
endothelin (ET) (Yanagisawa et al., 1988).  
Nitric oxide    
   The vascular endothelial cells manufacture nitric oxide from the amino acid, L-arginine, 
through the chemical reaction that is catalysed by the enzyme nitric oxide synthase (Palmer 
et al., 1988). While the production of nitric oxide is inhibited by L-arginine analogues, 
such as NG-monomethyl-L-arginine (L-NMMA), its formation is stimulated by the 
shearing force produced by flowing blood or by agonists such as acetylcholine, bradykinin 
or thrombin, that act on their own receptors expressed by the vascular endothelial cells 
(Pohl et al., 1986; Flammer and Lüscher, 2010). Nitric oxide induces vasorelaxation by 
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inducing the formation of its second messenger cyclic guanosine monophosphate (cGMP) 
via activation of the enzyme, soluble guanylate cyclase (sGC), in the vascular smooth 
muscle cells (Rapoport and Murad, 1983).     
 Endothelium-derived hyperpolarising factor (EDHF)  
 
    Stimulation of the vascular endothelium with shear stress or receptor-dependent agonists 
such as acetylcholine, bradykinin and substance P can induce vasorelaxation by 
mechanisms other than the release of NO such as hyperpolarisation of the underlying 
vascular smooth muscle cells. This vasorelaxation was found to be resistant to inhibitors of 
cycloxygenase, such indomethacin, or to agents that are known to block the synthesis 
and/or the actions of NO, such as L-NMMA, methylene blue and haemoglobin (Chen et 
al., 1988; Féléton and Vanhoutte 1988; Plane et al., 1995). Moreover, the resultant 
vasorelaxation does not correlate with increases in intracellular concentrations of second 
messengers, cGMP and cAMP, in the vascular smooth muscle cells. This hyperpolarisation 
was thought to be mediated by endothelium-derived hyperpolarisation factor(s) (EDHF) 
whose exact character is still under investigation. The vasorelaxation due to endothelium-
dependent hyperpolarisation has been reported in the human coronary circulation as well as 
in animal vascular beds such as rat arteries, rabbit saphenous and ear arteries, and the 
canine coronary arteries (Komori and Suzuki, 1987a; Suzuki, 1988; Chen et al., 1988; 
Feletou and Vanhoutte, 1988; Chen and Suzuki, 1989; Celemajer, 1997; Kozłowska et al., 
2007).  
   The exact character of the EDHF is still uncertain and there is a spectrum of molecules 
that are proposed to function as endothelium-derived hyperpolarisation factors depending 
on animal species and the vascular bed used (Matoba et al., 2000; Kozłowska et al., 2007; 
Griffith, 2004; Flammer and Lüscher, 2010). These include potassium ions (K+) (Edwards 
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et al., 1998; Féléton and Vanhoutte, 2000; Griffith, 2004; Kozłowska et al., 2007), 
metabolic products of cytochrome P-450 epoxygenases like epoxyeicosatrienoic acids 
(Rosolowsky and Campbell, 1993; Fisslthaler et al., 1999), hydrogen peroxide (H2O2) 
(Matoba et al., 2000; Féléton and Vanhoutte, 2000; Griffith, 2004; Shimokawa and 
Matoba, 2004; Kozłowska et al., 2007), a cannabinoid (Randall et al., 1996), C-type 
natriuretic peptide (Wei et al., 1994; Flammer and Lüscher, 2010). Alternatively, the 
EDHF process may function via electronic spread of endothelial hyperpolarisation to the 
underlying vascular smooth muscle cells through myoendothelial gap junctions that 
resulting in the closure of voltage-operated calcium channels with subsequent reduction in 
calcium influx leading to smooth muscle relaxation (Griffith, 2004; Griffith et al., 2004).  
Prostacyclin (Prostaglandin I2, PGI2)    
  This endothelium-derived mediator is synthesised by the vascular endothelial cells from 
arachidonic acid by the cycloxygenase-1 (COX-1) enzyme, but it has a short half-life (~2-3 
minutes) as it is rapidly transformed into its stable endproduct, 6-oxo-PGF1α (Moncada et 
al., 1976; Moncada, 1982; Féléton and Vanhoutte, 2000; Flammer and Lüscher, 2010). The 
relaxant actions of PGI2 are thought to be mediated by stimulating adenylate cyclase with 
the subsequent increase in intracellular concentration of the second messenger, cAMP 
(Gorman et al., 1977; Tateson et al., 1977). In some tissues such as the rabbit coronary 
arteries relaxation is accompanied by hyperpolarisation of the vascular smooth muscle 
cells as a result of opening of ATP-dependent potassium channels (KATP), as these effects 
are blocked by glibenclamide (Jackson et al., 1993; Féléton and Vanhoutte, 2000; Flammer 
and Lüscher, 2010). PGI2 cooperates with NO in preventing platelet aggregation and 
subsequent thrombus formation, however, it differs from nitric oxide in that the latter is 
released continuously from the vascular endothelium while the former is produced
 
transiently and does not therefore play a role in sustaining the resting vascular tone in 
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major arteries (Moncada, 1982). Furthermore, the release of PGI2 is provoked by a range of 
stimuli such as shear stress, bradykinin, angiotensin II, thrombin, calcium ionophore 
A23187, adenine nucleotides (ADP and ATP) and certain anti-hypertensive drugs such as 
bendroflumethiazide and nitroglycerine (Moncada, 1982; Jackson et al., 1993; Celemajer, 
1997; Flammer and Lüscher, 2010).  
Endothelin (ET)  
 Although there are three isoforms of endothelin (ET-1, ET-2 and ET-3), only ET-1 is 
known to be produced by the vascular endothelium. The biosynthesis of ET-1 consists of 
two stages; initially the polypeptide proET-1 is sliced by a furin-like endopeptidase to 
yield another polypeptide molecule, big ET-1 (38 amino acids), then the endothelin-
converting enzymes (ECEs) cleave the latter molecule to produce a 21-amino acid peptide, 
ET-1 (Yanagisawa et al., 1988; Kirkby et al., 2008; Barton and Yanagisawa, 2008; Thorin 
and Clozel, 2010).    
   ET-1 is the most potent spasmogens recognised so far and its pharmacological effects are 
proposed to be mediated through direct action on its own receptors, ETA and ETB (Masaki, 
1989; Boulanger and Lüscher, 1990; Lüscher, 1990; Celemajer, 1997; Flammer and 
Lüscher, 2010).   
  ETA receptors expressed by vascular smooth muscle cells and cardiomyocytes and 
mediate ET-1-induced contraction, and ETB receptors expressed by the vascular 
endothelial cells and facilitate vasodilatation, ET-1 uptake and regulation of ET-1 release 
(Kirkby et al., 2008; Barton and Yanagisawa, 2008; Thorin and Clozel, 2010). However, 
an additional minor component of ET-1-induced vasoconstriction is also thought to be 
mediated by stimulating the release of renin, secondary to renal vasoconstriction, and/or 
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enhancing sympathetic output as a result of its effects on the central nervous system 
(Masaki, 1989; Rubanyi, 1991).  
  The release of ET-1 can be stimulated by a range of stimuli such as adrenaline, shear 
stress, thrombin, angiotensin II, calcium ionophore A23187, hypoxia and oxidised low 
density lipoproteins (Yoshizumi et al., 1989; Kohno et al., 1989; Kourembanas et al., 
1991; Lüscher, 1990; Boulanger and Lüscher, 1990; Boulanger et al., 1992; Celemajer, 
1997; Flammer and Lüscher, 2010). Moreover, vasospasm induced by ET-1 can be 
antagonised by calcium antagonist, nitric oxide and parenteral nitrovasodilators.    
 Within physiological concentrations, ET-1 acts to maintain basal vascular tone whereas 
higher concentrations are reported in pathophysiological conditions such as pulmonary 
arterial hypertension (PAH), coronary heart disease and cardiac failure (Boulanger and 
Lüscher, 1990; Celemajer, 1997; Flammer and Lüscher, 2010). Pharmacological 
antagonists of ET-1 such as the selective ETA antagonists, sitaxsentan and ambrisentan, 
and the non-selective antagonist, bosentan, are currently prescribed for the treatment of 
PAH (Kirkby et al., 2008; Thorin and Clozel, 2010).  
Further focus on the role played by nitric oxide in the regulation of vascular tone. 
 Synthesis of nitric oxide 
  In 1980 the vascular endothelial cells were first recognised to synthesise a powerful 
vasodilating agent, endothelium-derived relaxing factor (EDRF), when Furchgott and 
Zawadzki (1980) noticed that rabbit aortic rings relaxed in response to acetylcholine only 
when they were endothelium-intact. Many subsequent studies showed that the physical, 
chemical and pharmacological properties of EDRF were identical to those of nitric oxide 
(Palmer et al., 1987). The major problem at that time, however, was that no system existed 
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that could detect nitric oxide at the nanomolar concentrations that promote vasodilatation. 
The breakthrough occurred in 1987, however, when a highly sensitive chemiluminescence 
detection system for nitric oxide was developed (Palmer et al., 1987). The use of this 
system demonstrated not only that endothelial cells produced NO, but also that they did so 
in amounts that could fully account for the vasodilator action of EDRF. 
 Cells other than the vascular endothelial cells, such as neurons in the peripheral and 
central nervous systems (Garthwaite et al., 1988; Gillespie et al., 1989) are also able to 
produce nitric oxide as a physiological mediator. In addition, it was found that 
immunologically-activated macrophages synthesise nitric oxide from the amino acid L-
arginine, (Marletta et al., 1987), and subsequent work showed that L-arginine was the 
substrate for the synthesis of nitric oxide in endothelial cells as well (Palmer et al., 1988).    
  Nitric oxide synthase (NOS), the key enzyme responsible for the production of NO, exists 
in three isoforms (Förstermann et al., 1991, Sader and Celemajer, 2002): NOS Ι or 
neuronal NOS (nNOS) is a soluble enzyme in the cytoplasm of the neurons of the central 
and peripheral nervous systems (Knowles et al., 1989; Toda and Toda, 2011); NOS ΙΙΙ or 
endothelial NOS (eNOS) which is mainly a particulate enzyme in the caveolae of the 
endothelial cell membrane (Förstermann et al., 1991). These two isforms are normally 
found in the cells in the inactive state and require formation of the calcium-calmodulin 
complex for their activation. They produce small amounts of NO for signalling purposes. 
On the other hand, NOS ΙΙ or inducible NOS (iNOS) is not normally expressed, but is 
synthesised by the macrophages, the vascular smooth muscle cells and other cell types 
after induction by cytokines, such as interferon-γ, or by bacterial endotoxins (Knowles et 
al., 1989; Buss & Mulsch, 1990; Gray et al., 1991; Toda and Toda, 2011), but does not 
require activation by the calcium-calmodulin complex. Tight calmodulin binding at low 
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concentrations of intracellular calcium ensures that iNOS is maximally active (assuming 
adequate supply of substrate, L-arginine) and makes massive amounts of NO that exert 
cytotoxic and cytostatic actions on invading microorganisms. This action represents an 
important component of the immune response. Thus, all three NOS isoforms catalyse the 
manufacture of nitric oxide from the cationic amino acid, L-arginine. 
  The reaction that yields nitric oxide requires the presence of oxygen as a co-substrate and 
results in the formation of the by-product, L-citrulline, in equimolar proportions (Bush et 
al., 1992; Toda and Toda, 2011). The reaction also requires 5 electrons supplied by the co-
factor NADPH, and these flow through FAD, FMN and tetrahydrobiopterin (BH4) to 
complete the synthesis of nitric oxide. This reaction is thought to be a two-stage reaction 
(Wallace & Fukuto, 1991; Pufahl et al., 1992). The first stage involves the NG-
hydroxylation of L-arginine to produce NG-hydroxy-L-arginine (NOHLA) followed by the 
subsequent formation of nitric oxide and L-citrulline (Figure 1.2). 
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Figure 1.2. Nitric oxide synthase catalyses the oxidation of one of the guanidino nitrogens 
of L-arginine to produce nitric oxide (Modified from Knowles and Moncada, 1994). 
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 Basal NO activity 
   It has been reported that the vascular endothelium generates nitric oxide in the absence of 
external stimuli, i.e. under basal conditions, and that this basal activity of nitric oxide 
exerts a tonic vasodilator effect that suppresses the actions of vasoconstrictor agents 
(Martin et al., 1986b; Rees et al., 1989; Moore et al., 1990; Mian & Martin, 1995). These 
findings are supported by the observation that removal of the endothelium from rat aortic 
rings results in an augmentation of contraction induced by vasoconstricting agents in 
comparison to those induced in control rings (Allan et al., 1983; Eglème et al., 1984).  
 
  A question raised is whether nitric oxide can satisfactorily account for the actions of both 
basal and agonist-stimulated EDRF activity. Kelm and co-workers (1998) found in 
cultured endothelial cells that bradykinin- and ATP-stimulation, produces nitric oxide as a 
free radical and this nitric oxide completely accounts for vasodilatation produced by 
EDRF. However, Mian and Martin (1995) found that superoxide generators, such as 
hypoxanthine/xanthine oxidase or pyrogallol, inhibit basal but not agonist-stimulated 
EDRF activity in rat aortic rings. Furthermore, they reported that the superoxide scavenger, 
superoxide dismutase (SOD) significantly enhanced basal EDRF activity, but it did not 
alter the acetylcholine-elicited EDRF activity. 
     
   The researchers who first documented the presence of basal nitric activity in rat aorta 
(Martin et al., 1986b; Rees et al., 1989; Moore et al., 1990) proposed that it was produced 
spontaneously by the vascular endothelium without the need for an external stimulus; this 
potentially excludes the existence of an intracellular signalling mechanism to control the 
synthesis of basal nitric oxide. This proposal was supported by the observations made by 
Rapoport and Murad (1983) that the resting levels of cGMP in entirely unstimulated 
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endothelium-containing rat aortic rings were 2-3-fold higher than those in endothelium-
denuded rings. Their findings too suggest that the basal nitric oxide activity in 
endothelium-containing rings occurs in the absence of any stimulus.  
 
  On the other hand, other researchers have proposed the existence of triggering stimuli that 
operate within the vascular endothelium to generate basal nitric oxide activity. Such 
stimuli may include calcium ions that pass from the contracting vascular smooth muscle 
cells through myo-endothelial gap junctions to the adjacent endothelial cells (Dora et al., 
2000; Jackson et al., 2008) where they (calcium ions) provoke the release of nitric oxide 
presumably via the calcium-calmodulin-mediated, calmidazolium-sensitive activation of 
endothelial nitric oxide synthase. Alternatively, Fleming et al (1999) proposed that 
isometric contraction may generate a mechanical stress on the endothelial cytoskeleton that 
triggers the release of nitric oxide via a phosphatidylinositol 3-kinase(PI 3-kinase)-
mediated, wortmannin-sensitive phosphorylation and activation of endothelial nitric oxide 
synthase, similar to that induced by shear stress generated by blood flow.  
 
 Agonist-stimulated nitric oxide activity 
  Receptor-dependent agonists, such as acetylcholine, bradykinin, ATP and substance P, or 
receptor-independent agonists, such as calcium ionophore A23187, react with the vascular 
endothelium to promote the production and release of nitric oxide by stimulating eNOS via 
calcium-dependent mechanism that is proposed to induce a conformational change that 
permits dissociation of the enzyme from its inhibitory anchor protein, caveolin-1 (Michel 
et al., 1997; Moncada et al., 1991; Schini and Vanhoutte, 1992; Dudzinski and Michel, 
2007). Moreover, the release of nitric oxide by this mechanism is inhibited by the 
calmodulin-antagonist, calmidazolium.   
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   On the other hand, the shearing force of flowing blood induces the generation of nitric 
oxide via a wortmannin-sensitive, calcium-independent phosphorylation of Ser1177/1179 
of eNOS through phosphatidylinositol 3-kinase and the downstream serine/threonine 
protein kinase Akt, resulting in enhanced NO formation (Fulton et al., 1999; Gallis et al., 
1999; Dimmeler et al., 1999; McCabe et al., 2000; Galley et al., 2004). Other sites on 
eNOS are also targets for phosphorylation by protein kinases. For example, threonine 495 
can be phosphorylated by AMP-activated kinase and protein kinase C (PKC) with the 
resultant suppression of eNOS enzymatic activity (Chen et al., 1999), and shear stress can 
result in phosphorylation of eNOS at Ser 116 (Gallis et al., 1999), however, the responsible 
protein kinase(s) and the functional implications of eNOS phosphorylation at this site are 
uncertain. Furthermore, the catalytic activity of eNOS can be reduced by phosphorylation 
of its tyrosine residues (Garćia-Gardeña et al., 1995) although the exact site(s) and the 
protein kinase(s) involved are not known. Certain agonists, including vascular endothelium 
growth factor (VEGF) and insulin, also stimulate nitric oxide production using this 
pathway (Zeng and Quon, 1996; Papapetropoulos et al., 1997; Fulton et al., 1999; Fleming 
et al., 2001).  
 
    Moreover, agonist-induced EDRF is more resistant to destruction by superoxide anion 
(O-2) than the basal EDRF (Mian and Martin, 1995). Further evidence that agonist-induced 
EDRF activity is resistant to destruction by superoxide anion has been reported in the 
rabbit aorta (Furchgott et al., 1994). These workers proposed that the identity of EDRF 
changed during stimulation with acetylcholine, such that it was resistant to destruction by 
superoxide anion immediately after activation, but became sensitive to destruction after 3-4 
minutes of stimulation. 
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Mechanisms of action of nitric oxide 
 The majority of the signalling actions of nitric oxide are produced by stimulation of the 
soluble isoform of guanylate cyclase (sGC) (Hobbs et al., 1999). The combination between 
nitric oxide and the enzyme's heme subunit results in structural changes that enhance the 
action of this enzyme about 400-fold and leads to the formation of intracellular second 
messenger, cGMP (Figure 1.3). The latter catalyse the activation of protein kinase G and 
results in a series of phosphorylation steps (Ignarro and Kadowitz, 1985; Waldman and 
Murad, 1987). Myosin light chain kinase is phosphorylated, thus preventing its activation 
by the calcium-calmodulin complex. Furthermore, calcium mobilisation in the smooth 
muscle cells is blocked through inhibition of calcium release by the inositol trisphosphate 
(IP3) mechanism, together with inhibition of calcium influx through the voltage-gated (L-
type) and store-operated calcium channels. As a result, phosphorylation of myosin light 
chains is inhibited, diminishing smooth muscle tone and causing dilatation of blood 
vessels. 
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Figure 1.3. Mechanisms of action of nitric oxide and prostacyclin in vascular smooth 
muscle and blood platelets (Modified from Jerca et al., 2002).  
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  In contrast to the effects of low concentrations of nitric oxide used as a signalling agent, 
high concentrations produced following induction of iNOS have different cellular targets 
that result in cytotoxic and cytostatic actions. In high concentrations, nitric oxide can result 
in constant suppression of the actions of certain enzymes such as complex I and complex II 
of the mitochondrial electron transport chain which is considered as a mechanism of 
macrophage-derived cytotoxicity (Nathan & Hibbs, 1991; Davis et al., 2001). Also, nitric 
oxide can slow down the action of ribonucleotide reductase, which is a regulatory enzyme 
in DNA synthesis. These actions of high concentrations cause nitric oxide to be cytotoxic 
or cytostatic to rapidly dividing cells or to invading microorganism (Figure 1.4). In 
addition, nitric oxide interacts with superoxide anion to yield the potent oxidant, 
peroxynitrite (Davis et al., 2001; Pacher et al., 2007). This agent can cause structural and, 
as a consequence, physiological injuries by nitrating and oxidising biological molecules 
such as proteins, lipids and nucleic acids.  
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Figure 1.4. Summary of the targets of nitric oxide, the direct effects of nitric oxide (A) are 
frequently produced at low concentrations of nitric oxide, whereas the indirect effects (B) 
are produced at high concentrations of nitric oxide (Modified from Davis et al., 2001). 
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The vascular endothelium and cardiovascular disease 
 
  The normal, healthy vascular endothelium plays a critical role in maintaining vascular 
homeostasis. Generally, this is achieved, as stated above, through maintaining the 
equilibrium between the productions of endothelium-derived relaxing and contracting 
factors, and between the coagulation and fibrinolytic systems in addition to regulating 
inflammatory reactions (Vanhoutte, 1989; Celemajer, 1997; Sader and Celemajer, 2002; 
Widlansky et al., 2003; Galley, et al. 2004; Flammer and Lüscher, 2010).  
 
  However, in the presence of cardiovascular risk factors, whether the conventional ones 
such as age, cigarette smoking, dyslipidaemia, hypertension and hyperglycaemia, or the 
more recently recognized ones such as obesity, reduced physical activity and chronic 
systemic infections, a long-lasting inflammatory process starts in the vascular endothelium 
that eventually disturbs vascular homeostasis (Sorensen et al., 1994; Steinberg et al., 1996; 
Libby et al., 2002; Prasad et al., 2002; Widlansky et al., 2003; Flammer and Lüscher, 
2010). As a result, the endothelium-dependent release of vasoconstricting and pro-
coagulant factors exceeds that of relaxing and anti-thrombotic ones. In addition, there is an 
abnormal increase in the expression of adhesion molecules and release of chemotactic 
factors and inflammatory mediators that promote adhesion of inflammatory cells, such as 
monocytes and lymphocytes, to endothelial cells and their subsequent migration into the 
vessel wall, the formation of foam cells (lipid-laden macrophages) and proliferation as well 
as migration of vascular smooth muscle cells. Finally, these events lead to the development 
of an atherosclerotic plaque. In addition, oxidative stress due to increased formation of 
reactive oxygen species (ROS) such as superoxide anion (O-2) or hydroxyl radical (HO˙) 
play a major role in the development of endothelial dysfunction; the former by destroying, 
and thus reducing the bioavailability of nitric oxide, and/or by the formation of 
 21
peroxynitrite (ONOO¯ ) that oxidatively damages the intracellular macromolecules such as 
DNA or enzymes responsible for maintaining cellular physiology. Moreover, pathological 
conditions that may be caused by, or result from, impaired function of the vascular 
endothelium, such as renal dysfunction, systemic hypertension, atherosclerosis and 
pregnancy-induced hypertension, are associated with increased production of ROS 
(Winquist et al., 1984; Oyama et al., 1986; Lockette et al., 1986; Durante et al., 1988; Cai 
and Harrison, 2000). Furthermore, inactivation of nitric oxide can also be induced by lipid 
radicals that are formed in the process of lipid oxidation and formation of oxidised low 
density lipoproteins (Tanner et al., 1991; Freeman et al., 1997; Cai and Harrison, 2000).      
 
  In addition, it was found that circulating concentrations of the endogenous inhibitor of 
endothelial nitric oxide synthase, asymmetric dimethylarginine (ADMA), increase in 
patients with pathological conditions that may be caused by, or result from, endothelial 
dysfunction such as renal dysfunction, systemic hypertension, atherosclerosis and 
pregnancy-induced hypertension (Vallance et al., 1992; Böger et al., 1998; Miyazaki et al., 
1999; Kielstein et al., 1999; Böger 2003; Leiper and Vallance, 2006; Siroen et al., 2006; 
Andersshon et al 2010). These high concentrations may be due to increased production, 
diminished catabolism or impaired excretion of this inhibitor secondary to vascular 
endothelial dysfunction. Moreover, these high concentrations of ADMA further inhibit the 
bioavailability of nitric oxide and add to the burden created by the dysfunctional 
endothelium.   
 Modulation of nitric oxide bioactivity 
  Modulation of nitric oxide activity in the body underlies the ability of many drugs to 
provide clinical benefit in a number of pathologies including inflammation, sexual 
dysfunction and cardiovascular disease (Napoli and Ignarro, 2003). Indeed, a number of 
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traditionally used and recently introduced medicines act wholly or partly by modifying the 
nitric oxide signalling pathway. Such agents include: 
Agents that enhance nitric oxide bioactivity 
 Superoxide dismutase 
  The main source of intracellular superoxide anions is the mitochondria through the 
respiratory chain enzymes (Yurkov et al., 2003). This generation process is enhanced when 
the cellular levels of nitric oxide are sufficient to inactivate mitochondrial enzymes such as 
cytochrome oxidase and NADH cytochrome c reductase (Poderoso et al., 1996). However, 
there are other generators of superoxide anion such as aldehyde oxidase, peroxidases, 
catecholamines and xanthine oxidase (Kerr et al., 1999). More recently, NADPH oxidase 
present on both endothelial and smooth muscle membranes has been implicated in the 
superoxide-mediated destruction of nitric oxide in a number of cardiovascular pathologies 
(Rajagopalan et al., 1996).  
  
   Interestingly, it has been demonstrated that when the cells are deprived of L-arginine, the 
substrate for NOS, or the cofactor BH4, NOS shifts from production of nitric oxide to 
superoxide anion (Pou et al., 1992; Xia et al., 1996; Pou et al., 1999; Rosen et al., 2002). 
Under such conditions, NOS becomes uncoupled such that the electrons supplied by 
NADPH are now used to reduce the co-substrate O2 to form superoxide anion (O-2).  
 
   One of the important pharmacological tools used so far to combat the destructive effects 
of O-2 against NO is the enzyme superoxide dismutase (SOD) (Gryglewski et al., 1986; 
Rubanyi and Vanhoutte, 1986; Martin et al., 1994; Mian and Martin, 1995; MacKenzie et 
al., 1999) and this protective effect of SOD extends to nitric oxide produced by the 
vascular endothelial cells and nitrergic nerves i.e. nitric oxide synthesised by eNOS and 
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nNOS, respectively. The proposed mechanism behind the protective action of SOD 
involves an oxidation-reduction (with the consumption of hydrogen ions) reaction that 
converts O-2 into hydrogen peroxide (H2O2) with the liberation of molecular oxygen 
(Fridovich, 1983).  
 
  Excessive formation of superoxide anions diminishes the bioavailability of NO and 
results in dysfunctional vascular endothelium. The latter is associated with a spectrum of 
pathological conditions such as diabetes mellitus, hypertension, ischaemic heart disease 
and atherosclerosis (Mohan and Das, 1997; Laight et al., 1998; MacKenzie et al., 1999). 
As a consequence, by scavenging superoxide anions, SOD represents a potential 
therapeutic intervention in the management of such pathophysiological conditions.   
 
   In addition to its usefulness in situations of oxidative stress, SOD induces endothelium-
dependent, nitric oxide-mediated relaxation in healthy blood vessels; an effect that is 
attributed to its ability to protect basal nitric oxide from destruction by superoxide anions 
produced by vascular endothelial cells under physiological circumstances (Gryglewski et 
al., 1986; Rubanyi and Vanhoutte, 1986; Ohlstein and Nichols, 1989; Mian and Martin 
1995; MacKenzie et al., 1999). However, in light of the mechanism of action of SOD, 
relaxation induced by SOD seems to have two distinct components; the first through 
protection of basal NO activity from destruction by superoxide anions. This pathway is 
sensitive to blockade by nitric oxide synthase inhibitors, such as L-NAME and L-NMMA 
(Palmer et al., 1988; Rees et al., 1989; Aisaka et al., 1989; Rees et al., 1990; Moore et al., 
1990; Hobbs et al., 1999; Masuda et al., 2002). The second mechanism is through 
production of hydrogen peroxide as a result of dismutating superoxide anion. Hydrogen 
peroxide induces both endothelium-dependent and endothelium-independent relaxations 
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and this pathway is inhibited by catalase (Rubanyi and Vanhoutte, 1986; Furchgott et al., 
1994; Yang et al., 1999; Iesaki et al., 1999; Itoh et al., 2003).          
Phosphodiesterase (PDE) inhibitors   
  There are eleven isoforms of PDE enzyme (Beavo, 1995) whose main intracellular action 
is to hydrolyse and thereby curtail the actions of the second messengers, cyclic AMP 
(cAMP) and cyclic GMP (cGMP). PDE 5 and 6 selectively degrade cGMP (Beavo et al., 
1994); PDE 3 and 4 are responsible for the decomposition of cAMP, while PDE 1 and 2 
can degrade both cyclic nucleotides. 
  Zaprinast was the first agent developed with PDE 5 inhibitory activity, but it lacked the 
selectivity and potency to reach the clinic (Ballard et al., 1998). Another example is 
sildenafil (Viagra) which is currently used for the treatment of erectile dysfunction. It is a 
very effective and selective inhibitor of PDE 5 that is highly expressed in human penile 
smooth muscle. Thus, it potentiates the actions of nitric oxide by preventing the 
degradation of its second messenger cGMP (Sakuma et al., 2002; Rossoni et al., 2007). 
  Tadalafil and vardenafil are two more recent examples of PDE 5 inhibitors used to treat 
erectile dysfunction (Porst, 2002; Pryor, 2002; Kindirci et al., 2004). These have a longer 
biological half-life than sildenafil, and may therefore have improved therapeutic 
usefulness. There has been renewed interest in the use of PDE inhibitors to treat 
cardiovascular diseases resulting from impaired nitric oxide activity. Indeed, PDE 5 
inhibitors may have utility in the treatment of pulmonary hypertension (Michelakis et al., 
2002; Guazzi et al., 2004).     
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Angiotensin-converting enzyme (ACE) inhibitors  
  Pharmacological compounds that inhibit the rennin-angiotensin-aldosterone axis can 
indirectly influence the actions of nitric oxide in more than one way. Since ACE is the 
principle enzyme responsible for the catabolism of bradykinin, ACE inhibitors can enhance 
the nitric oxide -releasing actions of the peptide (Taylor-McCabe et al., 2001). Moreover, 
by reducing angiotensin ІІ-mediated formation of superoxide anion by NADPH oxidase, 
ACE inhibitors indirectly prolong the half-life and actions of NO (Rajagopalan et al., 
1996; Mancini et al., 1996).  
Statins   
  The main indication of the 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) 
reductase inhibiting agents (statins) is to lower the blood cholesterol levels (Shepherd et 
al., 1995). However, it has been shown that these agents can increase the expression of 
NOS in the endothelial cells and exhibit anti-oxidant effects, even without altering the 
level of cholesterol in the blood. In addition, they can inhibit the increase in vascular tone 
due to reduced expression of eNOS in response to hypoxia (Laufs et al., 1997; Wilson et 
al., 2001; Filusch et al., 2008; Rossoni et al., 2008). Furthermore, randomised clinical 
trials showed that the administration of statins to patients with clinically evident 
atherosclerotic coronary artery disease produced an improvement of coronary arterial tone 
(Anderson et al., 1995; Treasure et al., 1995).  
Nitric oxide donors  
  These are pharmacologically effective agents that are able to donate nitric oxide in vivo or 
in vitro (Napoli and Ignarro, 2003).These agents are sub-categorised into: 
 
 
 26
Nitric oxide itself  
  Nitric oxide gas has a role in aiding respiration in premature infants and in adults with 
respiratory distress syndrome (ARDS). However, the use of NO gas has been restricted to 
the inhalational route of administration due to its limited half-life and quick interaction 
with molecular oxygen (Ignarro et al., 2002).  
Nitric oxide donors requiring metabolism    
  These agents need to be biotransformed by body enzymes to donate nitric oxide. They 
include nitroglycerine, amyl nitrite, isosorbide dinitrate, isosorbide mononitrate and 
nicorandil. These agents represent the classical type of nitric oxide substitution treatment 
and are commonly employed for the treatment of angina pectoris. Although highly 
effective, this category of drugs has limiting side effects such as the development of 
tolerance and haemodynamic adverse actions such as headache (Ignarro et al., 2002). On 
the other hand, sodium nitroprusside, a different class of nitric oxide donor, is indicated for 
the management of acute hypertensive crisis. The advantages of this medication are 
narrowed by its drawbacks of being active only parenterally and, following continuous 
therapy, the possibility of thiocyanate poisoning and the development of tolerance 
(Gruetter et al., 1981; Ignarro et al., 2002).  
Hybrid NO donors   
  These drugs are generated by adding functional NO-releasing groups, namely, nitrate 
esters and S-nitrosothiols groups to pharmacological compounds that are already in use 
without altering the therapeutic effectiveness of the principal drug (Ignarro et al., 2002). 
Nitrosocaptopril is an S-nitrosylated analogue of captopril, a vasodilator, angiotensin-
converting enzyme inhibitor and anti-thrombotic drug (Loscalzo et al., 1989). The blood 
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pressure-lowering actions of the ACE inhibitor are augmented by the vasodilatory actions 
of nitric oxide. 
  Nitric oxide -releasing non-steroidal anti-inflammatory drugs (NONSAIDs) such as nitric 
oxide-aspirin represent another class of hybrid nitric oxide donors. These agents have the 
same anti-inflammatory actions of traditional NSAIDs, but the nitric oxide releasing group 
reduces the incidence of gastric ulceration (Wallace et al., 1997). 
Agents that inhibit nitric oxide bioactivity 
 
Inhibitors of soluble guanylate cyclase  
  The majority of signalling actions of nitric oxide are mediated by its combination with the 
heme group of the soluble guanylate cyclase enzyme (Hobbs et al., 1999). This was 
confirmed by use of methylene blue (Gruetter et al., 1981; Martin et al., 1985), or the 
chemical agent 1H- [1, 2, 4] oxadiazolo [4, 3,-a] quinoxalin-1-one (ODQ) (Moro et al., 
1996; Toda and Toda, 2011), both of which inhibit the enzyme by oxidising its critical 
ferrous (Fe2+ ) haem group to the ferric (Fe3+) form.  
  
Agents that destroy nitric oxide e.g. superoxide anion  
   The different routes of superoxide anion (O-2) formation are discussed above. This free 
radical reacts with nitric oxide at a rate (7*109 M-1 s-1) that is somewhat faster than the rate 
(2*109 M-1 s-1) of its reaction with superoxide dismutase (Pryor & Squadrito, 1995; 
MacKenzie et al., 1999; Toda and Toda, 2011). This rapid, favourable reaction leads to the 
loss of biological activity of nitric oxide and the production of the damaging oxidant, 
peroxynitrite.   
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Inhibitors of nitric oxide synthesis  
 
The flavoprotein inhibitors 
  These agents, such as diphenylene iodonium (DPI), inhibit the NADPH-dependent 
flavoprotein (FAD) which is one of the important cofactors for the synthesis of nitric oxide 
(Stuehr et al., 1991). The inhibition of NOS by these agents is irreversible in a way that 
neither NADPH nor FAD is able to restore the action of NOS.  
 
The calmodulin inhibitors 
   These agents, such as calmidazolium and W 70, have the ability to inhibit the activity of 
constitutive NOS in the endothelial and neuronal cells but not the inducible NOS (Archer 
and Cowan, 1991; Schini and Vanhoutte, 1992). They therefore exert a degree of isoform 
selectivity.   
 
Isoform selective inhibitors 
 
  Isoform selective inhibitors are useful tools for exploring the role of the different 
isoforms in different physiological or pathological functions. For example, in cerebral 
ischaemia (stroke) there is an enhanced stimulation of nNOS as a result of glutamate 
release, which results in the formation of high amounts of nitric oxide (Zhang & Snyder, 
1995). This neuronal nitric oxide seems to augment neurotoxicity. Thus the use of nNOS 
selective inhibitors like 7-nitroindazole or NG-propyl-L-arginine have the potential to block 
this neurotoxicity, whereas non-selective inhibitors would have inhibited eNOS and nNOS 
and led to exacerbation of cerebral damage by further reducing blood supply to the brain 
(Dawson et al., 1991; Zhang & Snyder, 1995; Toda and Okamura, 2003; Toda et al., 
2009).  
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   Moreover, selective inhibitors of iNOS, such as 1-amino-2-hydroxy-guanidine (Wu et al., 
1995), have been shown to modulate the haemodynamic changes encountered in animal 
models of endotoxaemia. This indicates that these agents may have usefulness in the 
management of septic shock.     
 
Inhibitors of NOS expression e.g. corticosteroids  
 
  It is well established that the vascular endothelial cells, smooth muscle cells, immune 
cells or other cell types express the inducible isoform of nitric oxide synthase (iNOS) when 
these cells are exposed for several hours to inflammatory mediators such as interferon-γ 
(INF-γ), or the bacterial cell wall component, lipopolysaccharide (LPS), whether in 
experimental settings or in vivo, e.g. in inflammatory bowel diseases or septicaemia 
(Radomski et al., 1990; McCall et al., 1991; Saura et al., 1995; Simmons et al., 1996; 
Linehan et al., 2004). In addition, when this enzyme is induced, it is capable of producing 
copious amounts of nitric oxide hence the precipitous fall in blood pressure seen in septic 
shock. One of the therapeutic strategies employed in septic shock and inflammatory bowel 
diseases is the administration of anti-inflammatory glucocorticoids such as hydrocortisone 
and dexamethasone (Radomski et al., 1990; McCall et al., 1991; Saura et al., 1995; 
Simmons et al., 1996). These therapeutic agents are known to block the synthesis of 
proteins whose expression is induced in response to inflammatory mediators, such as 
iNOS. However, the precise molecular mechanism behind the effects of these drugs may 
be more complex, as more than one mechanism is implicated. For example, some 
researchers concluded that the glucocorticoids, hydrocortisone and dexamethasone, 
inhibited in a receptor-mediated mechanism(s) the expression of iNOS, but they did not 
exert a direct blocking action on functionality of the enzyme (Radomski et al., 1990). This 
blocking action of glucocorticoids is inhibited in a concentration-dependent manner by 
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cortexolone, a partial agonist of glucocorticoid receptors. Other researchers proposed that 
dexamethasone might have blocked the expression of iNOS directly or, indirectly, by 
inhibiting the production and/or action of the inflammatory cytokines implicated in 
inducing its expression (McCall et al., 1991). In agreement with this finding, Linehan and 
co-workers (2004) concluded that the therapeutic effectiveness of the corticosteroids, 
prednisolone and budesonide, in the treatment of inflammatory bowel diseases such as 
colitis, is attributed to their ability to inhibit the formation of inflammatory mediators, such 
as IL-1, IL-12, TNF-α and  prostaglandins, that are implicated in the induction of iNOS 
expression. However, another group of researchers reported that dexamethasone directly 
blocks both of the expression and functionality of the enzyme as a result of inhibition of 
the nuclear transcription factor, NF-κB, which controls the expression of iNOS (Saura et 
al., 1995). Moreover, a reduction in the accessibility of L-arginine and the cofactor, BH4  
for iNOS has been proposed to be the mechanism by which dexamethasone inhibits the 
activity of the enzyme in cytokine-induced endothelial cells of the cardiac 
microvasculature (Simmons et al., 1996). Steroids have no effect on expression or activity 
of eNOS or nNOS (Radomski et al., 1990).   
 
The guanidino (NG)-substituted analogues of L-arginine 
  In view of the finding that it is one of the equivalent guanidino nitrogens of L-arginine 
that is incorporated into nitric oxide (Yokoi et al., 1994), the earliest inhibitors of NOS 
were the guanidino (NG)-substituted analogues of L-arginine (Rees et al., 1989, 1990; 
Moore et al., 1990; Hobbs et al., 1999; Toda and Toda, 2011):  
 
NG-monomethyl-L-arginine (L-NMMA) 
NG-nitro-L-arginine (L-NOARG) 
NG –nitro-L-arginine methyl ester (L-NAME)        
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  These agents (Figure 1.5) are generally accepted to act as conventional competitive, 
reversible inhibitors of nitric oxide synthase, as it is possible to prevent or reverse their 
inhibitory effects by adding increasing concentrations of the endogenous substrate for 
nitric oxide synthase, L-arginine (Palmer et al., 1988). However, the use of these inhibitors 
has been almost entirely restricted to laboratory work where they are employed to 
investigate the importance of the L-arginine-nitric oxide pathway in the living body. This 
is probably because these agents indiscriminately block all the three isoforms of nitric 
oxide synthase which is perhaps not ideal for a potential therapeutic agent (Moncada et al., 
1991; Nathan, 1992). These agents are also stereo-selective, i.e. the D-isomer, for example 
D-NMMA is inactive and the effects of the active L-isomer inhibitors can be prevented or 
reversed by L-arginine but not D-arginine (Palmer et al., 1988). However, the ability of L-
arginine to reverse the blocking actions of these nitric oxide synthase inhibitors seems to 
be governed by the animal species, the vascular bed of interest and/or the inhibitor in 
question (Randall and Griffith, 1991). For example, in the rat aorta L-arginine was able to 
reverse the blockade of endothelium-dependent, acetylcholine-induced relaxation produced 
by L-NORG, 30 µM, but not that produced by 100 µM of the same inhibitor in the same 
tissue (Moore et al., 1990; Unmans, 1990). Moreover, L-arginine was only able to partially 
reverse the vasopressor effects induced by L-NOARG in the anaesthetised guinea pig, 
whereas those induced by L-NMMA were fully reversed (Steinberg et al., 1990). 
Furthermore, in the rabbit ear vascular bed, L-NAME produced a powerful blockade of 
basal as well as acetylcholine-induced nitric oxide activity, however, L-arginine was only 
able to reverse blockade of the former (Randall and Griffith, 1991). The authors attributed 
these findings to the possible mechanism behind nitric oxide production under basal and 
agonist-stimulated circumstances.    
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L-arginine
L-NMMA
L-NAME
L-NOARG
 
 
Figure 1.5. Structures of L-arginine and its guanidino (NG)-substituted analogues used as 
inhibitors of nitric oxide synthase (Modified from Rees et al., 1990). 
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Endogenous inhibitors of NOS (Endogenous guanidino (NG)-substituted analogues of 
L-arginine)      
   Figure 1.6 shows the three examples of endogenous guanidino (NG)-substituted 
analogues of L-arginine: NG-monomethylarginine (L-NMMA), NGNG- asymmetric 
dimethylarginine (ADMA) and NGN' G-symmetric dimethylarginine (SDMA). These 
compounds are produced by adding methyl groups from methionine to the arginine 
guanidino nitrogens in proteins. This posttranslational adjustment, which takes place in the 
nucleus, is regulated by enzymes known as protein arginine methyltransferases (PRMT) 
(McBride & Silver, 2001; Vallance et al., 1992; Siroen et al., 2006; Leiper and Vallance, 
2006). While ADMA and SDMA are synthesised by PRMT type 1 and type 2, 
respectively, L-NMMA can be synthesised by either type. The quantity of methylarginines 
produced is proportional to the level of arginine methylation in protein as well as to the 
rate of proteolysis, because these inhibitors are secreted into the plasma after proteolysis 
(Siroen et al., 2006).  
 
   ADMA is considered to be the major endogenous inhibitor of nitric oxide synthase 
(Vallance and Leiper, 2004; Siroen et al., 2006; Colonna et al., 2007; Anderssohn et al., 
2010), because under normal conditions the circulating concentration of ADMA (0.68 µM) 
is higher than that of L-NMMA (0.11 µM) and because SDMA does not appear to be a 
competitive inhibitor of nitric oxide synthase (Vallance et al., 1992; Sydow and Münzel, 
2003; Linz et al., 2012). Furthermore, it was found that circulating concentrations of 
ADMA increase in patients with renal dysfunction (Vallance et al., 1992; Kielstein et al., 
1999) and in other pathological conditions that may be caused by, or result from, impaired 
function of the vascular endothelium, such as systemic hypertension, atherosclerosis and 
pregnancy-induced hypertension (Böger et al., 1998; Miyazaki et al., 1999; Böger 2003; 
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Leiper and Vallance, 2006; Siroen et al., 2006; Andersshon et al 2010). In addition, high 
plasma levels of ADMA were found to be positively correlated with the manifestations of 
insulin resistance syndrome, and drugs that recover insulin sensitivity, e.g. the PPARγ 
agonist, rosiglitazone, also restored plasma levels of ADMA (Stühlinger et al., 2002). 
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Figure 1.6. Methylation of arginine residues within the context of a protein requires the 
methyl donor, S-adenosyl methionine (AdoMet), which is converted, into S-adenosyl 
homocysteine (AdoHcy) (McBride & Silver, 2001). 
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Differential actions of L-NMMA on basal and agonist-induced activity of NO 
 
   Although generally regarded as a classical competitive inhibitor of nitric oxide synthase 
(Rees et al., 1989, 1990; Hobbs et al., 1999; Moore et al., 1990; Vallance et al., 1992; 
Leiper and Vallance, 2006), some findings with L-NMMA appear to be inconsistent with 
this view. For example, L-NMMA has been found to act as a “mechanism-based” 
insurmountable inhibitor of, and an alternative substrate for iNOS in murine macrophages; 
it is converted to produce N-methyl-N-hydroxy-L-arginine, which tends to irreversibly 
inhibit the enzyme (Olken, 1991; Feldman et al., 1993; Olken and Marletta, 1993).  
Moreover, in a different study, L-NMMA stimulated the production of superoxide anion by 
nNOS (Pou et al., 1999). This study showed that this effect of L-NMMA seems to be not 
due to metabolism of L-NMMA, but due to competitive interaction between L-NMMA and 
L-arginine that prevents the latter from inhibiting superoxide anion production. 
    
   Other studies have reported that L-NMMA does not inhibit nitrergic nerve-mediated 
relaxation in the bovine retractor penis muscle (Martin et al., 1993), or in the bovine penile 
artery (Liu et al., 1991) or ciliary artery (Overend and Martin, 2007), while both L-NAME 
and L-NOARG are effective inhibitors. Quite surprisingly in these tissues, L-NMMA 
seemed to be a better substrate for the formation of nitric oxide, because it was more potent 
than the endogenous substrate, L-arginine, at protecting nitrergic transmission from 
inhibition by L-NAME and L-NOARG. In addition, Cellek and Moncada (1997) 
concluded that, like L-arginine, L-NMMA is able to both prevent and reverse the blockade 
of nitrergic nerve-mediated relaxation induced by L-NORAG in the rabbit anococcygeus 
muscle.     
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 Similar differential actions of L-NMMA have also been reported in blood vessels from 
other species. For example, while L-NMMA blocked acetylcholine-induced relaxation in 
rabbit aorta (Rees et al., 1989), it did not do so in rat aorta, although it did inhibit the basal 
activity of nitric oxide which exerts a powerful tonic vasodilator influence that opposes 
vasoconstriction in this tissue (Frew et al., 1993). In that study the inhibition of basal nitric 
oxide activity by L-NMMA was prevented by L-arginine. In contrast, L-NMMA behaved 
similarly to L-arginine in protecting acetylcholine- and ATP-induced relaxation from 
blockade by L-NOARG. Moreover, in rat aorta and pulmonary artery, L-NMMA behaved 
similarly to L-arginine, where both agents augmented nitric oxide production, assessed 
using a chemiluminescence assay, whereas L-NOARG produced the anticipated blockade 
of nitric oxide synthesis (Archer and Hampl, 1992). Thus, in rat aorta, L-NMMA has the 
curious effect of blocking basal nitric oxide activity in an L-arginine-reversible manner yet 
acts like L-arginine in preventing blockade of agonist-stimulated activity of nitric oxide by 
L-NOARG.  
 
Differential actions of ADMA on basal and agonist-induced activity of NO 
 
  The short-term actions of ADMA are thought to be achieved by blocking the enzymatic 
activity of NOS and, in turn, inhibiting nitric oxide production by the vascular 
endothelium. Such effects were restored by L-arginine, but not D-arginine (Vallance et al., 
1992; Cooke et al., 1997; Moncada & Higgs, 2002). 
  
   However, the correlation between elevated plasma levels of ADMA seen in various 
clinical conditions (Kielstein et al., 1999; Zoccali et al., 2002; Böger 2003) suggests that 
there are mechanisms other than simple inhibition of NOS that underlie the 
pharmacological actions of ADMA. 
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   For example, Suda and co-workers (2004) suggested that some of the long-term vascular 
effects of ADMA might be mediated via AT1 receptor activation, as they demonstrated that 
long-term administration of ADMA resulted in up-regulation of vascular ACE and 
enhanced the formation of superoxide anion in both wild-type and eNOS-knockout mice. 
Furthermore, they found that formation of both vascular and systemic nitric oxide was not 
affected by administration of ADMA and these effects of ADMA were not blocked by L-
arginine. In addition, blockade of ACE or the AT1 receptor abolished superoxide anion 
synthesis and the associated vascular actions of ADMA. 
 
   It is well-known that chronic administration of angiotensin II enhances the activity of 
vascular NADPH oxidases (Griendling et al., 1994) and most of the superoxide anion 
produced in blood vessels is through this pathway. These effects of angiotensin II are 
blocked by the AT1 blocker losartan. More recently, Veresh and co-workers (2008) found 
that ADMA decreased basal arteriolar diameter and blocked the arteriolar dilatation in 
response to flow in rat skeletal muscle arterioles. These actions of ADMA were found to 
be inhibited by the ACE inhibitor, quinalapril, the AT1 receptor blocker, losartan, the 
superoxide scavenger, superoxide dismutase, and by the inhibitor of NADPH oxidase, 
apocynin. As a result, the authors concluded that high concentrations of ADMA stimulate 
the RAS in the vascular wall, which in turn enhances the formation of angiotensin II and 
the latter stimulates the NAD(P)H oxidase pathway. The resultant production of 
superoxide anion reduces the biological activity of nitric oxide (Figure 1.7). 
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Figure 1.7. Proposed mechanisms by which ADMA induces oxidative stress and 
vasomotor dysfunction (Modified from Veresh et al., 2008).  
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   The structural similarities between ADMA and L-NMMA may suggest that these two 
NOS inhibitors share similar actions mediated by the same mechanisms. Both these 
substituted L-arginine analogues are asymmetric in terms of the distribution of methyl 
group(s) around nitrogen atoms such that the single methyl group of L-NMMA and the two 
groups of ADMA are attached to one of the two guanidino nitrogen atoms of L-arginine 
(Leiper and Vallance, 1999; Kielstein et al., 2007). As a result, and in view of the finding 
that it is one of the equivalent guanidino nitrogens of L-arginine that is incorporated into 
nitric oxide (Yokoi et al., 1994), ADMA might act as an alternative substrate for, and/or a 
“mechanism-based” irreversible inhibitor of, nitric oxide synthase in a way similar to that 
proposed for L-NMMA (Olken, 1991; Feldman et al., 1993; Olken and Marletta, 1993). 
Moreover, similar to L-NMMA (Frew et al., 1993), ADMA may be able to block basal but 
not agonist-stimulated activity of nitric oxide in rat aorta and to protect acetylcholine-
induced relaxation in rat aorta from blockade by L-NAME.   
 
   Thus, both L-NMMA and ADMA, two methylated analogues of L-arginine, exhibit 
anomalous actions that cannot be explained by a simple inhibition of NOS. Some of the 
pharmacology of L-NMMA and ADMA may arise from superoxide formation and some 
may arise from blockade of NOS. This dual pharmacology may explain some of the 
anomalous actions of these two agents.   
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Aim of the study  
   The aim of this study is to seek an explanation for some of the above differential actions 
of L-NMMA and ADMA. In particular, an attempt will be made to determine if a common 
mechanism is responsible for these differential actions of L-NMMA and ADMA. 
 
The specific aims of the study are to: 
 
    1. Determine if previous experiments demonstrating that L-NMMA blocks basal but not 
agonist-stimulated nitric oxide activity in rat aorta (Frew et al., 1993) can be confirmed. 
 
    2. Determine if ADMA, like L-NMMA, blocks basal but not acetylcholine-induced 
nitric oxide activity in rat aorta, and if so, investigate the possible mechanism(s) behind 
these differential abilities.   
 
   It was hoped that these studies would provide an explanation for the seemingly 
differential actions of L-NMMA and ADMA. Those arising from the actions of ADMA 
may be clinically relevant, because this agent is known to accumulate in a growing number 
of pathological conditions.  
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Chapter Two 
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     Introduction 
    Three decades have now elapsed since Furchgott and Zawadzki (1980) first discovered 
that the vascular endothelial cells produce a significant vasodilating agent, endothelium-
derived relaxing factor (EDRF), which subsequent work identified as nitric oxide (Palmer 
et al., 1987).  
 
    The bioactivity of nitric oxide is liable to inhibition by different classes of agents, and 
those of particular interest to this study are the guanidino (NG)-substituted analogues of L-
arginine that act by inhibiting nitric oxide synthase (Rees et al., 1989, 1990; Moore et al., 
1990; Hobbs et al., 1999). The initial representatives of this class were NG- monomethyl-
L-arginine (L-NMMA), NG- nitro-L-arginine (L-NOARG) and NG- nitro-L-arginine 
methyl ester (L-NAME). These agents are generally accepted to act as conventional 
competitive, reversible inhibitors of nitric oxide synthase, as it is possible to prevent or 
reverse their inhibitory effects by adding increasing concentrations of the endogenous 
substrate for nitric oxide synthase, L-arginine (Palmer et al., 1988). However, the use of 
these inhibitors has been almost entirely restricted to laboratory work where they are 
employed to investigate the importance of the L-arginine-nitric oxide pathway in the living 
body. This is probably because these agents indiscriminately block all the three isoforms of 
nitric oxide synthase which is perhaps not ideal for a potential therapeutic agent (Moncada 
et al., 1991; Nathan, 1992).  
 
   The interest in the properties of L-NMMA has increased when it was found that it was 
produced endogenously together with two other methylarginines: NGNG- asymmetric 
dimethylarginine (ADMA) and NGN'G-symmetric dimethylarginine (SDMA). These three 
methylarginines are formed following the breakdown of proteins that had been 
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posttransationally methylated by the enzyme protein arginine methyl transferase (Vallence 
et al., 1992; Siroen et al., 2006; Leiper and Vallence, 2006). In addition, it has been 
reported that the plasma levels of ADMA are raised in pathophysiological conditions that 
are caused by, or result from, vascular endothelial dysfunction (Vallance et al., 1992; 
Böger et al., 1998; Kielstein et al., 1999; Miyazaki et al., 1999; Böger 2003; Leiper and 
Vallence, 2006; Siroen et al., 2006; Andersshon et al 2010).   
 
   Thus, because of the current interest in ADMA as a potential contributor to human 
cardiovascular and other diseases, it seemed important to determine if this methylarginine 
showed some of the paradoxical actions of its closely related analogue, L-NMMA. 
Specifically, the aims of this part of the study were: 
 
• To determine if ADMA, like L-NMMA, blocks basal but not agonist-induced 
activity of nitric oxide in the rat aorta.   
 
• To determine if the blockade of basal activity of nitric oxide induced by ADMA is 
sensitive to reversal by L-arginine, the endogenous substrate for nitric oxide 
synthase.  
 
• To determine if the availability of L-arginine is critical for basal as well as for 
acetylcholine-stimulated release of nitric oxide in the rat aorta. 
 
•  To determine if the level of phenylephrine-induced tone has an influence on 
acetylcholine-induced relaxation in control and ADMA-treated rat aortic rings. 
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• To determine if the choice of the contractile agent used (phenylephrine vs 5-
hydroxytryptamine or PGF2α) has an influence on acetylcholine-induced relaxation 
in control and ADMA-treated rat aortic rings. 
 
• To determine if ADMA, similarly to L-arginine, protects acetylcholine-induced 
relaxation against blockade by L-NAME in the rat aorta.  
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Material and Methods  
 
Preparation of aortic rings  
 
    The preparation of aortic rings was essentially similar to that previously discussed (Al-
Zobaidy et al., 2010). Specifically, female Wistar rats weighing 150-200 g were killed by 
stunning and exsanguination. The descending thoracic aorta was exposed by removing the 
heart and lungs, and excised from just above the diaphragm to just below the aortic arch. 
The vessel was cleared of adhering fat and connective tissue, placed in a Petri dish 
containing Krebs' solution, and cut transversely into 2.5 mm wide rings using a device with 
parallel razor blades. The vessel was handled carefully to avoid unintentional damage to 
the intimal surface. In some experiments, the endothelium was removed from some rings 
by gently rubbing the intimal surface for 30 s with a wooden stick dampened in Krebs' 
solution. Care was taken not to over-stretch the rings during rubbing in order to avoid 
damaging their muscular layer. Endothelial denudation was considered successful if the 
endothelium-dependent vasodilator, acetylcholine (1 µM), failed to produce relaxation.  
 
 Tension recording  
   The aortic rings were mounted under 10 mN resting tension on two stainless steel hooks 
in 10 ml organ baths at 37 ºC. The upper hook was connected with thread to a tension 
transducer and the lower was connected to a rigid bar. The bathing solution was Krebs 
solution composed of (mM): NaCl 118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 24, glucose 11, and continuously gassed with 95% O2 and 5% CO2.  The 
temperature of the solution within the baths was maintained using a water jacket heated by 
a thermostatically controlled pump (Techne, Circulator C-85D). Contractions were 
recorded isometrically with Grass FT03C transducers and responses displayed and 
recorded on a PowerLab (AD Instruments, Hastings, UK). Tissues were allowed to 
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equilibrate for approximately 90 min, before executing experimental protocols, during 
which time the resting tension was re-adjusted to 10 mN when required.  
 
Cumulative concentration-effect curves to phenylephrine and the effects of the 
vascular endothelium on phenylephrine-induced contraction 
   The aims, from performing cumulative concentration-effect curves to phenylephrine in 
female rat endothelium-containing and endothelium-denuded aortic rings, were to 
determine if the contractions produced were concentration-dependent, to obtain the 
maximal response (Emax) and -log EC50 (pEC50), and to assess the vasodepressant effect of 
basal nitric oxide generated by the vascular endothelium on phenylephrine-induced 
contractions.  
 
       In these experiments, endothelium-containing or -denuded aortic rings were allowed to 
equilibrate for 90 min and the resting stretch was re-adjusted to 10 mN, if required. 
Phenylephrine was then added in increasing concentrations to the tissues in the organ baths 
using the sequence 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 µM, 3 µM and 10 µM, 
without washing out after each concentration. Each successive concentration of 
phenylephrine was added after stabilisation of tone produced by the preceding 
concentration. When the point was reached that the next concentration of phenylephrine 
failed to produce a further increment in tone, it was concluded that the maximal response 
to phenylephrine had been achieved. The drug was then either washed out to conduct 
another concentration-response curve, or papaverine (300 µM) was added to produce full 
relaxation of the tissues.     
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Cumulative concentration-effect curves to acetylcholine and the effects of the 
vascular endothelium on acetylcholine-induced relaxation 
   The aims, from performing cumulative concentration-effects curves to acetylcholine in 
female rat endothelium-containing and endothelium-denuded aortic rings, were to 
determine if relaxations were concentration-dependent, to obtain the  maximal response 
(Emax) and -log EC50 (pEC50), and to assess the endothelium-dependence of the relaxations 
produced.    
  
     In these experiments, endothelium-containing or -denuded aortic rings were allowed to 
equilibrate for 90 min and the resting stretch re-adjusted to 10 mN, if required. Tissues 
were precontracted to ~50% of maximal tone using phenylephrine (100-300 nM). After 
stabilisation of phenylephrine-induced tone, increasing concentrations of acetylcholine (1 
nM-10 µM) were added to the tissues in the organ baths using the sequence 1 nM, 3 nM, 
10 nM, 30 nM, 100 nM, 300 nM, 1 µM, 3 µM and 10 µM, without washing out after each 
concentration. Each successive concentration of acetylcholine was added after relaxation to 
the preceding concentration had maximised. When the point was reached that the next 
concentration of acetylcholine did not produce further relaxation, it was concluded that the 
maximal response to acetylcholine had been achieved. The drug was then either washed 
out to conduct another concentration-response curve, or papaverine (300 µM) was added to 
produce full relaxation of the tissues.      
 
The effect of L-arginine on basal nitric oxide activity 
   The rationale for conducting these experiments was to assess if the availability of L-
arginine, the endogenous substrate for nitric oxide synthase (Palmer et al., 1988; Schmidt 
et al., 1988), was limiting for production of the basal nitric oxide activity that suppresses 
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vasoconstrictor tone (Martin et al., 1986b; Moore et al., 1990; Rees et al., 1989; Mian & 
Martin, 1995). If the availability of L-arginine was limiting, it was expected that its 
addition would result in a fall in phenylephrine-induced tone.  
 
   The approach employed in these experiments involved induction of intermediate (10.7 ± 
1.0 mN) phenylephrine (50-70 nM) tone in female rat endothelium-containing aortic rings. 
After stabilisation of tone, L-arginine (10 mM, 1 h) was added to the tissues in the organ 
baths and its effects on tone assessed. Time-matched controls were treated with the solvent 
(0.9% normal saline solution) used in the preparation of L-arginine. 
 
The effect of L-arginine on acetylcholine-induced relaxation   
   The rationale for conducting these experiments was to assess if the availability of L-
arginine, the endogenous substrate for nitric oxide synthase, is limiting for the production 
of nitric oxide stimulated by acetylcholine. If the availability of L-arginine was limiting, it 
was expected that its addition would potentiate acetylcholine-induced relaxation.  
 
  In these experiments, control female rat endothelium-containing aortic rings and rings 
treated with L-arginine (10 mM, 1 h) were precontracted to ~50% of maximal 
phenylephrine tone. After stabilisation of tone, a full cumulative concentration-response 
curve to acetylcholine (1 nM-10 µM) was conducted as indicated previously. When the 
maximal response to acetylcholine had been achieved, the drug was then either washed out 
to conduct another concentration-response curve, or papaverine (300 µM) was added to 
produce full relaxation of tissues.     
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Effects of nitric oxide synthase inhibitors on basal nitric oxide activity 
  Basal activity of nitric oxide generated by the vascular endothelium exerts a tonic 
vasodilator effect that suppresses the actions of vasoconstrictor drugs (Martin et al., 1986b; 
Moore et al., 1990; Rees et al., 1989; Mian & Martin, 1995). As a result, agents that reduce 
the synthesis or actions of nitric oxide produce an enhancement of vasoconstrictor-induced 
tone by removing this endothelium-dependent suppression of vasoconstriction. Therefore, 
the aim of these experiments was to investigate the effects of nitric oxide synthase 
inhibitors on basal nitric oxide activity by assessing their ability to enhance phenylephrine-
induced contraction in female rat endothelium-containing aortic rings.   
 
   In these experiments two strategies were employed. In the first strategy, blockade of 
basal nitric oxide activity was assessed by measuring the enhancement of phenylephrine-
induced tone observed following the addition of nitric oxide synthase inhibitors to female 
rat endothelium-containing aortic rings. In these experiment, after the tissues had 
equilibrated and the resting stretch was re-adjusted to 10 mN, a low-level (~2–5 mN) tone 
was induced with phenylephrine (60 nM). After the tone had stabilised, the tissues were 
treated with L-NMMA, L-NAME, ADMA (all at 100 µM) or SDMA (1 mM) with the 
resulting enhancement of tone measured after 1 h. 
 
   In another experiment in this series, the ability of a range of concentrations of ADMA 
(0.3-300 µM) to enhance low-level phenylephrine-induced tone was assessed. The 
threshold concentration of ADMA, its pEC50 and the concentration producing maximal 
enhancement of
 
phenylephrine-induced tone were determined.  
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   In the second strategy, blockade of basal nitric oxide activity was evaluated by 
measuring the augmentation of phenylephrine-induced contractions occurring in female rat 
endothelium-containing aortic rings that had been pre-treated with the nitric oxide synthase 
inhibitors 1 h prior to constructing a cumulative concentration-effect curve to 
phenylephrine (1 nM-10 µM), when compared with time-matched controls.  
  Using this same approach, the concentration-dependent ability of ADMA to block basal 
nitric oxide activity in female rat aorta was also investigated. In these experiments, ADMA 
was added at three different concentrations (100, 300 and 1000 µM) for 1 h before 
performing a full concentration-response curve to phenylephrine (1 nM-10 µM).  
 
   This protocol was also employed to investigate the endothelium-dependent ability of 
ADMA to block basal nitric oxide activity in female rat aorta. In these experiments, 
endothelium-containing and endothelium-denuded rat aortic rings were treated with 
ADMA (100 µM, 1 h) prior to conducting a full concentration-response curve to 
phenylephrine (1 nM-10 µM) and the resulting contractions were compared in the two 
groups.  
 
The ability of L- or D-arginine to reverse and/or prevent the blockade of basal nitric 
oxide activity induced by nitric oxide synthase inhibitors 
   As will be seen in the Results, nitric oxide synthase inhibitors enhance phenylephrine-
induced tone by blocking basal nitric oxide activity in female rat endothelium-containing 
aortic rings. Further experiments were aimed to investigate whether this blockade can be 
reversed and/ or prevented by the substrate of nitric oxide synthase, L-arginine, or its 
optical isomer, D-arginine. 
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   In the experiments designed to investigate the ability of L- or D-arginine to reverse the 
blockade of basal nitric oxide activity, a low-level (~2–5 mN) of phenylephrine (60 nM) 
tone was induced and after the tone had stabilised, the tissues were treated with L-NAME, 
L-NMMA or ADMA (all at 100 µM) for 1 h or until the enhanced tone had stabilised.     
L- or D-arginine (10 mM) was then added to the tissues and the effects on tone assessed 
after 1 h.    
 
    In the experiments designed to investigate the ability of L- or D-arginine to prevent the 
blockade of basal nitric oxide activity, L- or D-arginine (10 mM) was added to the tissues   
for 1 h prior to the induction of a low-level (~2–5 mN) of phenylephrine (60 nM) tone. 
After the tone had stabilised, the nitric oxide synthase inhibitor was added and the effects 
on tone assessed after 1 h. 
 
The effect of ADMA on the contractile response to 5-hydroxytryptamine or 
prostaglandin F2α     
   These experiments were conducted to determine if the ability of ADMA (100 µM) to 
augment vasoconstrictor tone through blockade of basal nitric oxide activity in female rat 
aorta is independent of the nature of the contractile agent.    
 
    In these experiments, cumulative concentration-response curves were conducted to       
5-hydroxytryptamine (1 nM-100 µM) or prostaglandin F2α (1 nM-30 µM) in control and in 
ADMA (100 µM; 1 h)-treated female rat endothelium-containing aortic rings. 
Comparisons were then made of the contractile actions observed in control and ADMA-
treated rings.   
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The effects of nitric oxide synthase inhibitors on acetylcholine-induced nitric oxide 
activity
 
 
   The previous experiments in this Chapter investigated the effects of nitric oxide synthase 
inhibitors on basal nitric oxide activity in female rat aorta. The aim of these experiments 
was to investigate the effects of these inhibitors on acetylcholine-induced nitric oxide 
activity.  
 
   In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min and resting stretch was re-adjusted to 10 mN. The tissues were then 
treated with L-NAME (100 µM or 1 mM for 30 min), L-NMMA (100 µM or 1 mM for 45 
min), ADMA (100 µM or 1 mM for 1 h) or SDMA (1 mM for 1 h). After this time the 
treated tissues and their time-matched controls were pre-contracted to ~50% of maximal 
phenylephrine tone. Care was taken to induce comparable levels of tone both in control 
and treated tissues by using lower concentrations of phenylephrine in the latter. After 
stabilisation of tone, a full concentration-response curve to acetylcholine (1 nM-10 µM) 
was conducted. In some experiments involving L-NMMA at 100 µM or ADMA at 1 mM, 
this was followed by a second and a third concentration-response curve to acetylcholine 
where the tissues were washed out in between, and treated again with the same 
concentration of L-NMMA or ADMA and pre-contracted to ~50% of maximal 
phenylephrine tone . The aim here was to determine if the sensitivity of control tissues to 
acetylcholine or the blocking actions of L-NMMA or ADMA changed with time. 
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Effect of the level of tone on acetylcholine-induced relaxation in control and ADMA-
treated tissues 
  The aims of these experiments were to determine if the level of phenylephrine-induced 
tone affected the magnitude of acetylcholine-induced relaxation in control tissues or the 
ability of ADMA to block this relaxation in female rat endothelium-containing aortic rings. 
   In these experiments, endothelium-containing aortic rings were contracted to ~50% of 
maximal phenylephrine tone using phenylephrine (100-300 nM) before conducting a full 
concentration-response curve to acetylcholine (1 nM-10 µM). The tissues were then 
washed out and treated with ADMA (100 µM, for 1 h) before being contracted using the 
same concentration of phenylephrine (100-300 nM), which this time produced a higher 
level of tone, due to blockade of basal nitric oxide activity. A full concentration-response 
curve to acetylcholine (1 nM-10 µM) was then conducted at the highest level of tone. The 
tissues were then washed out, treated again with ADMA (100 µM, for 1 h) and this time 
contracted to the original ~50% of maximal phenylephrine tone using a lower 
concentration of phenylephrine before performing a full concentration-response curve to 
acetylcholine (1 nM-10 µM). The ability of acetylcholine to produce relaxation at each 
level of tone was then compared.  
 
    In another set of experiments, control endothelium-containing aortic rings and rings 
treated with ADMA (100 µM, for 1 h) were contracted using phenylephrine to different 
levels of tone ranging from low, maximal to supra-maximal, before full concentration-
response curves to acetylcholine (1 nM-10 µM) were conducted. The ability of 
acetylcholine to produce relaxation at these different levels of tone in control and ADMA-
treated tissues was then compared. 
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The effect of L-arginine, L-NMMA, ADMA and SDMA on blockade of acetylcholine-
induced relaxation by L-NAME 
    As will be seen in the Results, that when experiments were conducted at similar levels of 
sub-maximal tone that the inhibitor of nitric oxide synthase, L-NAME, produced powerful 
blockade of acetylcholine-induced relaxation in female rat endothelium-containing aortic 
rings, but L-NMMA and ADMA had little effect. Therefore, the aim of the current 
experiments was to investigate if L-NMMA or ADMA could interfere with the ability of 
L-NAME to produce blockade of acetylcholine-induced relaxation. The possibility that the 
substrate, L-arginine, or the inactive analogue, SDMA, could interfere with the ability of 
L-NAME to produce blockade of acetylcholine-induced relaxation was also investigated.  
 
    In these experiments two approaches were employed. In the first, to determine if 
blockade produced by L-NAME (30 µM) could be prevented by L-arginine, L-NMMA, 
ADMA or SDMA (all at 1 mM), the latter were added to the tissues in the organ baths 1 h 
prior to the addition of L-NAME. Matched intermediate tone was then induced with 
phenylephrine both in control and treated tissues to be followed by a full concentration-
response curve to acetylcholine (1 nM-10 µM). The ability of acetylcholine to produce 
relaxation in the different conditions was then compared 
 
   In the second approach, to determine if the L-NAME-induced blockade could be 
reversed by L-arginine, L-NMMA, ADMA or SDMA, the tissues were treated with L-
NAME (30 µM for 1 h) to establish the blockade then treated with L-arginine, L-NMMA, 
ADMA or SDMA (all at 1 mM) for 1 h prior to induction of matched intermediate 
phenylephrine-induced tone. After stabilisation of phenylephrine-induced tone, a full 
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concentration-response curve to acetylcholine (1 nM-10 µM) was conducted. The ability of 
acetylcholine to produce relaxation in the different conditions was then compared.  
 
Drugs and chemicals 
 
   Acetylcholine chloride (ACh), NG , NG –dimethyl-L-arginine dihydrochloride (ADMA), 
L-arginine hydrochloride, 5-hydroxytryptamine (5-HT), NG –nitro-L-arginine methyl ester 
(L-NAME), NG –monomethyl-L-arginine acetate (L-NMMA), papaverine hydrochloride, 
phenylepherine hydrochloride (PE) and prostaglandin F2α were all obtained from Sigma, 
Poole, UK. NG , N'G –dimethyl-L-arginine dihydrochloride (SDMA) was obtained from 
Enzo Life Sciences, Exeter, UK. All drugs were dissolved and diluted in 0.9% saline.  
 
 
Data analysis 
 
    Contractions were measured in milliNewtons. Papaverine (300 µM) was added at the 
end of each experiment to produce full relaxation of tissues and the relaxant responses to 
acetylcholine were expressed as percentage of this relaxation. Data are expressed as the 
mean ± S.E.M of n separate observations. Concentration-effect curves were analysed and 
drawn by fitting the data to following formula (Randall and Griffith, 1991): 
                                 
 
Where R is the percentage tissue response to agonist, A the concentration of agonist, 
Rmax the maximum response induced by agonist, nH is the slope and EC50 is the 
concentration of agonist that induces 50% of the maximal response. 
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   Statistical analysis was done by one-way analysis of variance followed by Bonferroni's 
post-test or by Student's t test, as appropriate, with the aid of a computer-based program 
(Graph Pad, San Diego, USA). Values were considered to be statistically different when P 
was ≤ 0.05.  
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Results  
 
Effects of the vascular endothelium and NG–nitro-L-arginine methyl ester on 
phenylephrine-induced contraction 
     A full concentration-effect curve to phenylephrine (1 nM-10 nM) in female rat 
endothelium-containing aortic rings resulted in an Emax of 14.4 ± 1.5 mN and a pEC50 of 
6.75 ± 0.07 (Figure 2.1). Removal of the endothelium or pretreatment with NG –nitro-L-
arginine methyl ester (L-NAME, 100 µM) significantly increased the tissue sensitivity to 
phenylephrine (pEC50 8.25 ± 0.14 and 7.80 ± 0.12, P< 0.001, respectively), but had no 
effect on the Emax (18.2 ± 1.0 mN and 18.2 ± 1.6 mN, P> 0.05, respectively), consistent 
with the presence of basal nitric oxide activity suppressing vasoconstrictor tone in this 
tissue.    
 
Effects of the vascular endothelium and L-NAME on acetylcholine-induced relaxation    
      
     Following sub-maximal (7.8 ± 0.6 mN, n= 7) contraction with phenylephrine (100-300 
nM), acetylcholine (1 nM-10 µM) produced concentration-dependent relaxation in 
endothelium-containing rings of female rat aorta (Emax 91.8 ± 1.6% and pEC50 of 7.70 ± 
0.02) (Figure 2.2). In endothelium-denuded (EC-) rings taken to the same sub-maximal 
level of tone as control tissues, acetylcholine failed to produce relaxation. In endothelium-
containing rings treated with the nitric oxide synthase (NOS) inhibitor, L-NAME (100 
µM), and taken to the same sub-maximal level of tone, acetylcholine-induced relaxation 
was significantly blocked (Emax 19.8 ± 1.6% and pEC50 of 6.35 ± 0.06).  
 
Effects of L-arginine on basal nitric oxide activity 
       
    Following induction of intermediate tone (10.7 ± 1.0 mN) in rat endothelium-containing 
aortic rings using phenylepherine (50-70 nM), subsequent addition of the NOS substrate, 
L-arginine (10 mM, 1 h), did not significantly affect the level of tone (Figure 2.3). It is 
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therefore unlikely that the availability of L-arginine is limiting for the production of basal 
nitric oxide activity that suppresses vasoconstrictor tone. 
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Figure 2.1. Cumulative concentration-effect curves showing contractile responses to PE in 
female rat aortic rings. Responses are shown for tissues in the presence (control) or in the 
absence (EC-) of endothelium, or tissues with endothelium but treated with L-NAME (100 
µM). The sensitivity of tissues was enhanced by both endothelial denudation and L-NAME 
treatment. Each point represents the mean ± SEM of 6-15 observations. 
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Figure 2.2.  Cumulative concentration-effect curves showing relaxation to acetylcholine in 
female rat aortic rings submaximally contracted with PE. Responses are shown for tissues 
in the presence (control) or the absence (EC-) of endothelium, or tissues with endothelium 
treated with L-NAME (100 µM). Acetylcholine-induced relaxation was powerfully 
blocked by both endothelial denudation and L-NAME treatment. Each point represents the 
mean ± SEM of 6-7 observations. *** P< 0.001 indicates a significant difference from 
control. 
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Figure 2.3. Histogram showing the contractile response to PE (50-70 nM) in female rat 
endothelium-containing aortic rings in the absence and presence of L-arginine (10 mM for 
1 h). L-arginine did not significantly affect PE-induced contraction. Data represent the 
mean ± SEM of 7 observations.  
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Effects of L-arginine on acetylcholine-induced relaxation  
      
     Following treatment with L-arginine (10 mM, 1h) and contraction to ~ 50% of maximal 
phenylephrine tone, acetylcholine-induced relaxation (Emax 75.4 ± 4.1% and pEC50 of 7.59 
± 0.02) was similar to that of control tissues (Emax 82.7 ± 2.7% and pEC50 of 7.63 ± 0.03) 
(Figure 2.4). It is therefore unlikely that the availability of L-arginine is limiting for the 
production of nitric oxide stimulated by acetylcholine. 
 
Effects of L-NAME on basal nitric oxide activity 
   
    Following induction of low tone (4.3 ± 0.6 mN) in female rat endothelium-containing 
aortic rings using phenylepherine (30-60 nM), subsequent addition of L-NAME (100 µM, 
1h) significantly potentiated the tone, consistent with blockade of basal nitric oxide activity 
(Figure 2.5). L-arginine (at 10 mM, 1 h), given as a post-treatment or pre-treatment, 
significantly reversed and prevented, respectively, the potentiation of phenylephrine-
induced tone by L-NAME. 
 
Effects of NG –monomethyl-L-arginine on basal nitric oxide activity 
     
    Following induction of low tone (4.0 ± 0.4 mN) in female rat endothelium-containing 
aortic rings using phenylephrine (30-60 nM), subsequent addition of NG –monomethyl-L-
arginine (L-NMMA, 100 µM for 1 h) significantly potentiated the tone, consistent with 
blockade of basal nitric oxide activity (Figure 2.6). L-arginine (at 10 mM, 1 h), given as a 
post-treatment or pre-treatment, significantly reversed and prevented, respectively, the 
potentiation of phenylephrine-induced tone by L-NMMA. 
 
Effects of NG, NG –dimethyl-L-arginine and   of NG, N,G–dimethyl-L-arginine on basal 
nitric oxide activity 
    Following induction of low tone (3.5 ± 0.5 mN) in female rat endothelium-containing 
aortic rings using phenylephrine (30-60 nM), subsequent addition of NG , NG –dimethyl-L-
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arginine (ADMA, 100 µM for 1 h) significantly enhanced the tone (18.3 ± 2.2 mN, P< 
0.001) consistent with blockade of basal nitric oxide activity (Figures 2.7 and 2.8). L-
arginine (10 mM, 1 h), given as a post-treatment or pre-treatment, significantly reversed 
and prevented, respectively, the potentiation of phenylephrine-induced tone by ADMA. In 
contrast, D-arginine, the other optical isomer of L-arginine, neither reversed nor prevented 
the potentiation of phenylephrine-induced tone by ADMA.  
 
     In contrast to ADMA, NG, N,G –dimethyl-L-arginine (SDMA, 1 mM for 1 h) did not 
affect phenylephrine-induced tone in rat endothelium-containing aortic rings (Figure 2.9). 
 
Concentration-dependence and endothelium-dependence of the ability of ADMA to 
block basal nitric oxide activity 
     Following induction of low tone (3.1 ± 0.6 mN) in rat endothelium-containing aortic 
rings using phenylepherine (30-60 nM), subsequent addition of ADMA (0.3-300 µM; the 
response to each concentration was measured after 1 h), resulted in a concentration-
dependent enhancement of the tone (Figure 2.10). The threshold concentration of ADMA 
enhancing tone was 0.3 µM, the pEC50 was 4.78 ± 0.06 and the maximum was obtained at 
100 µM.  
 
    A concentration-effect curve to phenylepherine (1 nM-10 µM) produced a maximal 
contraction of 14.4 ± 1.5 mN and a pEC50 of 6.75 ± 0.07 in rat endothelium-containing 
aortic rings (Figure 2.11). Pretreatment with ADMA (100 µM, 1 h) significantly enhanced 
both of the tissue maximal response (Emax 22.2 ± 0.8 mN) and sensitivity (pEC50 7.88 ± 
0.04) to phenylepherine. Increasing the concentration of ADMA to 300 or 1000 µM 
produced a very little further enhancement.  
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    In contrast to the effect on endothelium-containing rings, ADMA did not enhance 
phenylephrine-induced tone in the absence of the endothelium (Figure 2.12). 
 
 
Effects of ADMA on the contractile responses to 5-hydroxytryptamine   
 
  A full concentration-effect curve to 5-hydroxytryptamine (1 nM-100 µM) in rat 
endothelium-containing aortic rings resulted in an Emax of 17.7 ± 2.1 mN and a pEC50 of 
5.33 ± 0.13 (Figure 2.13). Pretreatment with ADMA (100 µM, 1 h) significantly enhanced 
both the tissue maximal response (Emax 24.3 ± 0.8 mN) and sensitivity (pEC50 5.83 ± 0.07) 
to 5-hydroxytryptamine, consistent with blockade of basal nitric oxide activity.  
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Figure 2.4. Cumulative concentration-effect curves showing relaxation to acetylcholine in 
female rat endothelium-containing aortic rings submaximally contracted with PE in the 
absence and presence of L-arginine (10 mM). L-arginine had no effect on acetylcholine–
induced relaxation. Each point represents the mean ± SEM of 6 observations. 
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Fig.2.5. Histogram showing the contractile response to PE (30-60 nM) in female rat 
endothelium-containing aortic rings.  Responses are shown for control PE-contracted 
tissues, PE-contracted tissues treated with L-NAME (100 µM for 1 h), PE-contracted 
tissues treated with L-NAME then with L-arginine (10 mM for 1 h), or tissues treated with 
L-arginine (10 mM for 1 h) before contraction with PE then treatment with L-NAME (100 
µM for 1 h). L-arginine, the substrate for nitric oxide synthase, both reversed and 
prevented the potentiation of PE-induced tone by L-NAME. Data represent the mean ± 
SEM of 4-9 observations. *** P< 0.001 indicates a significant difference from PE; ### P< 
0.001 indicates significant differences from tissues treated with L-NAME alone. 
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Figure 2.6. Histogram showing the contractile response to PE (30-60 nM) in female rat 
endothelium-containing aortic rings. Responses are shown for control PE-contracted 
tissues, PE-contracted tissues treated with L-NMMA (100 µM for 1 h), PE-contracted 
tissues treated with L-NMMA then with L-arginine (10 mM for 1 h), or tissues treated with 
L-arginine (10 mM for 1 h) before contraction with PE then treatment with L-NMMA (100 
µM for 1 h). L-arginine, the substrate for nitric oxide synthase, both reversed and 
prevented the potentiation of PE-induced tone by L-NMMA. Data represent the mean ± 
SEM of 4-9 observations. *** P< 0.001 indicates a significant difference from PE; ### P< 
0.001 indicates significant differences from tissues treated with L-NAME alone. 
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Figure 2.7. Trace showing a female rat endothelium-containing aortic ring contracted with 
PE to a low level of tone then treated with ADMA (for 1 h). ADMA powerfully 
potentiated PE-induced tone. Concentrations of PE and ADMA are given as log molar 
units. 
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Figure 2.8.  Histogram showing the contractile response to PE (30-60 nM) in female rat 
endothelium-containing aortic rings. Responses are shown for PE-contracted tissues, PE-
contracted tissues treated with ADMA (100 µM for 1 h), PE-contracted tissues treated with 
ADMA then with L-arginine or D-arginine (both at 10 mM for 1 h), or PE-contracted 
tissues treated with L-arginine or D-arginine (both at 10 mM for 1 h) before contraction 
with PE then treatment with ADMA (100 µM for 1 h). L-arginine, the substrate for nitric 
oxide synthase, but not D-arginine, both reversed and prevented the potentiation of PE-
induced tone by ADMA. Data represent the mean ± SEM of 6 observations. *** P< 0.001 
indicates a significant difference from PE; ### P< 0.001 indicates significant differences 
from tissues treated with ADMA alone. 
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Figure 2.9. Histogram showing the contractile response to PE (30-60 nM) in female rat 
endothelium-containing aortic rings.  Responses are shown for PE-contracted tissues or 
PE-contracted tissues treated with the L-arginine analogues, ADMA (100 µM for 1 h) or 
SDMA (1 mM for 1 h). PE-induced contraction was significantly enhanced by ADMA, but 
not by SDMA. Data represent the mean ± SEM of 6 observations. *** P< 0.001 indicates a 
significant difference from PE. 
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Figure 2.10. Concentration-effect curve showing the enhancement of low level PE (30-60 
nM)-induced contraction by ADMA in female rat endothelium-containing aortic rings. The 
response to each concentration of ADMA was measured after 1 h. Each point represents 
the mean ± SEM of 4-5 observations. 
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Figure 2.11. Cumulative concentration-effect curves showing contractile responses to PE 
in female rat endothelium-containing aortic rings in the absence and presence of ADMA 
(0.1 mM, 0.3 mM or 1 mM, all for 1 h). Contractions were almost maximally enhanced by 
0.1 mM ADMA; higher concentrations produced little additional enhancement. Each point 
represents the mean ± SEM of 8-15 observations. *** P< 0.001 indicates a significant 
difference from control. 
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Figure 2.12. Cumulative concentration-effect curves show contractile responses to PE in 
female rat endothelium-denuded aortic rings in the absence and presence of ADMA (100 
µM for 1 h). ADMA did not enhance PE-induced contractions in the absence of the 
endothelium. Each point represents the mean ± SEM of 6 observations.  
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Figure 2.13. Cumulative concentration-effect curves showing contractile responses to 5-
hydroxytryptamine (5-HT) in female rat endothelium-containing aortic rings in the absence 
and presence of ADMA (100 µM for 1 h). The sensitivity and maximal contraction to 5-
HT were enhanced in the presence of ADMA. Each point represents the mean ± SEM of 6 
observations. * P< 0.05 indicates a significant difference from control. 
 
 
 
 76
Effects of ADMA on the contractile responses to the prostaglandin F2α   
 
     A full concentration-effect curve to prostaglandin F2α (1 nM-30 µM) in rat endothelium- 
containing aortic rings resulted in an Emax of 19.4 ± 0.7 mN and a pEC50 of 4.96 ± 0.19 
(Figure 2.14). Pre-treatment with ADMA (100 µM, 1 h) significantly enhanced both the 
tissue maximal response (Emax 23.8 ± 0.8 mN) and sensitivity (pEC50 5.67 ± 0.13) to 
prostaglandin F2α, consistent with blockade of basal nitric oxide activity. 
 
Effects of L-NAME and L-NMMA on acetylcholine-induced relaxation    
      
    Following induction of ~ 50% of maximal phenylepherine-induced tone in rat 
endothelium-containing aortic rings in the presence of the NOS inhibitor, L-NAME (100 
or 1000 µM for 30 min), acetylcholine (1 nM-10 µM)-induced relaxation was powerfully 
blocked when compared with control tissues set at the same level of tone (Figure 2.15; 
Table 2.1).   
 
    In contrast to L-NAME, and as previously shown by Frew et al. (1993), L-NMMA (100 
or 1000 µM for 45 min) had little effect on acetylcholine-induced relaxation when 
experiments were conducted at ~ 50% of maximal phenylepherine-induced tone (Figure 
1.15; Table 1.1). When tissues were tested after 2 h and 3 h, there was a small progressive 
reduction in tissue sensitivity to the relaxant action of acetylcholine both in control and L-
NMMA (100 µM)-treated tissues (Figure 2.16). The maximal response of L-NMMA-
treated tissues to acetylcholine was not significantly different from that seen in time-
matched controls.  
 
Effect of ADMA and SDMA on acetylcholine-induced relaxation  
 
    Like L-NMMA, but unlike L-NAME, ADMA (100 or 1000 µM for 1 h) produced a 
small but significant decrease in tissue sensitivity to acetylcholine without affecting the 
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Emax when experiments were conducted at ~ 50% of maximal phenylepherine-induced tone 
(Figure 2.17; Table 2.1). When tissues were tested after 3 and 4.5 h, there was a small 
progressive reduction in tissue sensitivity to the relaxant action of acetylcholine both in 
control and ADMA (1 mM)-treated tissues, but with a greater reduction in the latter 
(Figure 2.18). However, the maximal response of ADMA-treated tissues to acetylcholine 
was not significantly different from that seen in time-matched controls.  
 
    On the other hand, following induction of ~ 50% of maximal phenylepherine-induced 
tone in female rat endothelium-containing aortic rings pre-treated with the inactive 
analogue, SDMA (1 mM, 1h), acetylcholine (1 nM-10 µM)--induced relaxation was 
similar to that of control tissues (Figure 2.19; Table 2.1). 
 
Effect of the level of tone on the apparent ability of ADMA to inhibit acetylcholine -
induced relaxation 
   When rat endothelium-containing aortic rings were contracted with phenylepherine (100-
300 nM) to an intermediate level of tone (11.9 ± 2.1 mN), acetylcholine (1 nM-10 µM) 
produced concentration-dependent relaxation with an Emax of 77.5 ± 7.8% and a pEC50 of 
7.30 ± 0.03 (Figures 2.20A and 2.21). When the tissues were washed and ADMA (100 
µM) added for 1 h, the same concentration of phenylepherine (100-300 nM) now produced 
a higher level of tone (18.8 ± 1.5 mN), consistent with blockade of basal activity of nitric 
oxide, and acetylcholine-induced relaxation appeared to be significantly blocked (Emax 22.1 
± 3.1%; pEC50 6.91 ± 0.04). However, when these same tissues were washed and 
constricted with a lower concentration of phenylepherine (10-30 nM) in the presence of 
ADMA to give an intermediate level of tone similar to control vessels, the maximal 
response to acetylcholine was no longer blocked (Emax 77.6 ± 4.0%), but there was a 
decrease in tissue sensitivity to acetylcholine by ~ 1.7 fold (pEC50 7.06 ± 0.04). It was 
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therefore possible that the apparently potent blockade of acetylcholine-induced relaxation 
seen with ADMA at a higher level of tone than control tissues might be due to 
physiological antagonism, rather than to blockade of NOS.       
 
The effect of the level of tone on control acetylcholine-induced relaxation 
 
    Having established that the level of tone was critical in determining whether or not 
ADMA appeared to block acetylcholine-induced relaxation, it became important to 
determine how the level of tone affected the magnitude of acetylcholine-induced relaxation 
in control tissues.    
 
    In control, rat endothelium-containing aortic rings precontracted with phenylephrine to 
two different but submaximal levels of tone (3.7 ± 0.4 and 10.3 ± 0.5 mN), acetylcholine 
(1 nM-10 µM) produced similar relaxant responses (Figure 2.22a). However, relaxation 
was significantly depressed when the level of phenylepherine-induced tone was maximal 
for endothelium-containing tissues (14.1 ± 0.5 mN). When tissues constricted with 
phenylephrine to sub-maximal levels of tone of 4.1 ± 0.6 or 10.2 ± 0.5 mN in the presence 
of ADMA (100 µM), the magnitude of acetylcholine-induced relaxation was similar to that 
in control tissues precontracted with phenylephrine to comparable levels of tone (Figure 
2.22b). When ADMA-treated tissues were constricted with phenylephrine to 15.7 ± 0.5 
mN tone, acetylcholine produced the same depressed maximal relaxation to that in control 
tissues precontracted to the same level of phenylephrine tone (Figures 2.22a, b). At levels 
of phenylepherine tone of 20.3 ± 0.7 mN and 24.7 ± 0.6 mN, which cannot be induced in 
control tissues, acetylcholine-induced relaxation was further depressed.  
  
    It was therefore clear that the level of tone is critical in determining the magnitude of 
acetylcholine-induced relaxation in both control and ADMA-treated tissues, and that little 
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blockade by the latter was seen when the level of tone was matched with that of control 
tissues. 
 
The effect of L-NMMA and ADMA on the blockade of acetylcholine-induced relaxation 
by L-NAME 
  Having established that L-NMMA and ADMA had little effect on acetylcholine–induced 
relaxation when tone was matched with that of control tissues, it was important to 
determine if they could interfere with the blocking action of L-NAME. 
 
   In the presence of L-NAME (30 µM, 1h) and following induction of ~50% of maximal 
phenylephrine-induced tone in rat endothelium-containing aortic rings, acetylcholine         
(1 nM-10 µM)-induced relaxation was reduced to a maximum of ~ 40% (Figure 2.23). 
This blockade by L-NAME was significantly prevented as well as reversed following pre-
treatment or post-treatment, respectively, with the endogenous substrate of NOS, L-
arginine (1mM, Figure 2.23a). L-NMMA (1 mM) alone decreased tissue sensitivity to the 
relaxant action of acetylcholine by ~2.6-fold without reducing the maximal response to 
acetylcholine (Figure 2.23b). Moreover, like with L-arginine, treatment with L-NMMA (1 
mM) both prevented and reversed the blockade of acetylcholine-induced relaxation by L-
NAME. ADMA (1 mM) too on its own produced a 3-fold reduction in sensitivity to 
acetylcholine without reducing its maximal relaxation (Figure 2.23c). It too largely 
prevented the blockade of acetylcholine-induced relaxation by L-NAME, but did not 
reverse it (Figure 2.23c). SDMA (1 mM) alone had no effect on acetylcholine-induced 
relaxation and it had no effect on blockade of acetylcholine-induced relaxation by L-
NAME (Figure 2.23d).  
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Figure 2.14. Cumulative concentration-effect curves show contractile responses to 
prostaglandin F2α in female rat endothelium-containing aortic rings in the absence and 
presence of ADMA (100 µM for 1 h). Contractions were significantly enhanced in the 
presence of ADMA. Each point represents the mean ± SEM of 6 observations. ** P< 0.01 
indicates a significant difference from control. 
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Figure 2.15. Cumulative concentration-effect curves showing relaxation to acetylcholine 
in female rat endothelium-containing aortic rings submaximally contracted with PE in the 
absence and presence of L-NAME or L-NMMA (both at 0.1 and 1mM). Maximal 
relaxation was powerfully blocked by L-NAME at both concentrations, but not affected by 
either concentration of L-NMMA. Each point represents the mean ± SEM of 6-9 
observations. *** P< 0.01 indicates a significant difference from control. 
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Figure 2.16. Concentration–effect curves showing relaxation to acetylcholine in female rat 
endothelium-containing aortic rings submaximally contracted with PE. Responses are 
shown for the same tissues treated with L-NMMA at 0.1 mM (a) for 45 minutes (L- 
NMMA 1), 2 h (L-NMMA 2) or 3 h (L-NMMA 3), and for their time-matched controls 
(b); control 1, control 2 and control 3, respectively. There is no significant time-dependent 
inhibition of maximal acetylcholine-induced relaxation by L-NMMA. Each point is the 
mean ± SEM of 6 observations. 
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Figure 2.17. Cumulative concentration-effect curves showing relaxation to acetylcholine 
in female rat endothelium-containing aortic rings submaximally contracted with PE in the 
absence and presence of ADMA (0.1 and 1 mM, 1h). ADMA produced a small but 
significant decrease in tissue sensitivity to acetylcholine without affecting the maximal 
relaxation. Each point represents the mean ± SEM of 5-9 observations. * P< 0.05 and    
*** P< 0.001 indicate significant differences from control. 
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Table 2.1   The effects of different NOS inhibitors on acetylcholine-induced relaxation in 
rat endothelium-containing aortic rings submaximally contracted with PE, together with 
their time-matched controls.  
  
Treatment                 Concentration             pEC50                               Emax ± SEM (%) 
 
 
Control 
 
 
 
--------------- 
 
7.54 ± 0.05 
 
81.7 ± 3.8 
ADMA    
 
 
0.1 mM (1 h)  7.13 ±  0.07  ** 84.3 ± 1.9 
ADMA  
 
 
 
1 mM (1 h)  7.16 ±  0.06  ** 83.8 ± 2.8 
Control 
 
 
--------------- 7.54 ± 0.05 86.0 ± 5.8 
L-NMMA    
 
 
0.1 mM (30 min)  7.34 ± 0.11  83.2 ± 2.8 
L-NMMA    
 
 
1 mM (30 min) 7.12 ± 0.04   * 89.0 ± 4.3 
L-NAME 
 
 
0.1 mM (30 min) 6.35 ± 0.10   ***  19.8 ± 5.1  *** 
L-NAME 
 
 
 
1 mM (30 min)    ND 3.0 ± 5.6  *** 
Control 
 
 
--------------- 7.51 ± 0.03 93.3 ± 2.8 
SDMA 
 
 
1 mM (1 h)  7.52 ± 0.04 91.2 ± 4.4 
 
Data are the mean ± SEM of 5-9 observations. * P< 0.05, ** P< 0.01 and *** P< 0.001 
indicate significant differences from relevant control. 
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Figure 2.18. Concentration–effect curves showing relaxation to acetylcholine in female rat 
endothelium-containing aortic rings submaximally contracted with PE. Responses are 
shown for the same tissues treated with ADMA at 1 mM (a) for 1 h (ADMA 1), 3 h 
(ADMA 2) or 4.5 h (ADMA 3), and for their time-matched controls (b); control 1, control 
2 and control 3, respectively. There was no significant time-dependent inhibition of 
maximal acetylcholine-induced relaxation by ADMA. Each point is the mean ± SEM of   
5-6 observations. 
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Figure 2.19. Cumulative concentration-effect curves showing relaxation to acetylcholine 
in female rat endothelium-containing aortic rings submaximally contracted with PE in the 
absence and presence of SDMA (1 mM, 1h). SDMA had no effect on acetylcholine-
induced relaxation. Each point represents the mean ± SEM of 6 observations. 
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Fig. 2.20. Traces show acetylcholine-induced relaxation in a control (trace A) 
endothelium-containing rat aortic ring submaximally contracted with PE (160 nM). When 
the same tissue was washed and treated with ADMA (100 µM for 1 h) and contracted with 
the same concentration of PE, the level of tone was higher (trace B) and acetylcholine-
induced relaxation seems to be blocked. However, when the same tissue was washed again, 
treated with ADMA and contracted to the same level as the control by using a lower 
concentration (25 nM) of PE (trace C), the blockade of acetylcholine-induced relaxation 
was almost entirely abolished. Concentrations of PE and ACh are given in log molar units.   
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Figure 2.21. Cumulative concentration-effect curves showing acetylcholine-induced 
relaxation in female rat endothelium-containing aortic rings contracted to an intermediate  
(I) level of tone with PE (100-300 nM). When ADMA (100 µM, 1 h) enhanced PE (100-
300)-induced tone to a high (H) level, acetylcholine-induced relaxation appeared 
powerfully inhibited. However, when these same tissues were washed, with intermediate 
PE (10–30 nM)-induced tone (I) re-established in the presence of ADMA, the blockade of 
acetylcholine-induced relaxation was almost entirely abolished. Each point is the mean ± 
SEM of six observations. *** P< 0.001 indicates a significant difference from control. 
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Figure 2.22. Cumulative concentration-effect curves showing relaxation to acetylcholine 
in female rat endothelium-containing aortic rings precontracted with PE to different levels 
of tone (shown in mN). Responses are shown for (a) control tissues and (b) ADMA-treated 
tissues (0.1 mM for 1 h). Acetylcholine-induced relaxation was significantly inhibited both 
in control and ADMA-treated tissues precontracted to high but not low or intermediate 
levels of PE-induced tone. Each point represents the mean ± SEM of 6-9 observations.      
* P< 0.05, ** P< 0.01 and *** P< 0.001 indicate significant differences from control.  
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Figure 2.23.  Concentration–response curves showing acetylcholine-induced relaxation in 
female rat endothelium-containing aortic rings submaximally contracted with PE and 
blockade of this relaxation with L-NAME (30 µM, 1 h). The ability of (a) L-arginine, (b) 
L-NMMA, (c) ADMA and (d) SDMA (all at 1 mM) to either protect against or reverse 
blockade by L-NAME is also shown. Note that the order of listing of drugs reflects their 
order of addition to tissues. Each point is the mean ± SEM of 6-9 observations. *** P< 
0.001 indicates significant blockade by L-NAME; ## P< 0.01 and ### P< 0.001 indicate 
significant protection against or reversal of blockade induced by L-NAME. 
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Discussion  
Basal nitric oxide activity in female rat aorta is significantly blocked by L-NAME, L-
NMMA and ADMA, but not affected by SDMA or L-arginine     
     It has been reported that the vascular endothelium generates nitric oxide in the absence 
of external stimuli, i.e. under basal conditions, and that this basal activity of nitric oxide 
exerts a tonic vasodilator effect that suppresses the actions of vasoconstrictor drugs (Martin 
et al., 1986b; Rees et al., 1989; Moore et al., 1990; Mian & Martin, 1995). These findings 
are supported by the observation that removal of the endothelium from rat aortic rings 
results in an augmentation of contraction induced by vasoconstricting agents in comparison 
to those induced in control rings (Allan et al., 1983; Eglème et al., 1984). As a 
consequence of these findings, it is generally accepted that agents that inhibit nitric oxide 
synthesis or block the actions of nitric oxide are expected to produce an enhancement of 
vasoconstrictor-induced tone by removing this endothelium-dependent suppression of 
vasoconstriction. 
 
    In agreement with the concept that basal activity of nitric oxide exerts a tonic vasodilator 
influence on blood vessels, the results of this study showed that endothelial denudation or 
treatment of endothelium-containing female rat aortic rings with the nitric oxide synthase 
inhibitors, L-NAME, L-NMMA or ADMA, resulted in augmentation of low level 
phenylephrine-induced tone. This augmentation of tone was both prevented and reversed 
by adding a high concentration of the endogenous substrate for nitric oxide synthase, L-
arginine, but D-arginine was ineffective. This suggests that L-arginine produced its effects 
in a stereospecific way (Eddahibi et al., 1992) and that the inhibition of basal nitric oxide 
activity by L-NAME, L-NMMA or ADMA takes place through classical surmountable 
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antagonism (Palmer et al., 1988; Rees et al., 1989; Aisaka et al., 1989; Rees et al., 1990; 
Moore et al., 1990; Hobbs et al., 1999; Masuda et al., 2002).  
 
    An additional important observation in this study is that L-arginine itself had no effect 
on phenylephrine-induced tone in endothelium-containing rings of rat aorta. This suggests 
that the availability of L-arginine is not limiting for the production of the basal nitric oxide 
activity that suppresses vasoconstrictor tone. This finding is in agreement with previous 
reports (Cooke et al., 1991; Moritoki et al., 1991) which showed that pre-treatment with L-
arginine did not affect the contractile responses to norepinephrine or phenylephrine in 
rabbit and rat aortic rings, respectively. Moreover, this finding is consistent with that 
reported by Jun and Wennmalm (1994) that intravenous infusion of L-arginine did not 
change mean arterial blood pressure in normotensive rats. Thus, the availability of L-
arginine does not appear to be limiting for basal production of nitric oxide either in vitro or 
in vivo.  
 
   A likely explanation for the inability of exogenous L-arginine to promote further basal 
nitric oxide synthesis may be found when we compare the endogenous level of L-arginine 
(100-300 µM) reportedly found in endothelial cells with estimates of its Km for nitric oxide 
synthase (2-3 µM). Thus, it would appear that endogenous levels are such saturated that 
the enzyme would normally be fully saturated (Sydow and Münzel, 2003; Teerlink et al., 
2009; Zhang et al., 2011). Moreover, within the context of the control experiments 
conducted in this study, there is no inhibitor of nitric oxide synthase such as ADMA 
presents, which would compete with L-arginine and thus necessitate additional substrate to 
overcome this surmountable inhibition. In vivo in humans, however, where evidence for 
the presence of ADMA has been presented (Böger, 2004; Bode-Böger et al., 2007; 
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Teerlink et al., 2009), the addition of L-arginine was, in contrast, seen to increase nitric 
oxide activity. This ability of exogenously administered L-arginine to enhance nitric oxide 
activity in vivo has been termed the “arginine paradox” and is believed to result from 
reversal of blockade by endogenous ADMA, rather than from an abnormally low 
endogenous level of L-arginine.  
 
   In addition, the results of the present study showed that SDMA did not affect 
phenylephrine-induced tone in rat endothelium-containing aortic rings, and so had no 
effect on basal nitric oxide activity, which is in agreement with previous data indicating 
that SDMA is not an inhibitor of nitric oxide synthase (Masuda et al., 2002; Siroen et al., 
2006).   
 
The blockade of basal nitric oxide activity by ADMA is both endothelium- and 
concentration-dependent  
    The results of this study showed that the threshold concentration of ADMA to enhance 
submaximal phenylephrine-induced contraction through blockade of basal nitric oxide 
activity in rat aorta, was 0.3-1 µM, which is consistent with the concentrations of ADMA 
reported in the plasma of patient with pathological conditions associated with renal 
dysfunction or vascular endothelial dysfunction (Vallance et al., 1992; Siroen et al., 2006). 
Moreover, this effect of ADMA seemed to be concentration dependent with an IC50 of 17 
µM and treatment with 100 µM of ADMA was almost enough to abolish basal activity of 
nitric oxide, as increasing the concentration to 1000 µM produced very little further effect.   
 
   It is worth noting that ADMA augmented submaximal contractions induced not just by 
phenylephrine, but by a range of different vasoconstrictors, such as 5-hydroxytryptamine 
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and prostaglandin F2α, in female rat endothelium-containing aortic rings. Thus, basal nitric 
oxide activity, suppresses tone induced by a range of vasoconstrictors in rat aorta.  
   
  In endothelium-denuded rat aortic rings, ADMA, like the other nitric oxide synthase 
inhibitors, L-NMMA and L-NAME, failed to augment phenylephrine-induced 
contractions. These findings were as expected, because endothelium-denuded vessels are 
unable to produce basal nitric oxide activity.   
 
Acetylcholine-induced relaxation in female rat aorta is endothelium-dependent and 
nitric oxide-mediated 
    Data from this study showed that the concentration-dependent relaxation induced by 
acetylcholine in rat aorta was abolished by endothelial denudation or treatment with the 
standard nitric oxide synthase inhibitor, L-NAME. These findings are consistent with 
previous reports (e.g. Furchgott & Zawadzki, 1980) that the lining endothelium of blood 
vessels plays a vital role in facilitating vasodilator responses to relaxant agents such as 
acetylcholine, substance P and the calcium ionophore A23187, due to the production of an 
endothelium-derived relaxing factor (EDRF), later shown to be nitric oxide (Palmer et al., 
1987).  
 
Acetylcholine-induced relaxation in female rat aorta is not affected by L-NMMA, 
ADMA or SDMA 
   Probably the most important finding of this study is that despite producing potent 
blockade of basal nitric oxide activity in rat aorta, ADMA at 100 µM produced only a very 
modest effect on acetylcholine-induced relaxation; there was a slight (2-3-fold) decrease in 
tissue sensitivity without affecting the maximal response to acetylcholine. Even increasing 
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the concentration of ADMA to 1000 µM and prolonging the duration of treatment to 3 h 
failed to produce further blockade.  Moreover, the ineffectiveness of ADMA against 
acetylcholine-induced relaxation was seen in rat aorta regardless of the agent used to 
induce contraction (phenylephrine, 5-hydroxytryptamine or PGF2α). Most experiments 
were conducted using submaximal phenylephrine-induced tone matched to that of control 
tissues, but very little blockade was seen.   
These effects of ADMA in blocking basal but not acetylcholine-induced activity of nitric 
oxide are similar to those of L-NMMA reported by Frew and co-workers (1993) in the 
same tissue.  
 
The level of tone has an influence on acetylcholine-induced relaxation in control and 
L-NMMA- or ADMA-treated female rat aorta rings  
   The results from this study showed that when phenylephrine-induced tone in the 
presence of ADMA or L-NMMA was held at intermediate levels, virtually no blockade of 
acetylcholine-induced relaxation was seen; there was a modest reduction in tissue 
sensitivity without any effect on the maximal relaxation. However, under conditions where 
ADMA had potentiated phenylephrine-induced tone to near maximal levels, it appeared to 
produce blockade of acetylcholine-induced relaxation. This latter effect of ADMA was 
almost certainly due to physiological antagonism rather than blockade of nitric oxide 
synthase, since matching this increased tone in control tissues with additional 
phenylephrine produced a similar degree of apparent blockade.  
 
    The findings of this study are clearly in conflict with previous studies on rat aorta which 
reported blockade of acetylcholine-induced relaxation by ADMA (Vallance et al., 1992; 
Jin and D'Alecy, 1996; Feng et al., 1998). Since these authors made no mention of 
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matching the tone in control and ADMA-treated tissues, it is likely that the “blockade of 
acetylcholine-induced relaxation” they reported resulted from physiological antagonism, 
due to over-contraction, rather than to blockade of nitric oxide synthase. 
   Furthermore, the results of this study showed that SDMA, the endogenously produced 
inert analogue of ADMA, had no effect on tissue sensitivity, or the maximal response, to 
acetylcholine, consistent with previous reports that SDMA has no effect on nitric oxide 
activity (Masuda et al., 2002; Siroen et al., 2006).   
 
   Although all of the results presented in this study relate to the anomalous abilities of L-
NMMA and ADMA to block basal but not agonist–stimulated activity of nitric oxide in 
female rat aorta, such actions seem not to be gender- or site-specific. Evidence for this has 
separately been reported in male rat aorta and in female rat carotid artery (AL-Zobaidy et 
al., 2011), where L-NMMA and ADMA each enhanced sub-maximal phenylephrine-
induced tone, consistent with blockade of basal nitric oxide activity, but they had almost no 
effect on acetylcholine-induced relaxation, whereas L-NAME uniformly inhibited both 
basal and agonist-stimulated activity .  
  
L-arginine availability for acetylcholine-stimulated nitric oxide activity    
   The results of this study showed that endothelium-dependent, nitric oxide-mediated 
relaxation to acetylcholine in female rat aortic rings, precontracted with phenylephrine, is 
not affected by treatment with L-arginine. This suggests that availability of the substrate 
for nitric oxide synthase is not limiting for the production of nitric oxide in response to 
acetylcholine in this tissue. These findings are in agreement with those reported by 
Moritoki and co-workers (1991) who found that endothelium-dependent acetylcholine-
induced relaxation in male rat aortic rings was not affected by pre-treatment with L-
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arginine although the substrate on its own induced a slowly developing, concentration-
dependent relaxation in both endothelium-containing and denuded rings. The authors 
attributed these relaxations to an endothelium-independent, but nitric oxide-mediated 
mechanism, as relaxation was blocked by the nitric oxide synthase inhibitors L-NMMA 
and L-NOARG. Moreover, Cooke and co-workers (1991) found that endothelium-
dependent, acetylcholine-induced relaxation in isolated aortic rings obtained from normal 
rabbits infused in vivo with L-arginine, was similar to that of untreated rabbits. These 
authors attributed their findings to the existence of a high intracellular concentration of L-
arginine which saturated endothelial nitric oxide synthase.  
 
   In contrast to the situation in normal animals, L-arginine supplementation does appear to 
improve endothelial function in animals with dysfunctional vascular endothelium resulting 
from hypercholesterolaemia (Böger et al., 1995; Candipan et al., 1996; Böger and Bode-
Böger, 2001). Similar findings were reported in humans with pathological conditions 
associated with vascular dysfunction (Rector et al., 1996; Blum et al., 1999; Watanabe et 
al., 2000; Böger and Bode-Böger, 2001). However, little or no effect of L-arginine has 
been reported in normal healthy volunteers. The vascular effects of L-arginine observed in 
pathological conditions caused by vascular endothelial dysfunction has been attributed to 
the higher circulating concentrations of ADMA in association with these conditions 
(Vallance et al., 1992; Böger et al., 1998; Kielstein et al., 1999; Miyazaki et al., 1999; 
Böger 2003; Leiper and Vallence, 2006; Siroen et al., 2006; Andersshon et al 2010). In 
addition, it has been reported that endothelium-independent mechanism(s) such as 
stimulating the release of histamine or vasodilator hormones such as insulin might 
contribute to the vascular actions of infused L-arginine (Smulders et al., 1994; Mehta et 
al., 1996; Guigliano et al., 1997).  
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  The possible explanations for the lack of vascular effect of L-arginine in rat isolated 
aortic rings demonstrated by the results of the present study include the lack of availability 
of vasodilator hormones that could potentially contribute to in vivo. Moreover, the aortic 
rings used in the present study were obtained from normal, healthy animals where it is 
known rats and it is well-known that the intracellular L-arginine concentrations (100-300 
µM) are high enough to saturate endothelial nitric oxide synthase (Km 2-3 µM) (Sydow and 
Münzel, 2003; Teerlink et al., 2009; Zhang et al., 2011).   
 
ADMA and L-NMMA, like L-arginine, protect acetylcholine-induced relaxation 
against blockade by L-NAME 
  The results of this study showed that the acetylcholine-induced, endothelium-dependent, 
nitric oxide-mediated, relaxation in female rat aorta was powerfully blocked by the 
standard nitric oxide synthase inhibitor, L-NAME. In addition, although the early findings 
of this study showed that L-NMMA, another inhibitor of nitric oxide synthase, blocked 
basal but not acetylcholine-induced relaxation, the subsequent results of this study showed 
that L-NMMA acted similarly to L-arginine, the endogenous substrate for nitric oxide 
synthase by both preventing and reversing the blockade of acetylcholine-induced 
relaxation produced by L-NAME. These findings are in agreement with those reported by 
Frew and co-workers (1993) who hypothesised that L-NMMA may function as an 
alternative substrate for nitric oxide synthase when it is stimulated with agonists like 
acetylcholine or ATP. Moreover, chemiluminescence detection has shown that L-NMMA, 
in common with L-arginine, increases the synthesis of nitric oxide in rat aorta and 
pulmonary artery, whereas L-NOARG inhibits it (Archer and Hampl, 1992).  
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  Therefore, in light of the similarities between ADMA and L-NMMA at blocking basal but 
not acetylcholine-stimulated activity of nitric oxide in rat aorta, it was interesting to 
investigate whether ADMA can protect acetylcholine-induced relaxation against blockade 
by L-NAME. Indeed, the results of this study showed that ADMA behaves similarly to L-
arginine; it protects acetylcholine-induced relaxation against blockade by L-NAME, 
however, it failed to reverse that blockade after an hour of treatment, perhaps due to a 
lower potency of ADMA than L-arginine or L-NMMA. Whether or not longer treatments 
on higher concentrations ADMA would have reversed the blockade by L-NAME was not 
investigated.  
 
    In light of the similarities between L-NMMA and ADMA found in this study so far, 
ADMA; like L-NMMA and L-arginine might have behaved as a substrate for 
acetylcholine-stimulated nitric oxide synthase so as to prevent the blockade by L-NAME.  
 
   It is unlikely that a demethylation reaction to form L-arginine explains the abilities of 
ADMA and L-NMMA to behave as alternative substrates for agonist-stimulated 
endothelial nitric oxide synthase, because the blockade they produce of basal nitric oxide 
activity is sustained, suggestive of on-going stability of these agents.  
 
Possible explanations for the anomalous abilities of L-NMMA and ADMA to block 
basal but not agonist–stimulated activity of nitric oxide 
   One theory that may explain these anomalous actions of ADMA and L-NMMA is the 
existence, within the vascular endothelial cells, of more than one isoform of nitric oxide 
synthase; one that catalyses the synthesis of nitric oxide under basal conditions, and 
another that catalyses agonist-stimulated nitric oxide production. Other workers, using 
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aorta from endothelial and neuronal nitric oxide synthase enzymes knockout mice, or 
studying the effects in intact rats or human volunteers of S-methyl-L-thiocitrulline, a 
presumably selective blocker of neuronal nitric oxide synthase, have postulated that the 
latter enzyme catalyses the synthesis of nitric oxide under basal conditions, and the 
endothelial nitric oxide synthase catalyses agonist-stimulated nitric oxide production 
(Wakefield et al., 2003; Nangle et al., 2004; Melikian et al., 2009; Seddon et al., 2009).  
   
    Another possible hypothesis behind the anomalous actions of ADMA and L-NMMA, is 
that the different signal transduction mechanisms triggered by different stimuli may result 
in structural or conformational changes in endothelial nitric oxide synthase that alter its 
requirement for substrates and inhibitors. Such changes could perhaps result in nitric oxide 
synthase recognising ADMA or L-NMMA as substrates rather than as inhibitors. For 
example, nitric oxide production induced by agonists that signal through calcium-
calmodulin pathway, such as acetylcholine (Schini and Vanhoutte, 1992), is little affected 
by ADMA, whereas flow-mediated production of nitric oxide, believed to be mediated 
through phosphorylation of nitric oxide synthase by the phosphatidylinositol 3-kinase/Akt 
pathway (Fulton et al., 1999; Gallis et al., 1999), is inhibited by ADMA in humans (Boger 
et al., 1998; Vladimirova-Kitova et al., 2008). Further studies would be required, however, 
to compare the effects of ADMA and L-NMMA against relaxant stimuli that bring about 
their effects through calcium-calmodulin or the phosphatidylinositol 3-kinase/Akt 
pathway, using same tissue.  
 
    One other potential explanation for the anomalous abilities of ADMA and L-NMMA to 
block basal but not agonist-stimulated activity of nitric oxide may relate to the degree to 
which endothelial nitric oxide synthase is stimulated. Specifically, the low level activation 
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of the enzyme which underpins basal activity of nitric oxide may be easier to block than 
the powerful enzyme activity resulting from agonist stimulation. Indeed, this is supported 
by previous work which suggests that the efficacy of the relaxant agonist is critical in 
determining the ability of nitric oxide synthase inhibitors to block endothelium-dependent 
relaxation (Martin et al., 1992). The results of testing this hypothesis will be presented in 
Chapter Four.   
 
    In conclusion, the findings so far demonstrate that in female rat aorta, the basal nitric 
oxide activity that suppresses vasoconstrictor tone is blocked, in an L-arginine-preventable 
and reversible manner, by the nitric oxide synthase inhibitors, L-NAME, L-NMMA and 
ADMA. In sharp contrast, however, acetylcholine-stimulated nitric oxide activity is little 
affected by L-NMMA or ADMA alone, but these agents like L-arginine oppose the 
blocking action of L-NAME.  
 
    A summary of the effects of L-arginine, L-NAME, L-NMMA, ADMA and SDMA on 
basal and acetylcholine-stimulated activity of nitric oxide in the rat aorta is shown below 
(Figure 2.24).  
 
 
 
 
 
 
 
 
 102
 
 
 
Nitric oxide activity in 
the rat aorta
Basal NO activityAgonist (ACh)-stimulated 
NO activity
Suppression of            
PE-induced tone
Endothelium-dependent 
relaxation
L
-N
A
M
E
Potent blockade of ACh-
induced relaxation
L-arginine
L-NMMA
ADAMA
SDMA No effect
Enhancement of PE-induced 
tone
Protection of ACh-
induced relaxation
L-arginine, L-NMMA  
ADAMA
SDMA
L-NAME
L-NMMA
ADMA
Little or no effect
L-arginine
 
 
 
Figure 2.24. Summary of the effects of L-arginine and methylarginines on basal and 
acetylcholine-stimulated activity of nitric oxide in the rat aorta. 
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  In the next Chapter the anomalous abilities of L-NMMA and ADMA to block basal but 
not agonist–stimulated activity of nitric oxide will be further explored by using different 
experimental approaches. For example, the effects of L-NMMA and ADMA on 
endothelium-dependent relaxation induced by superoxide dismutase or the 
phosphodiesterase isoform 5 inhibitor, T-0156, will be examined as these two agents are 
known to induce endothelium-dependent relaxation by potentiating basal nitric oxide 
activity (MacKenzie et al., 1999; Mochida et al., 2002; Mochida et al., 2004). Moreover, 
the effects of L-NMMA and ADMA will be examined on nitric oxide activity stimulated 
by a range of different agonists that are known to produce endothelium-dependent, nitric 
oxide-mediated relaxations in rat aorta, such as the calcium ionophore A23187 
(Weinheimer and Osswald, 1986; Schini and Vanhoutte, 1992), and calcitonin gene-related 
peptide-1 (Gray and Marshall, 1992; Wisskiechoen et al., 1999).   
 
    In addition, the transduction mechanism(s) that may play a role in the release of nitric 
oxide, under basal and stimulated conditions, will be explored using the calcium-
calmodulin antagonist, calmidazolium (Schini and Vanhoutte, 1992), and the 
phosphatidylinositol 3-kinase/Akt pathway inhibitor, wortmannin (Michell et al., 1999; 
Fulton et al., 1999; Dimmeler et al., 1999).   
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Chapter Three 
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Introduction  
   The findings of the first part of this study showed that L-NMMA and ADMA exhibit 
anomalous abilities to block basal but not agonist (acetylcholine)-stimulated activity of 
nitric oxide in female rat aorta. In addition, the powerful blockade of basal nitric oxide 
activity produced by these two inhibitors of nitric oxide synthase is surmountable, i.e. it 
can both be prevented and reversed by adding a higher concentration of L-arginine, the 
endogenous substrate for nitric oxide synthase. Although, L-NMMA and ADMA had little 
effect on acetylcholine-stimulated activity of nitric oxide, they displayed properties similar 
to L-arginine, i.e. they prevented the ability of L-NAME to block acetylcholine-induced 
relaxation. 
 
  The above effects of L-NMMA or ADMA on basal and agonist-stimulated activity of 
nitric oxide were examined by assessing their effects on phenylephrine-induced tone and 
on acetylcholine-induced relaxation in rat aortic rings, respectively. The purpose of this 
part of the study was to explore further these differential abilities of L-NMMA and ADMA 
to block basal but not agonist–stimulated activity of nitric oxide, using different 
experimental approaches. Specifically, superoxide dismutase is known to produce 
endothelium-dependent relaxation by protecting basal nitric oxide against inactivation by 
superoxide anions (Ohlstein and Nichols, 1989; Mian and Martin, 1995; MacKenzie et al., 
1999). In addition, phosphodiesterase isoform 5 inhibitors, including T-0156, are known to 
elicit endothelium-dependent relaxation because they potentiate basal nitric oxide activity 
by extending the life span of the nitric oxide-dependent second messenger, cyclic 
guanosine monophosphate (cGMP), by preventing its degradation in the vascular smooth 
muscle cells (Martin et al., 1986a; Mochida et al., 2002; Mochida et al., 2004). As a 
consequence, the effects of L-NMMA and ADMA on basal nitric oxide activity will be 
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examined by assessing the influence they exert on endothelium-dependent, nitric oxide-
mediated relaxation induced by superoxide dismutase and T0156 in female rat aorta.  
 
    On the other face of the coin, agonists such as calcitonin gene-related peptide-1 and the 
calcium ionophore A23187 are known to produce endothelium-dependent, nitric oxide-
mediated relaxation by receptor- and non-receptor-mediated actions, respectively 
(Weinheimer and Osswald, 1986; Gray and Marshall, 1992a; Schini and Vanhoutte, 1992; 
Wisskirchen et al., 1999). Thus, the effects of L-NMMA and ADMA on the activity of 
nitric oxide stimulated by these agonists in female rat aorta will be compared with their 
actions on that induced by acetylcholine.  
  
   In addition, the differential abilities of L-NMMA and ADMA to block basal but not 
agonist-stimulated activity of nitric oxide in rat aorta may be related to differences in the 
transduction mechanisms that control the generation of nitric oxide by nitric oxide synthase 
under basal and agonist-stimulated conditions. This hypothesis will be examined by 
assessing the influence of the calcium-calmodulin inhibitor, calmidazolium (Archer and 
Cowan, 1991; Schini and Vanhoutte, 1992), and the phosphatidylinositol 3-kinase 
inhibitor, wortmannin (Michell et al., 1999; Fulton et al., 1999; Dimmeler et al., 1999), on 
basal and agonist-stimulated nitric oxide activity. this will be done by comparing the 
impact they have on the endothelium-dependent, nitric oxide-mediated relaxation induced 
by superoxide dismutase and T0156, on the one hand, and on that induced by 
acetylcholine, A23187 and calcitonin gene-related peptide-1, on the other hand.  
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Materials and Methods  
 
Preparation of aortic rings for tension recording 
 
   The preparation of aortic rings for tension recording was essentially similar to that 
described in the previous Chapter except that the animals were killed by CO2 overdose.  
 
 
Role of the vascular endothelium in relaxation induced by superoxide dismutase or 
the PDE 5 inhibitor, T-0156 
    In the previous Chapter, basal nitric oxide activity was assessed by examining the 
enhancement of phenylephrine-induced tone seen upon the addition of nitric oxide 
synthase inhibitors. In this Chapter an alternative means of assessing this was sought by 
producing endothelium-dependent relaxation through potentiation of basal nitric oxide 
activity.  
 
  In these experiments, female rat endothelium-containing or endothelium-denuded aortic 
rings were allowed to equilibrate for 90 min and the resting stretch was re-adjusted to 10 
mN, if required. Some tissues were then treated with catalase (3600 u ml-1 for 30 min to 
remove any H2O2 present), L-NAME (100 µM for 30 min) or the combination of catalase 
and L-NAME. After this time the treated tissues and their time-matched controls were pre-
contracted to ~50% of maximal phenylephrine tone. Lower concentrations of 
phenylephrine were required to induce the same level of tone in endothelium-denuded and 
L-NAME treated tissues as in control tissues because of removal of the vasodepressant 
action of basal nitric oxide. After stabilisation of tone, increasing concentrations of SOD 
(0.1-300 u ml-1) were added cumulatively to the tissues in the organ baths using the 
sequence 0.1 u ml-1, 0.3 u ml-1, 1 u ml-1, 3 u ml-1, 10 u ml-1, 30 u ml-1, 100 u ml-1  and 300 u 
ml-1 and relaxation assessed. The drug was then either washed out to conduct another 
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concentration-response curve, or papaverine (300 µM) was added to produce full 
relaxation of the tissues.      
 
    As will be seen in the Results, SOD-induced relaxation appeared to comprise separate 
components due to nitric oxide and H2O2. As a consequence, all further experiments with 
SOD were conducted in the presence of catalase (3600 u ml-1) to ensure any relaxation 
produced was solely due to nitric oxide.  
 
    In another set of experiments, female rat endothelium-containing or endothelium-
denuded aortic rings were allowed to equilibrate for 90 min and the resting stretch was     
re-adjusted to 10 mN, if required. The tissues were then pre-contracted to ~50% of 
maximal tone using phenylephrine. After stabilisation of phenylephrine-induced tone, 
increasing concentrations of SOD or the PDE 5 inhibitor, T-0156, were added 
cumulatively to the tissues in the organ baths and relaxations assessed. The drug was then 
either washed out to conduct another concentration-response curve, or papaverine (300 
µM) was added to produce full relaxation of the tissues.     
 
Effects of nitric oxide synthase inhibitors on relaxation induced by superoxide 
dismutase or T-0156 
    In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min and resting stretch was re-adjusted to 10 mN, if required. The tissues 
were then treated with L-NAME (100 µM for 30 min), L-NMMA (100 µM 45 min) or 
ADMA (100 µM for 1 h). After this time the treated tissues and their time-matched 
controls were pre-contracted to ~50% of maximal phenylephrine tone. Care was taken to 
induce comparable levels of tone both in control and treated tissues by using lower 
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concentrations of phenylephrine in the latter. After stabilisation of tone, a full 
concentration-response curve to superoxide dismutase (0.1-300 u ml-1) or T-0156 (1-300 
nM) was conducted. Thereafter, papaverine (300 µM) was added to produce full relaxation 
of the tissues.      
 
Effects of calmidazolium and wortmannin on relaxation induced by superoxide 
dismutase or T-0156  
   The aim of these experiments was to determine the role of endothelial calcium and the 
phosphatidylinositol 3-kinase (PI 3-kinase) pathway in relaxation induced by SOD or T-
0156. This was investigated using the calcium-calmodulin antagonist, calmidazolium 
(Illiano et al., 1992; Schini and Vanhoutte, 1992), and the PI3 kinase inhibitor, wortmannin 
(Michell et al., 1999; Fulton et al., 1999; Dimmeler et al., 1999), respectively.      
 
     In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min and resting stretch was re-adjusted to 10 mN, if required. The tissues 
were then treated with calmidazolium (10 µM) alone, wortmannin (100 nM) alone, or with 
a combination of the two agents, for 1 h. After this time the treated tissues and their time-
matched controls were pre-contracted to ~50% of maximal phenylephrine tone. After 
stabilisation of tone, a full concentration-response curve to SOD (0.1-300 u ml-1) or T-
0156 (1-300 nM) was conducted and relaxation assessed. Thereafter, papaverine (300 µM) 
was added to produce full relaxation of the tissues.       
 
Effects of calmidazolium and wortmannin, compared with L-NAME, on basal nitric 
oxide activity assessed by their effects on phenylephrine-induced contraction          
The previous experiments in this Chapter investigated the effects of L-NAME, 
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calmidazolium and wortmannin on basal nitric oxide activity assessed by their ability to 
affect relaxation induced by SOD or T-0156 in female rat endothelium-containing aortic 
rings. The current experiments were conducted to investigate and compare the effects of 
these three agents, alone and in combination, on basal nitric oxide activity as assessed by 
their ability to enhance the contractile effects of phenylephrine.  
 
    In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min and the resting stretch was re-adjusted to 10 mN, if required. The 
tissues were then treated with calmidazolium (10 µM) alone, wortmannin (100 nM) alone, 
L-NAME (100 µM) alone, calmidazolium and L-NAME, wortmannin and L-NAME, 
calmidazolium and wortmannin, or a combination of the three agents, before performing a 
full concentration-response curve to phenylephrine (1 nM-10 µM). The differential ability 
of these treatments to enhance phenylephrine-induced contraction through inhibition of the 
depressant action of basal nitric oxide activity was then assessed.  
 
Effects of nitric oxide synthase inhibitors on relaxation induced by acetylcholine, 
calcium ionophore A23187 or calcitonin gene-related peptide-1 
    In the previous Chapter it was found that L-NMMA and ADMA had little effect on 
endothelium-dependent relaxation of rat aorta induced by acetylcholine, despite powerfully 
inhibiting basal nitric oxide activity. The aim of these experiments was to investigate the 
effects of L-NMMA and ADMA on the endothelium-dependent relaxation induced by a 
range of agents, i.e. acetylcholine, calcium ionophore A23187 or calcitonin gene-related 
peptide-1 (CGRP-1) in female in female rat endothelium-containing aortic rings.    
   In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min and resting stretch was re-adjusted to 10 mN, if required. The tissues 
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were then treated with L-NAME (100 µM, 30 min), L-NMMA (100 µM, 45 min) or 
ADMA (100 µM, 1 h). After this time, the treated tissues and their time-matched controls 
were pre-contracted to ~50% of maximal phenylephrine tone. Care was taken to induce 
comparable levels of tone both in control and treated tissues by using lower concentrations 
of phenylephrine in the latter. After stabilisation of tone, a full concentration-response 
curve to acetylcholine (1 nM-10 µM), A23187 (1 nM-1 µM) or CGRP-1 (0.1 nM-1 µM) 
was conducted. Thereafter, papaverine (300 µM) was added to produce full relaxation of 
the tissues.       
 
Effects of calmidazolium and wortmannin on relaxation induced by acetylcholine, 
calcium ionophore A23187 or calcitonin gene-related peptide-1 
  The aim of these experiments was to determine the role of endothelial calcium and the PI 
3-kinase pathway in relaxation induced by acetylcholine, A23187 or CGRP-1. This was 
investigated using the calcium-calmodulin antagonist, calmidazolium (Illiano et al., 1992; 
Schini and Vanhoutte, 1992), and the PI3 kinase inhibitor, wortmannin (Michell et al., 
1999; Fulton et al., 1999; Dimmeler et al., 1999), respectively. 
 
   In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min and resting stretch was re-adjusted to 10 mN, if required. The tissues 
were then treated with calmidazolium (10 µM) or wortmannin (100 nM) for 1 h. After this 
time the treated tissues and their time-matched controls were pre-contracted to ~50% of 
maximal phenylephrine tone. After stabilisation of tone, a full concentration-response 
curve to acetylcholine (1 nM-10 µM), A23187 (1 nM-1 µM) or CGRP-1 (0.1 nM-1 µM) 
was conducted and relaxation assessed. Thereafter, papaverine (300 µM) was added to 
produce full relaxation of the tissues.       
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Effects of L-NAME on relaxation induced by isoprenaline or forskolin  
  The rationale for conducting these experiments was to determine if isoprenaline or 
forskolin induce a nitric oxide-dependent component of relaxation that is susceptible to 
blockade by the nitric oxide synthase inhibitor, L-NAME, in female rat endothelium-
containing aortic ring. If so, this would give an opportunity to examine the effects of L-
NMMA and ADMA on agents that produce a component of relaxation via nitric oxide 
release stimulated by agents that elevate cAMP levels (Boo and Jo, 2003). 
   In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min and resting stretch was re-adjusted to 10 mN, if required. The tissues 
were then treated with L-NAME (100 µM, 30 min). After this time the treated tissues and 
their time-matched controls were pre-contracted to ~50% of maximal phenylephrine tone. 
Care was taken to induce comparable levels of tone both in control and treated tissues by 
using lower concentrations of phenylephrine in the latter. After stabilisation of tone, a full 
concentration-response curve to isoprenaline (1 nM-10 µM) or forskolin (1-300 nM) was 
conducted and relaxation assessed. Thereafter, papaverine (300 µM) was added to produce 
full relaxation of the tissues.    
 
Drugs and chemicals  
    Acetylcholine chloride (ACh), asymmetric NG, NG-dimethyl-L-arginine dihydrochloride 
(ADMA), calmidazolium chloride, NG-nitro-L-arginine methyl ester (L-NAME), NG-
monomethyl-L-arginine acetate (L-NMMA), papaverine hydrochloride, phenylephrine 
hydrochloride (PE), superoxide dismutase (SOD; from bovine erythrocytes), isoprenaline 
hydrochloride and forskolin hydrochloride were all obtained from Sigma, UK. Calcium 
ionophore A23187 and wortmannin were obtained from Enzo Life Sciences, UK. Catalase 
(bovine liver) and calcitonin gene-related peptide-1 (human) were obtained from 
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Calbiochem, UK. T-0156 (2-(2-methylpyridin-4-yl) methyl-4-(3,4,5-trimethoxyphenyl)-8-
(pyrimidin-2-yl)methoxy-1,2-dihydro-1-oxo-2,7-naphthyridine-3-carboxylic acid methyl 
ester hydrochloride) was obtained from Tocris, UK. All drugs were dissolved and diluted 
in 0.9% saline, with the exceptions of calmidazolium, T-0156, calcium ionophore A23187 
and wortmannin, which were dissolved in 100% DMSO, and calcitonin gene-related 
peptide-1 which was dissolved in 5% acetic acid (all 10 mM stocks). 
 
Data analysis 
   Contractions were measured in milliNewtons. Papaverine (300 µM) was added at the end 
of each experiment to produce full relaxation of tissues and the relaxant responses to 
agonists were expressed as a percentage of the full relaxation induced by this agent. Data 
are expressed as the mean ± S.E.M of n separate observations. Concentration-effect curves 
were analysed and drawn by fitting the formula mentioned on page 56, and statistical 
analysis was performed using one-way analysis of variance followed by Bonferroni's post-
test or by Student's t test, as appropriate, with the aid of a computer-based program (Graph 
Pad, San Diego, USA). Values were considered to be statistically different when P was ≤ 
0.05.  
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Results  
Superoxide dismutase-induced relaxation 
 
   Following induction of ~ 50% of maximal phenylephrine tone in female rat endothelium-
containing aortic rings, superoxide dismutase (SOD, 0.1-300 u ml-1) induced 
concentration-dependent relaxation (maximal relaxation 63.3 ± 6.0% of initial tone; Figure 
3.1). This relaxation was not significantly affected by 30 min pretreatment with catalase at 
3600 u ml-1 , but it was partially blocked following a 30-min pretreatment with the NOS 
inhibitor, L-NAME, at 100 µM. However, in the presence of catalase, SOD-induced 
relaxation was almost completely abolished by L-NAME (Figure 3.1), or after endothelial 
denudation (Figure 3.2). Since SOD-induced relaxation appeared to comprise separate 
components due to nitric oxide and H2O2, all further experiments with this agent were 
conducted in the presence of catalase to allow further study of the former component only. 
 
Two other NOS inhibitors, ADMA and L-NMMA (both at 100 µM) in the presence of 
catalase, significantly blocked SOD-induced relaxation in endothelium-containing vessels 
(Emax 15.9 ± 4.2 and 21.5 ± 3.6 for ADMA and L-NMMA, respectively; Figure 3.3).  
 
    SOD-induced relaxation in endothelium-containing rat aortic rings was not changed by 
either the PI 3-kinase inhibitor, wortmannin (100 nM) alone, or the calmodulin antagonist, 
calmidazolium (10 µM) alone, but the combination of the two agents resulted in a slight 
but significant inhibition of relaxation (Figure 3.4).  
 
    It is therefore likely that in the presence of catalase, SOD-induced relaxation is mediated 
by protecting basal nitric oxide activity from destruction by superoxide anions, and that 
this explains its blockade by endothelial denudation or pretreatment with NOS inhibitors. 
 115
The PI 3-kinase and calcium-calmodulin pathways are likely to play only a minor role in 
basal nitric oxide production.   
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Figure 3.1. Cumulative concentration-effect curves showing relaxation to superoxide 
dismutase (SOD) in rat endothelium-containing aortic rings sub-maximally contracted with  
PE. Responses are shown for control tissues, tissues in the presence of (3600 u ml-1) of 
catalase alone, or L-NAME (100 µM) alone, or tissues treated with both catalase and L-
NAME. Although SOD-induced relaxation was significantly depressed in the presence of 
L-NAME, it was completely abolished by L-NAME in the presence of catalase. Each point 
represents the mean ± SEM of 5-6 observations. * P< 0.05 and *** P< 0.001 indicate 
significant differences from control. 
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Figure 3.2. Cumulative concentration-effect curves showing relaxation to SOD in rat 
aortic rings submaximally contracted with PE in the presence (control) and absence (EC-) 
of endothelium. SOD-induced relaxation was completely abolished by endothelial 
denudation. All experiments were conducted in the presence of catalase (3600 u ml-1) to 
remove the influence of any H2O2 produced. Each point represents the mean ± SEM of 6 
observations. *** P< 0.001 indicates a significant difference from control. 
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Figure 3.3.  Cumulative concentration-effect curves showing relaxation to SOD in rat 
endothelium-containing aortic rings submaximally contracted with PE in the absence and 
presence of L-NAME, L-NMMA or ADMA, all at 100 µM. SOD-induced relaxation was 
powerfully blocked by each of the three nitric oxide synthase inhibitors. All experiments 
were conducted in the presence of catalase (3600 u ml-1) to remove the influence of any 
H2O2 produced Each point represents the mean ± SEM of 5-6 observations. *** P< 0.001 
indicates a significant difference from control. 
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Figure 3.4. Cumulative concentration-effect curves showing relaxation to SOD in rat 
endothelium-containing aortic rings submaximally contracted with PE in the absence and 
presence of wortmannin (Wtm) at 100 nM, calmidazolium (CMZ) at 10 µM, or both. 
Neither wortmannin nor calmidazolium alone had an effect on SOD-induced relaxation, 
however, the combination of the two drugs produced significant blockade. All experiments 
were conducted in the presence of catalase (3600 u ml-1) to remove the influence of any 
H2O2 produced. Each point represents the mean ± SEM of 5-7 observations. * P< 0.05 
indicates a significant difference from control. 
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Relaxation induced by the PDE 5 inhibitor, T-0156   
    The PDE 5 inhibitor, T-0156 (1-300 nM), produced more powerful relaxation in 
endothelium-containing than in endothelium-denuded rings of rat aorta (Emax 89.9 ± 3.2% 
and 53.5 ± 3.4%, respectively; Figure 3.5). The endothelium-dependent component of T-
0156-induced relaxation was significantly blocked by each of the NOS inhibitors, L-
NAME, L-NMMA or ADMA, all at 100 µM (Figure 3.6).  
 
     Relaxation induced by T-0156 in endothelium-containing aortic rings was not affected 
by either wortmannin (100 nM) alone, or calmidazolium (10 µM) alone, but the 
combination of the two agents resulted in a slight but significant inhibition of relaxation 
(Figure 3.7).   
 
     The endothelium-dependent component of T-0156-induced relaxation is likely to occur 
through potentiation of basal nitric oxide activity and this explains its blockade by the NOS 
inhibitors. These experiments also suggest that the PI 3-kinase and calcium-calmodulin 
pathways are likely to play only a minor role in basal nitric oxide production.   
 
Effects of wortmannin and calmidazolium on basal nitric oxide activity assessed by their 
effects on PE-induced contractions 
      The maximal response as well as the sensitivity of rat endothelium-containing aortic 
rings to phenylephrine (1nM-10 µM) was significantly enhanced by pretreatment with L-
NAME (100 µM), consistent with blockade of basal nitric oxide activity (Figure 3.8). 
Wortmannin (100 nM) alone, calmidazolium (10 µM) alone, and the combination of the 
two also led to an enhanced sensitivity and maximal response to phenylephrine, but the 
magnitude of these was much lower than for L-NAME. Moreover, the ability of 
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wortmannin or calmidazolium, either alone or combined, to enhance PE-induced 
contraction was abolished when the tissues were pre-treated with L-NAME.   
    
   Therefore, basal nitric oxide activity which suppresses vasoconstrictor tone is greatly 
blocked by pre-treatment with the NOS inhibitor, L-NAME. These experiments suggest 
that the PI 3-kinase and calcium-calmodulin pathways play a role in basal nitric oxide 
production, but only to a minor extent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122
 
 
-10 -9 -8 -7 -6
0
10
20
30
40
50
60
70
80
90
100
EC-
Control
***
Log [T-0156] M
Re
la
xa
tio
n
 
( %
 
)
 
 
Figure 3.5. Cumulative concentration-effect curves showing relaxation to the PDE 5 
inhibitor, T-0156, in rat aortic rings submaximally contracted with PE in the presence 
(control) and absence (EC-) of endothelium. T-0156 has both endothelium-dependent and 
endothelium-independent components of relaxation. Each point represents the mean ± 
SEM of 6 observations. *** P< 0.001 indicates a significant difference from control. 
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Figure 3.6. Cumulative concentration-effect curves showing relaxation to T-0156 in rat 
endothelium-containing aortic rings submaximally contracted with PE in the absence and 
presence of L-NAME, L-NMMA or ADMA, all at 100 µM . The endothelium-dependent 
component of T-0156-induced relaxation was significantly blocked by each of the three 
nitric oxide synthase inhibitors. Each point represents the mean ± SEM of 6 observations. 
*** P< 0.001 indicates a significant difference from control. 
 
 124
 
 
 
 
-10 -9 -8 -7 -6
0
10
20
30
40
50
60
70
80
90
100
Wtm + CMZ
Control
CMZ
Wtm
**
*
*
*
**
Log [T-0156] M
Re
la
xa
tio
n
 
( %
 
)
 
 
Figure 3.7. Cumulative concentration-effect curves showing relaxation to T-0156 in rat 
endothelium-containing aortic rings submaximally contracted with PE in the absence and 
presence of wortmannin (Wtm) at 100 nM, calmidazolium (CMZ) at 10 µM, or both. 
Neither wortmannin nor calmidazolium alone had an effect on T-0156-induced relaxation; 
however, the combination of the two drugs produced a slight but significant blockade. 
Each point represents the mean ± SEM of 5-7 observations. * P< 0.05 and ** P< 0.01 
indicate significant differences from control. 
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Figure 3.8.  Cumulative concentration-effect curves showing contractile response to PE in 
rat endothelium-containing aortic rings in the absence or presence of (a) wortmannin 
(Wtm; 100 nM), L-NAME (100 µM) or both, (b) calmidazolium (CMZ; 10 µM), L-NAME 
or both, and (c) wortmannin and calmidazolium, L-NAME or all the three agents.  PE-
induced contraction was significantly enhanced by L-NAME or by wortmannin or 
calmidazolium alone and combined. However, the magnitude of the enhancement of PE-
induced contraction produced by wortmannin and calmidazolium, either alone or in 
combination was lower than that produced by L-NAME. Each point represents the mean ± 
SEM of 5-7 observations. * P< 0.05, ** P< 0.01 and *** P< 0.001 indicate significant 
differences from control. 
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Acetylcholine-induced relaxation 
   Having established the effects of NOS inhibitors, wortmannin or calmidazolium on basal 
nitric oxide activity, it became important to investigate the effects of these agents on 
agonist-stimulated nitric oxide activity. 
    
   Following induction of ~ 50% of maximal phenylephrine tone in rat endothelium-
containing aortic rings, acetylcholine (1 nM-10 µM) produced concentration-dependent 
relaxation that was significantly blocked by L-NAME (100 µM), but little affected by L-
NMMA or ADMA (both at 100 µM; Figure 3.9a), in keeping with findings in the previous 
Chapter.  
 
   Acetylcholine-induced relaxation was significantly blocked by calmidazolium (10 µM), 
but unaffected by wortmannin (100 nM; Figure 3.9b).  
 
Thus, acetylcholine-induced relaxation appears to involve calcium-calmodulin but not 
the PI 3-kinase pathway. 
 
Relaxation induced by the calcium ionophore A23187  
    After induction of submaximal phenylephrine-induced tone in rat endothelium-
containing aortic rings, the calcium ionophore A23187 (1 nM-1 µM), produced 
concentration-dependent relaxation (Emax 96.2 ± 1.2%) that was significantly blocked by 
pre-treatment with 100 µM L-NAME (Emax 36.4 ± 1.6%); Figure 3.10a). A23187-induced 
relaxation was powerfully blocked by pre-treatment with 10 µM calmidazolium (Emax 56.7 
± 2.7%), but unaffected by wortmannin (100 nM; Figure 3.10b).  
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   Therefore, relaxation produced A23187, like that to acetylcholine, seems to be 
susceptible to blockade by L-NAME, but not L-NMMA or ADMA, and occurs via the 
calcium-calmodulin but not the PI 3-kinase pathway. 
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Figure 3.9. Cumulative concentration-effect curves showing relaxation to acetylcholine in 
rat endothelium-containing aortic rings submaximally contracted with PE in the absence 
and presence of (a) L-NAME, L-NMMA or ADMA (all at 100 µM), or (b) wortmannin 
(Wtm) at 100 nM or calmidazolium (CMZ) at 10 µM. Relaxation was significantly 
blocked by L-NAME or calmidazolium, but not by L-NMMA, ADMA or wortmannin. 
Each point represents the mean ± SEM of 6-15 observations. *** P< 0.001 indicates a 
significant difference from control. 
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Figure 3.10. Cumulative concentration-effect curves showing relaxation to calcium 
ionophore A23187 in rat endothelium-containing aortic rings submaximally contracted 
with PE in the absence and presence of (a) L-NAME, L-NMMA or ADMA (all at 100 
µM), or (b) wortmannin (Wtm) at 100 nM or calmidazolium (CMZ) at 10 µM. Relaxation 
was significantly blocked by L-NAME or calmidazolium, but not by L-NMMA, ADMA or 
wortmannin. Each point represents the mean ± SEM of 5-7 observations. *** P< 0.001 
indicates a significant difference from control.  
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Relaxation induced by calcitonin gene-related peptide-1 
     After induction of submaximal phenylephrine -induced tone in rat endothelium-
containing aortic rings, calcitonin gene-related peptide-1 (CGRP-1; 0.1 nM-1 µM) elicited 
concentration-dependent relaxation (Emax 57.6 ± 3.2%) that was significantly blocked by L-
NAME (100 µM; Figure 3.11a). Unlike with acetylcholine and A23187, however, CGRP-
1-induced relaxation was also blocked by L-NMMA and ADMA (both 100 µM).  
 
   CGRP-1-induced relaxation was also powerfully blocked by calmidazolium (10 µM), but 
not by wortmannin (100 nM; Figure 3.11b). 
 
  Thus, surprisingly, despite appearing to operate by the same calcium-calmodulin-
dependent, PI 3-kinase-independent pathway used by acetylcholine and A23187, CGRP-1-
induced relaxation is blocked by all three NOS inhibitors and not just L-NAME. Why 
CGRP-1 behaves so differently from acetylcholine and A23187 in this regard requires 
further investigation. 
 
Relaxation induced by isoprenaline and forskolin  
   After induction of ~ 50% of maximal phenylephrine tone in female rat endothelium-
containing aortic rings, isoprenaline (1 nM-10 µM) and forskolin (1 nM- 300 nM) each 
produced relaxation that was only slightly depressed by L-NAME (100 µM; Figure 3.12a 
and b). Since there was no substantial nitric oxide-dependent component to relaxation by 
these agents, the effects of L-NMMA, ADMA, wortmannin and calmidazolium were not 
examined.  
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Figure 3.11. Cumulative concentration-effect curves showing relaxation to calcitonin 
gene-related peptide-1 (CGRP-1) in rat endothelium-containing aortic rings submaximally 
contracted with PE in the absence and presence of (a) L-NAME, L-NMMA or ADMA (all 
at 100 µM), or (b) wortmannin (Wtm) at 100 nM or calmidazolium (CMZ) at 10 µM. 
Relaxation was significantly blocked by L-NAME, L-NMMA, ADMA and calmidazolium, 
but not by wortmannin. Each point represents the mean ± SEM of 5-6 observations. *** P< 
0.001 indicates a significant difference from control.  
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Figure 3.12. Cumulative concentration-effect curves showing relaxation to (a) isoprenaline  
(ISP) or (b) forskolin (FK) in rat endothelium-containing aortic rings submaximally 
contracted with PE in the absence or presence of L-NAME (100 µM). Relaxations were 
only slightly depressed in the presence of L-NAME. Each point represents the mean ± 
SEM of 6 observations. * P< 0.05, ** P< 0.01 and *** P< 0.001 indicate significant 
differences from control. 
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Discussion  
Superoxide dismutase-induced relaxation in the presence of catalase in female rat 
aorta occurs through potentiation of basal nitric oxide activity and is blocked by L-
NAME, L-NMMA and ADMA     
   The findings of this part of the study showed that superoxide dismutase produced a 
concentration-dependent relaxation in endothelium-containing rings of rat aorta that was 
partially blocked by pre-treatment with L-NAME. However, in the presence of the 
hydrogen peroxide scavenger, catalase, superoxide dismutase-induced relaxation was 
virtually abolished by L-NAME or endothelial denudation. These findings are consistent 
with previous work showing that the concentration-dependent, endothelium-mediated 
relaxation induced by superoxide dismutase is attributed to protection of basal nitric oxide 
from destruction by superoxide anion (˙O-2) (Gryglewski et al., 1986; Rubanyi and 
Vanhoutte, 1986; Ohlstein and Nichols, 1989; Mian and Martin 1995; MacKenzie et al., 
1999). However, the partial blockade of superoxide dismutase-induced relaxation by L-
NAME in the absence of catalase indicates that this relaxation has at least two components; 
an L-NAME-sensitive nitric oxide-mediated component and a catalase-sensitive hydrogen 
peroxide-mediated component, as relaxation was almost completely blocked by co-
treatment with L-NAME and catalase (Rubanyi and Vanhoutte, 1986; Furchgott et al., 
1994; Yang et al., 1999; Iesaki et al., 1999; Itoh et al., 2003).    
 
    Therefore, in the presence of catalase, superoxide dismutase-induced relaxation is likely 
to be mediated solely through protecting basal nitric oxide activity from breakdown by 
superoxide anion. L-NMMA and ADMA, like L-NAME, were also able to significantly 
block superoxide dismutase-induced relaxation suggesting that they too block the synthesis 
of basal nitric oxide. The outcome of these experiments is therefore consistent with those 
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in the previous Chapter where L-NMMA and ADMA were deemed to block basal nitric 
oxide activity as assessed by their ability to enhance phenylephrine-induced tone in 
endothelium-containing rings.  
 
 
The endothelium-dependent component of relaxation to the PDE isoform 5 inhibitor, 
T-0156, occurs through potentiation of basal nitric oxide activity and is abolished by 
L-NAME, L-NMMA and ADMA 
  Previous reports showed that the phosphodiesterase isoform 5 inhibitors, zaprinast (M&B 
22948), T1032 and T0156, exhibit endothelium-dependent and endothelium-independent 
components of relaxation (Martin et al., 1986a; Hobbs et al., 1999; Mochida et al., 2002; 
Kimura et al., 2003; Mochida et al., 2004; Galley et al., 2004; Bauer and Sotnikova, 2010).  
The endothelium-dependent component has been attributed to potentiation of basal nitric 
oxide activity generated by the vascular endothelium, as the activation induced by these 
agents is associated with elevation of the nitric oxide-dependent second messenger, cyclic 
guanosine phosphate (cGMP), within the vascular smooth muscle cells. These previous 
results provide an explanation for findings from this study which showed that T0156 
produced more powerful relaxation in endothelium-containing rat aortic rings than in 
endothelium-denuded. In addition, the nitric oxide synthase inhibitors, L-NAME, L-
NMMA and ADMA, each produced a blockade of T0156-induced relaxation that was as 
powerful as that produced by endothelial denudation. These findings, like those with 
superoxide dismutase, are therefore consistent with the ability of L-NAME, L-NMMA and 
ADMA to block basal nitric oxide activity in rat aorta.  
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Calcium-calmodulin and the phosphatidylinositol 3-kinase pathways have a minor 
role in basal nitric oxide production in female rat aorta 
   A difference in the transduction mechanisms that govern basal and agonist-stimulated 
synthesis of nitric oxide could potentially explain the ability of L-NMMA and ADMA to 
block the former but not the latter in rat aorta. However, the researchers who first 
documented the presence of basal nitric oxide activity in rat aorta (Martin et al., 1986b; 
Rees et al., 1989; Moore et al., 1990) proposed that it was produced spontaneously by the 
vascular endothelium without the need for an external stimulus; this potentially excludes 
the existence of an intracellular signalling mechanism to control the synthesis of basal 
nitric oxide. This proposal was supported by the observations made by Rapoport and 
Murad (1983) that the resting levels of cGMP in entirely unstimulated endothelium-
containing rat aortic rings were 2-3-fold higher than those in endothelium-denuded rings. 
Their findings too suggest that the basal nitric oxide activity in endothelium-containing 
rings occurred in the absence of any stimulus.  
 
   On the other hand, other researchers have proposed the existence of triggering stimuli 
that operate within the vascular endothelium to generate basal nitric oxide activity. Such 
stimuli may include calcium ions that pass from the contracting vascular smooth muscle 
cells through myo-endothelial gap junctions to the underlying endothelial cells (Dora et al., 
2000; Jackson et al., 2008) where they (calcium ions) provoke the release of nitric oxide 
presumably via a calcium-calmodulin-mediated, calmidazolium-sensitive activation of 
endothelial nitric oxide synthase. Alternatively, Fleming et al (1999) proposed that 
isometric contraction may generate a mechanical stress on the endothelial cytoskeleton that 
triggers the release of nitric oxide via a phosphatidylinositol 3-kinase-mediated, 
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wortmannin-sensitive phosphorylation and activation of endothelial nitric oxide synthase, 
similar to that induced by shear stress generated by blood flow.  
 
  The findings of this study showed that calmidazolium and wortmannin each produced a 
statistically significant augmentation of phenylephrine-induced contraction which may 
suggest an inhibitory effect of these agents on basal nitric oxide production in rat aorta. 
However, the extent to which calmidazolium or wortmannin enhanced phenylephrine-
induced contraction by blocking basal nitric oxide synthesis was substantially smaller than 
that produced by L-NAME. Moreover, neither of these agents blocked the endothelium-
dependent nitric oxide mediated relaxation induced by superoxide dismutase or T0156 to a 
significant extent, although a combination of the two did produce a small degree blockade. 
Taken together, these data indicate that calcium-calmodulin-dependent and 
phosphatidylinositol 3-kinase-mediated activation of endothelial nitric oxide synthase play 
only a minor role in basal nitric oxide production in female rat aorta. The major component 
of basal nitric oxide production appears to occur, however, through spontaneous, 
unstimulated activity of the enzyme.  
 
Relaxation induced by calcitonin gene-related peptide-1 and calcium ionophore 
A23187 in female rat aorta is differentially sensitive to blockade by L-NMMA and 
ADMA 
   One of the main findings from this study was that although L-NAME powerfully blocked 
acetylcholine-induced relaxation, L-NMMA and ADMA had a small inhibitory effect on 
tissue sensitivity to acetylcholine (2-3-fold) but did not affect the maximal response to this 
agent; this finding with L-NMMA supports the earlier observations of Frew and co-
workers (1993). The aim of this part of the study was to determine if L-NMMA and 
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ADMA were poor inhibitors of relaxations induced by other agents, namely calcitonin 
gene-related peptide-1 and calcium ionophore A23187.  
 
  The data from this study showed that calcitonin gene-related peptide-1 induced 
endothelium-dependent, nitric oxide-mediated relaxation in rat aorta, as relaxation is 
powerfully blocked by the nitric oxide synthase inhibitor, L-NAME. Surprisingly, 
however, and in contrast with the findings with acetylcholine, both L-NMMA and ADMA 
powerfully blocked relaxation to calcitonin gene-related peptide-1. These data are in 
agreement with previous reports (Gray and Marshall, 1992; Abdelrahman et al., 1992, de 
Hoon et al., 2003; Thakor and Giussani, 2005) which showed that the endothelium-
dependent relaxation induced by gene-related peptide-1 is mediated by nitric oxide.  
 
  In addition, the findings of this study showed that relaxation induced by calcium 
ionophore A23187, which acts to increase endothelial calcium levels by a receptor-
independent mechanism, is powerfully blocked by L-NAME. This strongly suggests that 
this relaxation is endothelium-dependent and nitric oxide-mediated, which is consistent 
with previous reports (Weinheimer and Osswald, 1986; Schini and Vanhoutte, 1992; 
Taniguchi et al., 1999; Shi et al., 2007). As with acetylcholine, but unlike with calcitonin 
gene-related peptide-1, L-NMMA and ADMA, had little effect on relaxation induced by 
calcium ionophore A23187. It was clear, therefore, that an explanation was required for the 
ability of L-NMMA and ADMA to block the endothelium-dependent, nitric oxide-
mediated relaxation induced by calcitonin gene-related peptide-1, but not by acetylcholine 
or A23187.  
 
  One potential explanation for these differential effects of L-NMMA and ADMA is the 
possibility that the endothelium-dependent relaxation induced by calcitonin gene-related 
 138
peptide-1 in the female rat aorta is mediated by relaxing factor(s) other than nitric oxide as 
has been proposed in other tissues such as the male rat aorta, cultured human umbilical 
vein endothelial cells or rabbit cutaneous microvasculature (Grace et al., 1987; Crossman 
et al., 1987; Hughes and Brain, 1994). This explanation can be ruled out, however, because 
in keeping with previous reports (Gray and Marshall, 1992a; Abdelrahman et al., 1992, 
Hoon et al., 2003; Thakor and Giussani, 2005), the standard nitric oxide synthase inhibitor, 
L-NAME, virtually abolished relaxation to calcitonin gene-related peptide-1, showing it is 
almost certainly mediated by nitric oxide.  
 
   Another potential explanation for the differential effects of L-NMM and ADMA on 
relaxation induced by calcitonin gene-related peptide-1, acetylcholine and A23187 is that 
these agonists might stimulate the release of nitric oxide by nitric oxide synthase through 
the activation of different transduction pathways, and this is explored in the next section.   
 
The endothelium-dependent, nitric oxide-mediated relaxation induced by 
acetylcholine, calcium ionophore A23187 and calcitonin gene-related peptide-1 are all 
mediated by the calcium-calmodulin pathway 
    Previous work has shown that the shearing force of flowing blood induces the 
generation of nitric oxide via the wortmannin-sensitive, phosphatidylinositol 3-kinase/Akt 
pathway which activates endothelial nitric oxide synthase through a calcium-independent 
phosphorylation of serine 1177 (Dimmeler et al., 1999; Fulton et al., 1999; McCabe et al., 
2000). Certain agonists, including VEGF and insulin, also stimulate nitric oxide production 
using this pathway (Zeng and Quon, 1996; Papapetropoulos et al., 1997; Fulton et al., 
1999; Fleming et al., 2001). In contrast, the generation of nitric oxide by other agonists 
such as acetylcholine, A23187 or substance P is stimulated via the calmidazolium-
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sensitive, direct activation of nitric oxide synthase by calcium-calmodulin (Weinheimer 
and Osswald, 1986; Archer and Crowan, 1991; Schini and Vanhoutte, 1992; Taniguchi et 
al., 1999; Sunagawa et al., 2000; Schneider et al., 2003). In agreement with this latter 
conclusion, data from the present study showed that calmidazolium powerfully blocked the 
endothelium-dependent, nitric oxide-mediated relaxation induced by acetylcholine, 
A23187 or calcitonin gene-related peptide-1, while the phosphatidylinositol 3-kinase 
inhibitor, wortmannin, had no effect. These findings strongly suggest that these three 
distinct agonists signal through a seemingly similar calcium-calmodulin-dependent 
transduction mechanism to stimulate the release of nitric oxide in rat aorta. It is therefore 
clear that the ability of L-NMMA and ADMA to block relaxation to calcitonin gene-
related peptide-1, but not to acetylcholine or A23187, cannot be explained by these 
agonists acting via different transduction pathways.  
 
Isoprenaline and forskolin possess endothelium-dependent and endothelium-
independent components of relaxation in female rat aorta 
   The non-selective β-adrenoceptor agonist, isoprenaline, and the adenylate cyclase 
activator, forskolin, have been reported to relax rat aorta by two distinct mechanisms: an 
endothelium-dependent, nitric oxide-mediated component, and a component due to direct 
effect on the vascular smooth muscle cells (Kamata et al., 1989; Gray and Marshall, 
1992b; Karasu et al., 1997).   
 
   The endothelium-dependent component of relaxation to isoprenaline and forskolin is 
believed to be due to the calcium-independent activation of endothelial nitric oxide 
synthase through phosphorylation of serine 1177 by cyclic AMP-dependent protein kinase 
A (PKA). A potential opportunity thus arose to compare the effects of L-NMMA and 
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ADMA with those of L-NAME on relaxation induced through activation of endothelial 
nitric oxide synthase by PKA-mediated phosphorylation. 
  
  The data from this study showed that isoprenaline and forskolin each induced potent 
concentration-dependent relaxation of endothelium-containing rings. However, in the 
presence of L-NAME, the relaxations obtained to both agents were not substantially 
different from those in control tissues. Why this study appeared to generate a smaller 
component due to nitric oxide than previous studies (Gray and Marshall, 1992b; Mikio et 
al., 1997) is unclear. One possibility relates to the level of tone employed in the different 
studies. In this study, the levels of tone were carefully matched in control and L-NAME-
treated preparations. The previous reports (Gray and Marshall, 1992b; Mikio et al., 1997) 
did not indicate the level of tone used, so it is possible that in these the level of tone was 
substantially higher in treated tissues than in controls due to blockade of basal nitric oxide 
activity. If so, the substantially higher levels of blockade reported might have resulted from 
physiological antagonism rather than blockade of agonist-stimulated production of nitric 
oxide. 
 
    Thus, because no substantial endothelium-dependent, nitric oxide-mediated component 
of relaxation could be observed in response to isoprenaline or forskolin it was, therefore, 
impossible to conduct the planned experiments to determine the effects of L-NMMA and 
ADMA on this component.  
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The ability of L-NMMA and ADMA to block endothelium-dependent, nitric oxide-
mediated relaxation in female rat might be determined by the efficacy of the relaxant 
agent 
   Previous studies (Grace et al., 1987; Gray and Marshall, 1992a) showed that calcitonin 
gene-related peptide-1 induced concentration-dependent relaxation in endothelium-
containing rat aortic rings, and the maximal response elicited by this agonist was lower 
than that induced by acetylcholine in the same tissue. Moreover, these studies showed that 
calcitonin gene-related peptide-1-induced relaxation was powerfully blocked by L-NMMA 
and L-NOARG.  
 
    The results of the present study also showed that the maximum relaxation calcitonin 
gene-related peptide-1 produced in female rat aorta is lower than that elicited by 
acetylcholine or A23187. Also, the results of this study showed that this relaxation, in 
contrast to that induced by acetylcholine or A23187, was powerfully blocked by L-NMMA 
and ADMA.   
 
     It is possible therefore that the ability of L-NMMA and ADMA to block relaxation to 
calcitonin gene-related peptide-1 but not to acetylcholine or A23187 might somehow 
related to the maximum relaxation these agents can elicit. In light of this possibility, a 
question emerged of whether the lower efficacy of calcitonin gene-related peptide-1, in 
comparison with that of acetylcholine or A23187, was the reason why relaxation induced 
by this agent was susceptible to blockade by L-NMMA or ADMA. This point will be 
further investigated in the next Chapter by use of the M3 receptor partial agonist, 
butyrylcholine, and by lowering the apparent efficacy of acetylcholine by using the 
irreversible alkylating agent, phenoxybenzamine (Martin et al., 1992).   
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Chapter Four 
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 Introduction  
   The findings of the present study so far showed that, in the female rat aorta, the inhibitors 
of nitric oxide synthase, L-NMMA and ADMA, have seemingly differential abilities to 
block basal but not agonist (acetylcholine or A23187)-stimulated activity of nitric oxide. 
However, the findings also showed that these inhibitors significantly blocked the 
endothelium-dependent, nitric oxide-mediated relaxation induced by calcitonin gene-
related peptide-1 in the same tissue.   
 
   It was clear that the ability of L-NMMA and ADMA to block relaxation to calcitonin  
gene-related peptide-1 but not to acetylcholine or A23187 was not related to differences in 
transduction mechanisms used by these agents to produce relaxation, since all these agents 
seemed to stimulate endothelial nitric oxide production via the same calcium-calmodulin-
dependent, calmidazolium-sensitive pathway.  
 
  One other aspect that also appeared to differentiate calcitonin gene-related peptide-1 from 
acetylcholine and A23187 was its lower maximal relaxant capacity. It is therefore possible 
that the differential effects of L-NMMA and ADMA might be related to the efficacy of the 
relaxant agonist.  
 
   This possibility is supported by a previous report showing that the ability of L-NAME to 
block endothelium-dependent, nitric oxide-mediated relaxation in the rabbit jugular vein is 
determined by the efficacy of the relaxant agent (Martin et al., 1992). In this latter study, 
the researchers found in rat aorta that L-NAME produced powerful blockade of 
acetylcholine-induced, endothelium-dependent, nitric oxide-mediated relaxation, whereas 
in rabbit jugular vein L-NAME had little effect on same relaxation. However, in the latter 
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tissue L-NAME powerfully blocked endothelium-dependent relaxation induced by           
α-methyl-5-hydroxytryptamine, a partial agonist at endothelial 5-HT2 receptors (Leff et al., 
1987), or relaxation induced by the M3 muscarinic receptor partial agonists, pilocarpine 
and butyrylcholine. The researchers concluded that the differential effects of L-NAME 
were not due to different receptor subtypes or to different endothelium-derived relaxing 
factors, but were potentially attributed to the effectiveness of receptor-effector coupling. 
To test this hypothesis, the researchers employed the irreversible alkylating agent, 
phenoxybenzamine, to reduce the apparent efficacy of acetylcholine in the rabbit jugular 
vein to the extent that acetylcholine behaved similar to a partial agonist. Under these 
conditions they showed that L-NAME now produced powerful blockade of acetylcholine-
induced relaxation in rabbit jugular vein. Taking these observations together, Martin and 
co-workers (1992) concluded that the ability of L-NAME to block endothelium-dependent, 
nitric oxide-mediated relaxation in the rabbit jugular vein is determined by the efficacy of 
the relaxant agent.  
  
   With the finding of Martin and co-workers (1992) in mind, the aim of the experiments in 
this part of the study was to determine whether the ability of L-NMMA or ADMA to block 
relaxation induced by calcitonin gene-related peptide-1 but not acetylcholine or A23187 is 
attributed to the lower maximal response elicited by this agonist.      
 
   This possibility was investigated using the M3 receptor partial agonist, butyrylcholine, 
and by lowering the apparent efficacy of acetylcholine using the irreversible alkylating 
agent, phenoxybenzamine (Martin et al., 1992).  
 
 
 145
Material and Methods  
Preparation of aortic rings for tension recording 
 
   The preparation of aortic rings for tension recording was essentially similar to that 
described in the previous Chapter except that the animals were killed by CO2 overdose.  
 
 
The effects of L-NMMA and ADMA on acetylcholine- and butyrylcholine-induced 
relaxation  
    Experiments from the previous Chapters investigated and compared the effects of the 
nitric oxide synthase inhibitors, L-NMMA and ADMA, on relaxation induced by 
acetylcholine, A23187 or calcitonin gene-related peptide-1 in female rat endothelium-
containing aortic rings.  
 
   The aims of these experiments were to investigate if the limited ability of L-NMMA and 
ADMA to block relaxation induced by acetylcholine or A23187, on the one hand, but 
significantly block relaxation induced by CGRP-1, on the other hand, is related to the 
efficacy of the relaxant agonist. This was examined by comparing the effects of L-NMMA 
and ADMA on relaxation induced by the full agonist, acetylcholine, with those on 
relaxation to the M3 partial agonist, butyrylcholine (Martin et al., 1992).   
. 
    In experiments involving the muscarinic partial agonist, butyrylcholine, female rat 
endothelium-containing aortic rings were allowed to equilibrate for 90 min with the resting 
stretch re-adjusted to 10 mN, if required. The tissues were then treated with L-NMMA 
(100 µM or 1 mM for 30 min) or ADMA (100 µM or 1 mM for 1 h). After this time the 
treated tissues and their time-matched controls were pre-contracted to ~50% of maximal 
phenylephrine tone. Care was taken to induce comparable levels of tone in control and 
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treated tissues by using lower concentrations of phenylephrine in the latter. After 
stabilisation of tone, a full concentration-response curve to butyrylcholine (100 nM-300 
µM) was conducted. Thereafter, papaverine (300 µM) was added to produce full relaxation 
of the tissues.      
 
Effects of the contractile agent on relaxation induced by butyrylcholine or 
acetylcholine  
   The aim of these experiments was to determine if the ability of acetylcholine or 
butyrylcholine to induce endothelium-dependent relaxation in rat aorta differed depending 
on the contractile agent used to raise tone. These preliminary experiments were required 
because, as will be seen later, experiments were conducted to lower the apparent efficacy 
of acetylcholine using the irreversible alkylating agent, phenoxybenzamine. Since this 
agent also inhibits the contractile effects of phenylephrine, a suitable alternative contractile 
agent needed to be identified.   
 
     In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min and the resting stretch re-adjusted to 10 mN, if required. The tissues 
were then pre-contracted to a submaximal level of phenylephrine- or endothelin-1 (20-40      
nM)-induced tone. After stabilisation of tone, a full concentration-response curve to 
acetylcholine (1 nM-10 µM) or to butyrylcholine (100 nM-300 µM) was conducted. 
Thereafter, papaverine (300 µM) was added to produce full relaxation of the tissues.      
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Effects of L-NMMA or ADMA on acetylcholine-induced relaxation in tissues pre-
contracted with endothelin-1 
    The aim of these experiments was to investigate if the limited ability of L-NMMA or 
ADMA to block the endothelium-dependent relaxation induced by acetylcholine in rat 
aorta is also seen when endothelin-1 is used as the contractile agent.  
 
    In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min with the resting stretch re-adjusted to 10 mN, if required. The tissues 
were then treated with L-NMMA (100 µM or 1 mM for 30 min) or ADMA (100 µM or 1 
mM for 1 h). After this time the treated tissues and their time-matched controls were pre-
contracted to a submaximal level of endothelin-1-induced tone. Care was taken to induce 
comparable levels of tone in control and treated tissues by using lower concentrations of 
endothelin-1 in the latter. After stabilisation of tone, a full concentration-response curve to 
acetylcholine (1 nM-10 µM) was conducted. Thereafter, papaverine (300 µM) was added 
to produce full relaxation of the tissues.       
 
Effects of phenoxybenzamine on relaxation induced by acetylcholine or 
butyrylcholine 
  The aim of these experiments was to determine the extent to which the irreversible 
alkylating agent, phenoxybenzamine (Martin et al., 1992), reduced the efficacy of the full 
agonist, acetylcholine, and the partial agonist, butyrylcholine, in rat aorta. 
 
    In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min with the resting stretch re-adjusted to 10 mN, if required. Some 
tissues were then treated with phenoxybenzamine (3 µM for 30 min followed by washout) 
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and others were left as controls. The tissues were then pre-contracted to a submaximal 
level of endothelin-1-induced tone before conducting a full concentration-response curve 
to acetylcholine (1 nM-10 µM) or butyrylcholine (10 µM-300 µM). Thereafter, papaverine 
(300 µM) was added to produce full relaxation of the tissues.       
       
Effects of L-NMMA and ADMA on acetylcholine-induced relaxation after treatment 
with phenoxybenzamine 
    The aim of these experiments was to determine if the limited ability of L-NMMA and 
ADMA to block acetylcholine-induced relaxation in female rat endothelium-containing 
aortic rings was influenced by lowering the apparent efficacy of acetylcholine using the 
irreversible alkylating agent, phenoxybenzamine.  
 
    In these experiments, female rat endothelium-containing aortic rings were allowed to 
equilibrate for 90 min with the resting stretch re-adjusted to 10 mN, if required. Some 
tissues were then treated with phenoxybenzamine (1 µM or 3 µM, for 30 min followed by 
washout) and others were left as controls. Some of the phenoxybenzamine-treated tissues 
were then treated with L-NMMA (100 µM or 1 mM, 30 min) or ADMA (100 µM or 1 
mM, 1 h), respectively. After this time the treated tissues and their time-matched controls 
were pre-contracted to a submaximal level of endothelin-1-induced tone. Care was taken to 
induce comparable levels of tone both in control and nitric oxide synthase inhibitor-treated    
tissues by using lower concentrations of endothelin-1 in the latter. After stabilisation of 
tone, a full concentration-response curve to acetylcholine (1 nM-10 µM) was conducted. 
Thereafter, papaverine (300 µM) was added to produce full relaxation of the tissues.  
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Drugs and chemicals  
    Acetylcholine chloride (ACh), asymmetric NG, NG-dimethyl-L-arginine dihydrochloride 
(ADMA), NG-monomethyl-L-arginine acetate (L-NMMA), papaverine hydrochloride, 
phenylephrine hydrochloride (PE), endothelin-1 (ET-1; human), butyrylcholine chloride 
(BCh) and phenoxybenzamine hydrochloride were all obtained from Sigma, UK. All drugs 
were dissolved and diluted in 0.9% saline except phenoxybenzamine which was dissolved 
in 100% ethanol.  
 
Data analysis 
    Papaverine (300 µM) was added at the end of each experiment to produce full relaxation 
of tissues and the relaxant responses to agonists were expressed as a percentage of the full 
relaxation induced by this agent. Data are expressed as the mean ± S.E.M of n separate 
observations. Concentration-effect curves were analysed and drawn by fitting the data to 
formula detailed on page 56, and statistical analysis was performed by using one-way 
analysis of variance followed by Bonferroni's post-test or by Student's t test, as appropriate, 
with the aid of a computer-based program (Graph Pad, San Diego, USA). Values were 
considered to be statistically different when P was ≤ 0.05.  
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Results  
Butyrylcholine-induced relaxation  
    The muscarinic partial agonist, butyrylcholine (100 nM-300 µM), elicited concentration-
dependent relaxation in female rat endothelium-containing aortic rings precontracted to 
~50% of maximal PE tone (Figure 4.1a and b; Table 4.1). Consistent with its action as a 
partial agonist, butyrylcholine had a significantly lower Emax of 72.6 ± 5.4% than that seen 
with the full agonist, acetylcholine (Emax 91.8 ± 1.5%; P< 0.01; Figure 4.2). Unlike with 
acetylcholine (Chapter Two), relaxation to butyrylcholine was significantly blocked in a 
concentration-dependent manner by L-NMMA and ADMA (both at 0.1 or 1 mM).  
 
   Thus, L-NMMA or ADMA appears to block relaxation induced by the partial agonist, 
butyrylcholine, but not to the full agonist, acetylcholine (Chapter Two). The possibility 
that the efficacy of the relaxant agonist determines whether or not relaxation will be 
blocked by L-NMMA or ADMA seems worthy of further investigation.   
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Figure 4.1 Cumulative concentration-effect curves showing relaxation to butyrylcholine 
(BCh) in female rat endothelium-containing aortic rings submaximally contracted with PE 
in the absence and presence of (a) L-NMMA for 30 minutes or (b) ADMA for 1 h (both at 
0.1 and 1 mM).  Both L-NMMA- and ADMA-treated tissues show concentration-
dependent blockade of relaxation. Each point represents the mean ± SEM of 6-12 
observations. * P< 0.05 and *** P< 0.001 indicate significant differences from control. 
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Table 4.1   The effects of ADMA (for 1 h) or L-NMMA (for 30 min) on butyrylcholine-
induced relaxation in female rat endothelium-containing aortic rings submaximally 
contracted with PE. 
 
Treatment                                      pEC50                              Emax ± SEM (%) 
 
 
Control 
 
 
 
5.11 ± 0.05 
 
72.6 ± 5.4 
ADMA 0.1 mM   
 
 
4.95 ± 0.07 49.5 ± 4.9   * 
ADMA  1 mM   
 
 
4.92 ± 0.83 10.5 ± 3.9   *** 
L-NMMA  0.1 mM   
 
 
4.78 ± 0.08   ** 41.1 ± 2.9   *** 
L-NMMA 1 mM   
 
 
4.97 ± 0.1 26.3 ± 6.0   ***  
 
Data are the mean ± SEM of 6-12 observations. * P< 0.05, ** P< 0.01 and *** P< 0.001 
indicate a significant difference from control. 
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Effect of the contractile agent on relaxation induced by butyrylcholine or acetylcholine  
   Butyrylcholine (100 nM-300 µM) produced concentration-dependent relaxation in 
female rat endothelium-containing aortic rings precontracted to ~50% of maximal PE tone 
(Emax 72.6 ± 5.4%; pEC50 5.11 ± 0.05) (Figure 4.2a), however, the tissue sensitivity as well 
as its maximal relaxation to butyrylcholine were decreased when it was precontracted to a 
similar level with endothelin-1, achieved using (20-40 nM).   
 
    When acetylcholine (1 nM-10 µM) was the relaxant agent, it induced concentration-
dependent relaxation (Emax 91.8 ± 1.5%; pEC50 7.70 ± 0.03) in tissues submaximally 
contracted with PE (Figure 4.2b). The tissue sensitivity was reduced (pEC50 7.29 ± 0.03, 
P< 0.001), but its maximal response to acetylcholine was not significantly affected when 
endothelin-1 was used to induce submaximal tone.     
 
    In the forthcoming experiments when the tissues are to be treated with the irreversible 
alkylating agent, phenoxybenzamine, in order to reduce the efficacy of acetylcholine, and 
contraction to PE is no longer possible, endothelin-1 will be used to induce submaximal 
tone.  
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Figure 4.2. Cumulative concentration-effect curves showing relaxation to (a) 
butyrylcholine and (b) acetylcholine in female rat endothelium-containing aortic rings 
submaximally contracted with PE or endothelin-1 (ET-1). Tissues precontracted with ET-1 
show a decrease in sensitivity to the two relaxants than those precontracted with PE, with 
the greater reduction occurring with the partial agonist, butyrylcholine. Each point 
represents the mean ± SEM of 6-13 observations. ** P< 0.01 indicates a significant 
difference from PE.  
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Effect of L-NMMA or ADMA on acetylcholine-induced relaxation in tissues 
precontracted with endothelin-1 
  Acetylcholine (1 nM-10 µM) induced concentration-dependent relaxation in female rat 
endothelium-containing aortic rings precontracted with endothelin-1 (Figure 4.3). This 
relaxation was unaffected by treatment with L-NMMA at 0.1 or 1 mM or by ADMA at 0.1 
mM. However, ADMA at 1 mM produced a very slight depression of maximal relaxation 
to acetylcholine.  
 
    Therefore, regardless of whether tissues are contracted with PE or with endothelin-1, 
acetylcholine-induced relaxation appears to be largely resistant to blockade by L-NMMA 
or ADMA. 
 
Effects of phenoxybenzamine on relaxation induced by butyrylcholine or acetylcholine 
When female rat endothelium-containing aortic rings were treated with the irreversible 
alkylating antagonist, phenoxybenzamine (3 µM for 30 min), followed by washout and 
subsequent constriction with ET-1, dilatation to butyrylcholine (100 nM-300 µM) or 
acetylcholine (1 nM-10 µM) was significantly blocked in comparison to their time-
matched control tissues (Figure 4.4a and b, respectively). Relaxation to the partial agonist, 
butyrylcholine, was almost abolished (Emax 53.9 ± 2.7 and 8.5 ± 1.9 for control and treated 
tissues, respectively), while that to acetylcholine was reduced but to a lesser degree (Emax 
87.9 ± 2.6 and 63.3 ± 3.5 for control and treated tissues, respectively).  
 
    Moreover, following treatment with phenoxybenzamine, acetylcholine (1 nM-10 µM)-
induced relaxation was inhibited by both L-NMMA and ADMA (both at 0.1 or 1 mM) 
(Figure 4.5a and b; Tables 4.2 and 4.3, respectively).  
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  Therefore, although L-NMMA and ADMA have little effect on acetylcholine-induced 
relaxation in control tissues, they produce powerful blockade when the efficacy of 
acetylcholine is reduced to that of a partial agonist, by reducing the number of functional 
muscarinic receptors through the use of the irreversible alkylating agent, 
phenoxybenzamine.    
 
    Thus, these experiments, when taken together with those using the partial agonist, 
butyrylcholine, suggest that the ability of L-NMMA or ADMA to block agonist-induced 
relaxation seems to be determined by the efficacy of the relaxant agonist.  
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Figure 4.3. Cumulative concentration-effect curves showing relaxation to acetylcholine in 
rat endothelium-containing aortic rings submaximally contracted with endothelin-1 in the 
absence and presence of (a) L-NMMA for 30 minutes or (b) ADMA for 1 h (both at 0.1 
and 1 mM).  Relaxation was very slightly depressed in the presence of 1 mM ADMA, but 
was unaffected by L-NMMA. Each point represents the mean ± SEM of 5-11 observations. 
* P< 0.05 indicates a significant difference from control. 
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Figure 4.4. Cumulative concentration-effect curves showing relaxation to (a) 
butyrylcholine and (b) acetylcholine in rat endothelium-containing aortic rings 
submaximally contracted with endothelin-1. Responses are shown for control tissues and 
for tissues treated with the irreversible alkylating agent, phenoxybenzamine (3 µM for 30 
minutes followed by washout). Relaxations to both relaxants were significantly blocked by 
phenoxybenzamine; however, those in response to the partial agonist, butyrylcholine, were 
more powerfully blocked. Each point represents the mean ± SEM of 6-13 observations. 
*** P< 0.001 indicates a significant difference from control.  
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Figure 4.5. Cumulative concentration-effect curves showing relaxation to acetylcholine in 
rat endothelium-containing aortic rings precontracted with endothelin-1. Responses are 
shown for control tissues, tissues treated with phenoxybenzamine 1 µM (a) or 3 µM (b) for 
30 minutes followed by washout, and tissues treated with phenoxybenzamine then with L-
NMMA for 30 minutes (a) or ADMA for 1 h (b) (both at 0.1 and 1 mM). Following 
treatment with phenoxybenzamine, L-NMMA and ADMA produced potent blockade of 
relaxation. Each point represents the mean ± SEM of 5-10 observations. *** P< 0.001 
indicates a significant difference from control; ### P< 0.001 indicates significant 
differences from phenoxybenzamine only-treated tissues.     
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Table 4.2   Effects of phenoxybenzamine (PBZ; 1 µM for 30 min followed by washing) 
alone or PBZ then L-NMMA (0.1 or 1 mM, for 30 min) on acetylcholine-induced 
relaxation in female rat endothelium-containing aortic rings submaximally contracted with 
endothelin-1.                                                                                  
 
Treatment                                      pEC50                              Emax ± SEM (%) 
                         
 
Control 
 
 
7.12 ± 0.05 
 
78.0 ± 3.7 
PBZ   
 
 
6.35 ± 0.11   *** 51.1 ± 1.2    *** 
PBZ + L-NMMA  (0.1 mM) 
 
 
6.35 ± 0.13   ***  25.4 ± 2.2     *** 
                     # # #   
PBZ + L-NMMA (1 mM) 
 
 
6.28 ± 0.09   ***   27.1 ± 1.8     *** 
                # # #     
 
Data are the mean ± SEM of 5-10 observations. *** P< 0.001 indicates a significant 
difference from control; ### P< 0.001 indicates a significant difference from PBZ-treated 
tissues.  
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Table 4.3   Effects of phenoxybenzamine (PBZ; 3 µM for 30 min followed by washing) 
alone or PBZ then ADMA (0.1 or 1 mM, for 1 h) on acetylcholine-induced relaxation in rat 
endothelium-containing aortic rings submaximally contracted with endothelin-1.                                   
 
Treatment                                   pEC50                            Emax ± SEM (%) 
                          
 
Control 
 
 
7.27 ± 0.04 
 
87.9 ± 2.7 
PBZ     
 
 
6.42 ± 0.11  *** 63.3 ± 3.5  ***  
PBZ + ADMA (0.1 mM) 
 
 
6.39 ± 0.11  *** 
 
41.3 ± 3.9  ***   
                  # # #   
PBZ + ADMA (1 mM) 
 
 
6.28 ± 0.16  ***  15.6 ± 2.3  *** 
           # # #      
 
 
Data are the mean ± SEM of 6 observations. *** P< 0.001 indicates a significant 
difference from control; ### P< 0.001 indicates a significant difference from PBZ-treated 
tissues. 
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Discussion  
Butyrylcholine-induced relaxation 
   The findings of this part of the study showed that the M3 partial agonist, butyrylcholine 
(Martin et al., 1992), induced concentration-dependent relaxation in female rat 
endothelium-containing aortic rings. As expected, the maximal relaxant response elicited 
by this relaxant agent was lower than that by the full agonist, acetylcholine, in the same 
tissue. Strikingly, the nitric oxide synthase inhibitors, L-NMMA and ADMA, which have 
relatively little effect on acetylcholine-induced relaxation, produced potent blockade of 
butyrylcholine-induced relaxation. 
 
    Previous results of this study showed that calcitonin gene-related peptide-1 induced 
concentration-dependent relaxation in female rat endothelium-containing aortic rings, but 
the maximal response elicited by this agonist was lower than that elicited by acetylcholine 
or A23187 in the same tissue (Chapter Three). Furthermore, the nitric oxide synthase 
inhibitors, L-NMMA and ADMA, almost abolished relaxation induced by calcitonin gene-
related peptide-1, whereas they had little effect on relaxation induced by acetylcholine or 
A23187 in the same tissue.  
 
     Previous work by others has suggested that the efficacy of the relaxant agonist is critical 
in determining the ability of L-NAME to block endothelium-dependent, nitric oxide-
mediated relaxation (Martin et al., 1992). Taken together, it seemed possible that the lower 
relaxant efficacy of calcitonin gene-related peptide-1 and butyrylcholine, in comparison 
with acetylcholine or A23187, was the reason why either relaxant effect was susceptible to 
blockade by L-NMMA or ADMA. This possibility was investigated further in this study by 
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lowering the apparent efficacy of acetylcholine using the irreversible alkylating agent, 
phenoxybenzamine (Martin et al., 1992).  
 
Effect of the contractile agent on relaxation induced by butyrylcholine or 
acetylcholine  
   The aim of conducting these experiments was to determine whether the contractile agent 
used to induce tone has an influence on the ability of acetylcholine or butyrylcholine to elicit 
endothelium-dependent relaxation in rat aorta. These preliminary experiments were required 
because, as will be seen later, experiments were conducted to lower the apparent efficacy of 
acetylcholine using the irreversible alkylating agent, phenoxybenzamine. Since this agent also 
inhibits the contractile effects of α-adrenergic agonists such as phenylephrine (Kirpekar and 
Wakade, 1970; Nina and Guzzetta, 2007), a suitable alternative contractile agent needed to be 
identified.  
 
  Previous results from this study (Chapter Two) showed that acetylcholine-induced 
relaxation in female rat endothelium-containing aortic rings (Emax 81.7 ± 3.8%, pEC50 7.54 
± 0.05) was relatively similar regardless of the contractile agent used to induce tone. 
However, neither 5-hydroxytryptamine nor prostaglandin F2α, proved to be suitable 
alternatives to phenylephrine. 5-hydroxytryptamine-induced contraction is also blocked by 
phenoxybenzamine (Trevor et al., 2008) and prostaglandin F2α-induced contraction was 
insufficiently stable in the presence of this blocking agent. Endothelin-1 was therefore 
tested as a replacement for phenylephrine.  
 
   The results showed that in female rat endothelium-containing aortic rings, the tissue 
sensitivity and maximal response to the relaxant action of the partial agonist, 
butyrylcholine, were significantly reduced when the tissues were precontracted with 
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endothelin-1 in comparison to their time-matched controls precontracted with 
phenylephrine to the same level of tone. However, when the tissues were precontracted 
with endothelin-1 instead of phenylephrine, and acetylcholine was the relaxant agent, the 
tissue sensitivity was reduced but its maximal response was not affected. In these 
experiments 100-300 nM phenylephrine was needed to induce an intermediate level of 
tone, whereas only 10-40 nM endothelin-1 was needed to induce a comparable level of 
tone.  
 
    The above outcomes could be potentially attributed to the greater vascular reactivity of 
endothelin-1 when compared phenylephrine (Kurcer et al., 2006), which resulted in a kind 
of physiological antagonism that opposed relaxation to the partial agonist, butyrylcholine, 
more powerfully than to the full agonist, acetylcholine.   
 
    As a consequence of the above, when the tissues were to be treated with 
phenoxybenzamine to lower the apparent efficacy of acetylcholine, new control 
concentration-response curves were required for acetylcholine in the presence of 
endothelin-1-induced submaximal tone. 
 
   The findings of this study showed that as with phenylephrine-induced tone, the nitric 
oxide synthase inhibitors, L-NMMA and ADMA, did not block acetylcholine-induced 
relaxation in female rat endothelium-containing aortic rings precontracted with endothelin-
1, apart from a slight depression in the maximal response caused by ADMA at 1000 µM. 
These results are in general agreement with previous work (Frew et al., 1993) and in 
agreement with the results from Chapters two and three of this study which showed that 
acetylcholine-induced relaxation is largely resistant to blockade by L-NMMA or ADMA, 
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regardless of animal gender (female vs male), the blood vessel examined (rat aorta vs 
carotid artery) or the contractile agent used (phenylephrine, 5-hydroxytryptamine or 
prostaglandin F2α).  
 
Effects of phenoxybenzamine on relaxation induced by acetylcholine or 
butyrylcholine in female rat aorta 
   The aim of conducting these experiments was to determine the extent to which the 
irreversible alkylating agent, phenoxybenzamine (Martin et al., 1992), reduced the relaxant 
efficacy of the full agonist, acetylcholine, and the partial agonist, butyrylcholine, in rat aorta. 
 
   The findings of this study showed that when female rat endothelium-containing aortic 
rings were treated for 30 minutes with phenoxybenzamine (3 µM), followed by washout 
and then submaximally contracted with endothelin-1, relaxation to acetylcholine or 
butyrylcholine was significantly blocked in comparison to control tissues, however, those in 
response to the partial agonist, butyrylcholine, were more powerfully blocked. Previous work 
showed that in rabbit jugular vein, similarly treated with phenoxybenzamine, acetylcholine 
now acted as a partial agonist and induced approximately 75% of its normal maximal 
response (Martin et al., 1992). However, in that study, butyrylcholine induced a maximal 
response in control tissues higher than that induced in the control rat aortic rings used in 
the present study. This difference may due to the presence of significantly more spare 
receptors in the rabbit jugular vein in comparison to rat aorta (Martin et al., 1992), as the 
maximal response elicited by a partial agonist is enhanced when the population of 
receptors is increased (Tan et al., 2003).     
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   By definition, butyrylcholine as a partial agonist which even when occupies 100% of 
endothelial M3 receptors will fail to produce the same maximum response as the full 
agonist, acetylcholine (Stephenson, 1956; Schild, 1957; Furchgott, 1966; Pliška, 1999; 
Foreman and Johansen, 2003; Kenakin, 2004). Moreover, the full agonist, acetylcholine, 
can elicit its maximal relaxant effect by occupying only a small percentage of the total 
endothelial M3 receptor pool, i.e. there is a considerable receptor reserve. The population 
of functional receptors available to bind the agonist can be reduced using irreversible 
receptor antagonists (Stephenson, 1956; Furchgott, 1966; Foreman and Johansen, 2003). 
These are chemically reactive molecules that combine with the ligand binding subunit of 
the receptor. The resultant covalent bond between the receptor protein and the irreversible 
antagonist molecule results in irreversible blockade of the receptor and new receptor 
molecules need to be synthesised before binding agonist and responsiveness can resume. 
Moreover, in the presence of an irreversible antagonist the number of active drug-receptor 
complexes that can be formed, which determine the magnitude of agonist effect, is 
decreased, so that the maximal response elicited by the agonist is depressed and the 
resultant dose-response curve is shifted to the right. Thus, on the basis of receptor theory 
one would predict that phenoxybenzamine would reduce the maximal relaxant effect elicited 
by the partial agonist, butyrylcholine, to a far greater extent than to the full agonist, 
acetylcholine. Thus, the findings of this study in rat aorta are entirely consistent with receptor 
theory.  
  
  The most important finding of this study, however, was that when the apparent efficacy of 
acetylcholine was reduced to that of a partial agonist using phenoxybenzamine, both L-
NMMA and ADMA, which normally have little effect, now produced potent 
concentration-dependent blockade of the relaxation. The degree of inhibition by L-NMMA 
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and ADMA was similar to their blocking effect on relaxation induced by butyrylcholine. 
Previous work showed in rabbit jugular vein that when the apparent efficacy of 
acetylcholine was reduced, using 3 µM phenoxybenzamine for 30 minutes, so that it 
attained approximately 75% of its normal maximum effect, L-NAME now produced 
powerful blockade of relaxation, similar to its blocking effect on relaxation induced by the 
partial agonist, α-methyl-5-hydroxytryptamine (Martin et al., 1992).   
 
  Thus, the ability of L-NMMA and ADMA to block relaxation to the partial agonist, 
butyrylcholine, and to acetylcholine when its efficacy is reduced is in striking contrast with 
their lack of effect when acetylcholine is acting as a full agonist.  
 
  Previous findings of this study (Chapter Three) showed that the endothelium-dependent, 
nitric oxide-mediated relaxation induced by the low efficacy agonist, calcitonin gene-
related peptide-1, but not by the powerful agents, acetylcholine and A23187, was 
powerfully blocked by L-NMMA and ADMA in rat aorta. When taken together with the 
results of the present chapter, these findings strongly suggest that the efficacy of the 
relaxant agonist is critical in determining the ability of L-NMMA and ADMA to block 
endothelium-dependent, nitric oxide-mediated relaxation. This conclusion is supported by 
previous findings in rabbit jugular vein that efficacy of relaxant agonist is critical in 
determining the blocking ability of L-NAME (Martin et al., 1992).  
 
   Thus, the major conclusion of this study is that the seemingly differential abilities of L-
NMMA and ADMA to block basal, but not acetylcholine-induced relaxation in rat aorta 
may be explained by the blocking action being critically determined by the efficacy of the 
relaxant stimulus (presumably low efficacy basal activity vs high efficacy acetylcholine-
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induced stimulated activity). A summary of the effects of L-NMMA and ADMA on 
relaxation induced by acetylcholine or butyrylcholine in the rat aorta is shown below 
(Figure 4.6).  
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Figure 4.6. Summary of the effects of L-NMMA and ADMA on relaxation induced by 
acetylcholine or butyrylcholine in the rat aorta. 
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Chapter Five 
General Discussion 
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  The findings from the first part of this study showed that ADMA has differential abilities 
to block basal but not acetylcholine-stimulated activity of nitric oxide in rat aorta. These 
actions of ADMA are similar to those of L-NMMA in the same tissue (Frew et al., 1993), 
but in contrast to the actions of the standard nitric oxide synthase inhibitor, L-NAME, 
which similarly blocks basal as well as acetylcholine-stimulated nitric oxide activity in rat 
aorta.  
 
     It has been reported that the vascular endothelium generates nitric oxide in the absence 
of external stimuli, i.e. under basal conditions, and that this basal activity of nitric oxide 
exerts a tonic vasodilator effect that suppresses the actions of vasoconstrictor drugs (Martin 
et al., 1986b; Rees et al., 1989; Moore et al., 1990; Mian & Martin, 1995). Therefore, 
agents that inhibit nitric oxide synthesis or block the actions of nitric oxide are expected to 
produce an enhancement of vasoconstrictor-induced tone by removing this endothelium-
dependent suppression of vasoconstriction. 
 
    In agreement with this concept, the results of this study showed that endothelial 
denudation or treatment of endothelium-containing female rat aortic rings with the nitric 
oxide synthase inhibitors, L-NAME, L-NMMA or ADMA, resulted in augmentation of 
low level phenylephrine-induced tone. This augmentation of tone was both prevented and 
reversed by adding a high concentration (10 mM) of the endogenous substrate for nitric 
oxide synthase, L-arginine. These findings suggest that all of these inhibitors of nitric 
oxide synthase act as classical competitive antagonists of the enzyme responsible for basal 
nitric oxide synthesis (Palmer et al., 1988; Rees et al., 1989; Aisaka et al., 1989; Rees et 
al., 1990; Moore et al., 1990; Hobbs et al., 1999; Masuda et al., 2002).     
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  Additionally, the findings showed that the availability of L-arginine is not limiting for the 
production of the basal nitric oxide activity that suppresses vasoconstrictor tone. This latter 
finding is supported by previous in vitro and in vivo studies (Cooke et al., 1991; Moritoki 
et al., 1991; Jun and Wennmalm, 1994) and it may be due to the high endogenous level of 
L-arginine (100-300 µM) reportedly found in endothelial cells compared with estimates of 
the Km for nitric oxide synthase (2-3 µM). Thus, under normal circumstances, the enzyme 
would normally be fully saturated with substrate (Sydow and Münzel, 2003; Teerlink et 
al., 2009; Zhang et al., 2011).  
 
  Also, the findings of this study showed that ADMA augmented the contractile responses 
to a range of spasmogens (phenylephrine, 5-hydroxytryptamine or prostaglandin F2α). 
While the threshold concentration of ADMA to block basal nitric oxide activity, as 
assessed by enhancement of phenylephrine-induced tone, in rat aorta was at 0.3–1 µM, it 
had almost completely blocked basal activity at a concentration of 100 µM. Furthermore, 
SDMA, the inert isomer of ADMA, had no effect on basal nitric oxide activity consistent 
with data indicating that SDMA is not an inhibitor of nitric oxide synthase (Masuda et al., 
2002; Siroen et al., 2006).   
 
    Probably the most important finding of this study is that ADMA at a concentration of 
100 µM, which almost completely blocks basal nitric oxide activity, has virtually no effect 
on acetylcholine-induced relaxation when the level of control and treated tissues was 
matched; there was a slight (2-3-fold) decrease in tissue sensitivity without affecting the 
maximal response to acetylcholine. Even increasing the concentration of ADMA to 1000 
µM and prolonging the duration of treatment to 3 h failed to produce further blockade.  
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   In contrast, under conditions where ADMA had been permitted to potentiate 
phenylephrine-induced tone as a result of blockade of basal nitric oxide activity, it 
appeared to produce blockade of acetylcholine-induced relaxation. This latter effect of 
ADMA was almost certainly due to physiological antagonism rather than blockade of nitric 
oxide synthase, since matching this increased tone in control tissues with additional 
phenylephrine produced a similar degree of apparent blockade. These findings are clearly 
in conflict with previous studies on rat aorta which reported blockade of acetylcholine-
induced relaxation by ADMA (Vallance et al., 1992; Jin and D'Alecy, 1996; Feng et al., 
1998). These authors made no mention of matching the tone in control and ADMA-treated 
tissues, so the observed “blockade of acetylcholine-induced relaxation” was likely to have 
been due to physiological antagonism rather than to blockade of nitric oxide synthase.  
 
   The results of this study also showed that ADMA did not inhibit acetylcholine-induced 
relaxation in rat aortic rings contracted submaximally with other agents, i.e. 5-
hydroxytryptamine or prostaglandin F2α. Also, the inert isomer, SDMA, has no effect on 
acetylcholine-induced relaxation in rat aorta consistent with previous reports that this agent 
has no effect on nitric oxide synthase (Masuda et al., 2002; Siroen et al., 2006). In 
addition, the results showed that the availability of L-arginine is not limiting for the 
production of nitric oxide in response to acetylcholine in rat aorta. This finding could be 
attributed to the existence of a high intracellular concentration of L-arginine which 
saturates endothelial nitric oxide synthase (Cooke et al., 1991; Moritoki et al., 1991) 
although exogenous supplementation of L-arginine does appear to improve endothelium-
dependent vasodilatation in humans and animals with pathological conditions associated 
with vascular dysfunction (Böger et al., 1995; Candipan et al., 1996; Rector et al., 1996; 
Blum et al., 1999; Watanabe et al., 2000; Böger and Bode-Böger, 2001).  
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   In a further deviation from the classically expected outcome, the results of this study also 
showed that both of L-NMMA and ADMA behaved similarly to the endogenous substrate, 
L-arginine, by protecting acetylcholine-induced relaxation against blockade by the 
standard nitric oxide synthase inhibitor, L-NAME. L-arginine and L-NMMA both 
prevented and reversed blockade by L-NAME, however, ADMA failed to reverse that 
blockade after an hour of treatment, perhaps due to a lower potency of ADMA than L-
arginine or L-NMMA. These findings are supported by previous reports suggesting that L-
NMMA may act as an alternative substrate for nitric oxide synthase and thereby increase 
the synthesis of nitric oxide in rat aorta and pulmonary artery (Archer and Hampl, 1992; 
Frew et al., 1993). Thus, L-NMMA and ADMA behaved more like alternative substrates 
for acetylcholine-induced activity of nitric oxide in rat aorta despite acting as classical 
competitive antagonists of basal nitric oxide synthesis.  
 
  One theory that could potentially explain these anomalous actions of ADMA and L-
NMMA to block basal but not acetylcholine-stimulated activity of nitric oxide is the 
existence, within the vascular endothelial cells, of more than one isoform of nitric oxide 
synthase; one that catalyses the synthesis of nitric oxide under basal conditions, and 
another for agonist-stimulated production.   
 
    Another possible hypothesis behind these anomalous actions of ADMA and L-NMMA, 
is that the different signal transduction mechanisms triggered by different stimuli may 
result in unique structural or conformational changes in endothelial nitric oxide synthase 
that alter its requirement for substrates and inhibitors.   
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    One other potential explanation for these anomalous abilities of ADMA and L-NMMA 
may relate to the degree to which endothelial nitric oxide synthase is stimulated.   
 
   In the second section of this study the above possibilities were explored by employing a 
variety of different experimental approaches.  
 
    The results from the second section of this study showed that, in the presence of catalase 
(to remove any formed hydrogen peroxide), L-NMMA and ADMA, like L-NAME, were 
able to almost completely abolish relaxation induced by superoxide dismutase; this 
relaxation is attributed to protection of basal nitric oxide from destruction by superoxide 
anion (˙O-2) (Gryglewski et al., 1986; Rubanyi and Vanhoutte, 1986; Ohlstein and Nichols, 
1989; Mian and Martin 1995; MacKenzie et al., 1999). Also, the results showed that these 
nitric oxide synthase inhibitors each produced blockade of relaxation induced by the 
phosphodiesterase isoform 5 inhibitor, T0156, that was as powerful as that produced by 
endothelial denudation; this relaxation is attributed to potentiation of basal nitric oxide 
activity generated by the vascular endothelium due to slowed hydrolysis of its second 
messenger cGMP (Martin et al., 1986a; Hobbs et al., 1999; Mochida et al., 2002; Kimura 
et al., 2003; Mochida et al., 2004; Galley et al., 2004; Bauer and Sotnikova, 2010). Thus, 
the uniform outcome is that L-NMMA and ADMA block basal activity of nitric oxide 
irrespective of whether it is assessed via SOD- or T0156-induced relaxation or through 
enhancement of phenylephrine-induced tone.  
 
  As has been mentioned before, a difference in the transduction mechanisms that govern 
basal and agonist-stimulated synthesis of nitric oxide could potentially explain the ability 
of L-NMMA and ADMA to block the former but not the latter in rat aorta. However, the 
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use of calmidazolium or wortmannin indicated that calcium-calmodulin-dependent and 
phosphatidylinositol 3-kinase-mediated activation of endothelial nitric oxide synthase 
appears to play only a minor role in basal nitric oxide production in female rat aorta. The 
major component of basal nitric oxide production appears to occur, however, through 
spontaneous, unstimulated activity of the enzyme.  
 
   The finding of this study that L-NMMA and ADMA have a little effect on the receptor-
dependent acetylcholine-induced relaxation in rat aorta seems to be not unique for this 
agonist, since these nitric oxide synthase inhibitors also have little effect on relaxation 
induced by calcium ionophore A23187 in the same tissue. This relaxant agent is known to 
produce endothelium-dependent, nitric oxide-mediated relaxation via a receptor-
independent elevation of intracellular endothelial calcium levels (Weinheimer and 
Osswald, 1986; Schini and Vanhoutte, 1992; Taniguchi et al., 1999; Shi et al., 2007). In 
stark contrast, this study showed that both L-NMMA and ADMA powerfully blocked 
relaxation to calcitonin gene-related peptide-1, which induces endothelium-dependent, 
nitric oxide-mediated relaxation in rat aorta (Gray and Marshall, 1992; Abdelrahman et al., 
1992, de Hoon et al., 2003; Thakor and Giussani, 2005). Another apparent difference 
among the three agents was that the maximal response elicited by calcitonin gene-related 
peptide-1 was lower than that elicited by acetylcholine or A23187 in the same tissue. In 
addition, the results from this section of the study showed that these three agonists 
(acetylcholine, A23187 and calcitonin gene-related peptide-1) signal through a seemingly 
similar calmidazolium-sensitive, calcium-calmodulin-dependent transduction mechanism 
to stimulate the release of nitric oxide in rat aorta. Taken together, it is clear that the ability 
of L-NMMA and ADMA to block relaxation to calcitonin gene-related peptide-1, but not 
to acetylcholine or A23187, cannot be explained by these agonists acting via different 
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transduction pathways. It is possible therefore that the differential effect L-NMMA and 
ADMA exert on relaxations induced by these three agonists might somehow related to the 
maximum relaxation these agents can elicit. This possibility is further supported by 
previous work suggesting that the efficacy of relaxant agonist is critical in determining the 
ability of L-NAME to block endothelium-dependent, nitric oxide-mediated relaxation 
(Martin et al., 1992). Thus, this possibility was investigated in the next section of the study 
using the muscarinic M3 receptor partial agonist, butyrylcholine, and by lowering the 
apparent efficacy of acetylcholine by using the irreversible alkylating agent, 
phenoxybenzamine (Martin et al., 1992). 
 
    The results from this part of the study showed that the M3 partial agonist, butyrylcholine 
(Martin et al., 1992), induced concentration-dependent relaxation in female rat 
endothelium-containing aortic rings. As expected, the maximal relaxant response elicited 
by this partial agonist was lower than that of the full agonist, acetylcholine, in the same 
tissue. Strikingly, the nitric oxide synthase inhibitors, L-NMMA and ADMA, which have 
relatively little effect on acetylcholine-induced relaxation, produced powerful blockade of 
butyrylcholine-induced relaxation.  
 
  Previous results of this study showed similar findings with the low efficacy agonist, 
calcitonin gene-related peptide-1.  
   
  Taken together, it seemed possible that the lower relaxant efficacy of calcitonin gene-
related peptide-1 and butyrylcholine, in comparison with acetylcholine or A23187, might 
explain why these relaxant effects were susceptible to blockade by L-NMMA or ADMA. 
This possibility was investigated further in this study by lowering the apparent efficacy of 
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acetylcholine using the irreversible alkylating agent, phenoxybenzamine (Martin et al., 
1992). 
 
   The results showed that when the apparent efficacy of acetylcholine was reduced (by 
~50%) to that of a partial agonist using phenoxybenzamine, both of L-NMMA and ADMA 
produced concentration-dependent blockade of the relaxation. The degree of inhibition by 
L-NMMA and ADMA was similar to their blocking effect on relaxation induced by 
butyrylcholine.  
 
   In conclusion, the findings of this study strongly suggest, in common with previous 
findings with L-NAME (Martin et al., 1992), that the efficacy of the relaxant agonist is 
critical in determining the degree to which L-NMMA and ADMA can block endothelium-
dependent, nitric oxide-mediated relaxation. An explanation for the ability of L-NMMA 
and ADMA to block acetylcholine-induced relaxation therefore rests on this conclusion.  
 
  A summary of the differential actions of L-NMMA and ADMA on basal and agonist-
stimulated activity of nitric oxide in the rat aorta is shown below (Figure 5.1). 
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Figure 5.1. Summary of the differential actions of L-NMMA and ADMA on basal and 
agonist-stimulated activity of nitric oxide in the rat aorta 
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